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You're only given a little spark of madness. You mustn't lose it.  
                                    - Robin Williams -
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1 Introduction 
1.1 Autoimmune diseases 
 
The general aim of the immune system is to protect the body against infectious diseases and 
disregulated cell populations like tumor cells. The variety of agents that can be detected 
range from bacteria, viruses and fungi to protozoa which must be clearly distinguished from 
the body’s own cell and tissue environment. Invading organisms and tumor cells are attacked 
by the body’s innate immune system as well as acquired humoral and cellular immune 
responses to protect the host organism against damage. The differentiation between non-self 
antigens that need to be dealt with, and self antigens that should be ‘tolerised/ignored’, is 
one of the most intricate tasks of the immune system. This tolerance is ensured by 
mechanisms during the development and maturation of lymphocytes which leads to the 
depletion and inactivation of autoreactive immune cells.  
 
Self antigen
Self-reactive
receptor
lymphocyte
A
cell deleted
B
receptor edited
C
intrinsically regulated
D
extrinsically regulated
 
 
Figure 1: Cellular strategies used for the regulation of self-reactive B cell receptors. (A) Deletion of the cell by cell 
death induction. (B) Receptor editing to a less self-reactive receptor. (C) Changes in gene expression dampens 
the ability of self reactive receptors in cell activation. (D) Limitation of self reactive cells in autoimmunity by 
extrinsic suppression and limitation of essential growth factors, costimuli and inflammatory mediators. Picture was 
taken from ref [1].  
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The control of potential autoreactive cells is sometimes inadequate and some lymphocytes 
may escape this selection process. It is obvious that a low level of autoreactivity is 
physiologic and crucial for normal immune function. Autoantigens help to form the repertoire 
of mature lymphocytes and the survival of mature T cells and B cells in the periphery 
requires continuous exposure to autoantigens [2]. Since there is no fundamental difference 
between the structure of self antigens (or autoantigens) and that of foreign antigens, some 
have speculated that lymphocytes have evolved, not to distinguish self from foreign, but 
rather to respond to antigen only in certain microenvironments, generally in the presence of 
inflammatory cytokines [3-5]. Since autoreactivity is physiologic, the challenge is to 
understand how it becomes a pathologic process and how T cells and B cells contribute to 
tissue injury. There are more than 80 autoimmune diseases described in the literature known 
to be major causes of morbidity and mortality throughout the world. The physical, 
psychological and economic burden of these diseases is particularly devastating as they 
often affect young adults. With the exception of rheumatoid arthritis [6] and autoimmune 
thyroiditis [7], the diseases individually are rare but together they affect up to 5 percent of the 
population in western countries. Some diseases e.g. diabetes Type I attack specific organs 
[8] whereas others such as systemic lupus erythematosus (SLE) affects several tissues and 
organs [9]. Strangely enough, more than 70% percent of people with autoimmune disorders 
are women. The reason for that is still unknown but a prominent role for sexual hormones 
that influence the severity of an autoreactive disease [10] is speculated. Several mouse 
experiments showed that estrogens and androgens bias the production of proinflammatory 
cytokines like TNF-α and IL-1β after infection with a pathogen [11, 12].  
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Figure 2: Female-male ratio of the major autoimmune diseases. The numbers above the bars refer to the number 
of disease cases (x 100.000) in the USA. Picture was taken from ref [13]. 
 
Some pathogens that invade the body have the potential to elicit manifestations of a specific 
autoimmune disease. This phenomenon is based upon sequence similarities between 
foreign and self-peptides and is called “molecular mimicry” [14-16]. It is assumed that cross-
activation of autoreactive lymphocytes by pathogen-derived proteins leads to their pathologic 
nature. Epidemiologic studies have demonstrated that the genetic susceptibility of an 
organism relating to multiple genes and risk factors is another factor for the triggering of an 
autoimmune response [17, 18]. There are three main groups of genes connected to 
immunoglobulins, T cell receptors and major histocompatibility complexes (MHC) that are 
thought to be highly correlated with autoimmune diseases. Most autoimmune diseases are 
linked to special class I HLA molecules e.g. HLA-DR2 (multiple sclerosis, systemic lupus 
erythematosus) [19] or HLA-DR4 (rheumatoid arthritis, type I diabetes mellitus, myasthenia 
gravis) [20, 21], but the majority of diseases are multigenic with many susceptibility genes 
working together to produce an “abnormal phenotype” [22]. Other important components in 
determining the occurence of self reactive cell populations are specific environmental factors 
like different toxic compounds and nutrition constituents [23]. Main focus of this area of 
research is the contribution of regulatory Th17 cells in the development of autoimmune 
diseases [24, 25]. This cell population is substantially involved in immune reactions to 
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bacteria or fungi but their activation and strong upregulation can be observed in autoimmune 
reactions as well. They are connected in a specific way to the so called “aryl hydrocarbon 
receptor” (AhR), which is activated by a wide range of chemicals like e.g. dioxin, upon 
exposure to food antigens [26] or high hormone levels [27]. After activation of the receptor, a 
specific enzyme cascade is activated that reduces the toxic effects of the compounds. In 
autoimmune diseases it could be observed that activation of the AhR stimulates the effect of 
Th17 cells and enhance their reactive potential, leading to acceleration of autoimmune 
development and an increase in severity of symptoms [28]. Currently available therapies for 
the treatment of autoimmune diseases have limited success as they are lacking highly 
specific mechanisms to suppress pathologic immune responses without systemically 
interfering with the immunity in the patients’ body. These therapies have either 
immunosuppressive, anti-inflammatory effects but nevertheless lack specificity in efficient 
depletion of pathologic T and B cell populations. There has been some success in blocking 
inflammatory cytokines like tumor necrosis factor (TNF) by applying specific antibodies or 
soluble ligands in rheumatoid arthritis [29, 30]. In addition, the use of integrin-specific 
antibodies to prevent the homing of autoreactive lymphocytes into the brain of patients with 
multiple sclerosis showed promising results [31]. At present, the most common therapies are 
immunosuppressive (e.g. cyclosporin) or anti-inflammatory (corticosteroids) and more 
specific approaches still remain to be developed.  
 
1.2 The role of B cells in autoimmune diseases 
 
For over 20 years, especially T lymphocytes attracted major attention due to their 
predominant presence in acute inflammatory lesions [32], their potential to transfer an 
autoimmune disease from one organism to another [33] and the link between specific MHC 
class II alleles and specific autoimmune diseases like rheumatoid arthritis, multiple sclerosis 
and type I diabetes mellitus. Presently antibody-secreting B lymphocytes get more and more 
in the focus of autoimmune diseases researchers because of recent strong evidence of their 
central role in the induction and maintenance of inflammatory reactions [34-36]. Their main 
pathologic potential is based on the secretion of autoreactive antibodies that are able to bind 
and opsonize autoantigens, followed by stimulation of macrophages and fixation of the 
body’s complement system [37, 38]. Moreover, autoreactive B cells can strongly enhance the 
T cell response by presenting processed autoantigens in combination with MHC molecules 
on their surface [39, 40]. The regulatory activation of T lymphocytes and the above 
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mentioned capability of steady secretion of autoreactive antibodies are the main pathological 
functions of autoreactive B lymphocytes. Thus, as the etiology of autoimmune diseases is 
based on the interaction of different lymphocyte populations, specific elimination of 
pathologically relevant cells may be beneficial. With the application of a B cell-specific 
antibody that targets the CD20 receptor on mature B cells which subsequently results in their 
depletion [41, 42], the symptoms of patients with multiple sclerosis [43], rheumatoid arthritis 
[44], systemic lupus erythematosus [45] and other autoimmune diseases have been strongly 
reduced. This antibody, called Rituximab® (MabThera®/Rituxan®; Roche Pharmaceuticals, 
Basel, Switzerland; Genentech, South San Francisco, USA; IDEC Pharmaceuticals, San 
Diego, USA) was invented in 1997 for the specific treatment of B cell non-Hodgkin lymphoma 
[46] and showed an effective and safe depletion of B cell lymphoma cells via natural killer cell 
activation with more than 370.000 succesful therapy cases until now. The interest in using 
the anti-CD20 antibody for the treatment of autoimmune diseases is growing because 
rituximab has a high efficacy in depleting normal B lymphocytes and is, in general, a well-
tolerated drug [47]. The antibody has been evaluated in a variety of different autoimmune 
diseases where B cells and autoreactive antibodies play a major role in contributing to the 
pathologic state of the disease. Different clinical trials [48-52] targeting B lymphocytes in 
chronic idiopathic thrombocytopenia, antineutrophil cytoplasmic autoantibody-positive 
Wegener’s granulomatosis, autoimmune hemolytic anemia and in phase I/II open-label trials 
in systemic lupus erythematosus, showed a strong effect of rituximab. The benefit of 
rituximab was likewise demonstrated in rheumatoid arthritis and ongoing multiple sclerosis 
trials, both autoimmune diseases in which T and B cells play an important role [53, 54]. The 
first results of these trials are very encouraging but the optimal therapeutic dose of the 
antibody, its mode of action, and its effect on the immune system beyond the depletion of B 
lymphocytes still remains to be determined. Nevertheless the targeting and depletion of 
autoreactive B lymphocytes via the CD20 receptor using rituximab still lacks antigen-specific 
selectivity as it depletes the vast majority of all B cells, leading to immunodeficiency on the 
base of the humoral response without specific elimination of antigen-specific B cell 
populations. Therefore, the development of novel antigen-specific therapeutics for the 
directed elimination of autoreactive B lymphocytes without affecting the body’s general 
humoral defense, which is currently lacking, could be extremely beneficial.  
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1.3 Multiple sclerosis - overview, pathophysiology, therapy  
 
Multiple sclerosis (MS) is an inflammatory demyelinating autoimmune disease of the central 
nervous system triggered by the body’s own immune system reacting against self-antigens. 
The disease mostly starts during young adulthood and peaks at between 25-30 years. MS is 
characterized by a chronic progressive etiopathology leading to an increase of neurological 
disorders. The average prevalence across Europe and the USA is approximately 0.1% with a 
2:1 ratio of women to men [55]. The disease is generally responsible for a variety of physical 
and mental disabilities ranging from hypoesthesia, muscle weakness, difficulty in moving and 
in balance (ataxia), problems in speech, to visual problems, fatigue, chronic pain and bowel 
and bladder problems [56]. More than 50% of MS patients are unable to walk without 
assistance 15 years after disease onset [57]. In general the clinical course of multiple 
sclerosis begins with a relapsing-remitting disease pattern that is characterized by 
unpredictable immune attacks (relapse phase) and proximate phases with no clinical 
symptoms for months to years (remission phase). Later on, in 80% the disease is followed by 
a secondary progression phase that features neurological disfunctions between relapses 
without remission phases. A certain subgroup of patients develop a so-called ‚benign MS’ 
where a relapsing-remitting course is always followed by a resolution of neurological deficits 
and no or little disability is detectable after 10 or more years. A rather rare MS course (10% 
of patients) is distinguished by a non-remission disease pattern with a continuous decline of 
the patients’ health. This primary progressive course is mainly observed in patients with a 
disease onset at older age. The rarest form of multiple sclerosis is called ‚progressive 
relapsing’ and is characterised by constant relapsing events and superimposed attacks 
without remission phases. The different disease courses of MS are shown in Figure 3. 
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Figure 3: The different disease courses of multiple sclerosis. The Progressive-Relapsing subtype (A) is the least 
common course and includes acute exacerbation phases and a steady neurologic decline without the return of 
physiological functions. Individuals with Secondary-Progressive MS (B) are characterized by a relapsing disease 
pattern over a time period of 10-15 years followed by a severe progressive state without remission phases. The 
recovery from autoimmune attacks disappears followed by an increase of neurological deficits and physical 
disabilities.  The general characteristic of the Primary-Progressive subtype (C) is a slow steady disease onset, 
mostly beginning with walking difficulties. This state is followed by continuous worsening of motor dysfunctions 
and increased disability. Relapsing-Remitting MS (D) patients suffer from sporadic immunological attacks 
(relapses) that can last for varying periods and are followed by partial or total recovery and remission. Picture was 
taken from www.disaboom.com. 
 
The pathology of MS is thought to be initiated in the periphery by an unknown antigenic 
trigger that activates T lymphocytes. Upon activation, the T cells are able to infiltrate the 
central nervous system (CNS) breaking the blood brain barrier (BBB) [58]. There, activated T 
lymphocytes are reactivated by CNS antigens leading to the triggering of an immune 
response to proteins of the myelin sheaths around the nerves in the brain and the spinal 
cord. In detail, the infiltrated lymphocytes, mainly activated CD4+ T lymphocytes initiate a 
cell-mediated (Th1) inflammatory reaction followed by an immunological cascade that 
recrutes CD8+ T lymphocytes, B cells and macrophages to inflammatory lesions. The 
resulting cellular environment leads to the formation of demyelinating lesions (‘plaques’) and 
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subsequent axonal injury. The degradation of myelin proteins results in the release of 
antigens that is thought to further enhance inflammatory reactions in the lymphoid tissue by 
antigenic spread. Autoreactive B and T lymphocytes as well as activated macrophages and 
the bodies complement system contribute to, and maintain the inflammatory lesions in brain 
and spinal cord: T cells are thought to be activated in the perivascular space by antigen-
presenting macrophages before they can pass the BBB. After passaging the BBB, activated 
T lymphocytes secrete pro-inflammatory cytokines (e.g. IFN-γ, IL-2, TNF-α, TNF-β) resulting 
in activation of macrophages and microglia cells. These cells produce a set of pro-
inflammatory monokines and chemokines (e.g. oxygen and nitrogen free radicals) that in turn 
activate astrocytes and endothelial cells, leading to the upregulation of adhesion molecules 
followed by disruption of the BBB [59]. In addition, they are responsible for the presentation 
of antigen, the production of myelinotoxic and neurotoxic factors and the phagocytosis of 
myelin constituents.  
The humoral response is activated by cytokine secretion of autoreactive T lymphocytes 
leading to the occurence of autoreactive B lymphocytes in MS lesions. B cells, plasma cells 
and immunoglobulins (Ig) are clearly detectable in MS lesions and contribute to the 
pathologic state by presenting antigens to activated T lymphocytes and secreting anti-myelin 
antibodies. These antibodies (Ab) are involved in complement fixation [60] with a subsequent 
myelin degradation process and the Ab-mediated phagocytosis by activated macrophages. 
IgG deposits on myelin proteins correspond with the appearence of the complement proteins 
C1q and C3 around the actively demyelinating lesions in MS plaques [61-63]. In the most 
active lesions, a colocalization between Igs and structures positive for C3d was observed. All 
the described cell populations essentially contribute to the development and maintenance of 
the inflammatory state of the disease, offering several windows for therapeutic intervention. 
Even though there is no curative therapy for MS patients until now, some therapeutic 
approaches showed beneficial effects on the progression slow down of the disease. The 
most common therapy for acute relapses until now is the application of anti-inflammatory and 
immunosuppressive drugs like corticosteroids (e.g. methylprednisolon) [64]. These agents 
inhibit the transcription of diverse interleukin (e.g. IL-1, IL-2, IL-6, IL-8) and Fc receptor genes 
leading to the suppression of the cell-mediated immunity of T and B lymphocytes. 
Furthermore glucocorticoids are able to inhibit prostaglandins and leukotriens two of the 
major pro-inflammatory compounds present in inflamed lesions in the body. In 2007, six 
immunoregulatory drug agents were approved, and available for the treatment of relapsing-
remitting (RR) multiple sclerosis. Interferon-1α (Avonex®, Rebif®) and Interferon-1β 
   
                                                                                                                                 Introduction   
 
     
9 
(Betaseron®, Betaferon®) have to be applied weekly in patients with RR multiple sclerosis 
and are able to reduce the rate of MS relapses in a range of 18-38% [65, 66]. Their 
therapeutic effect is based upon their anti-inflammatory effect and improvement of the BBB 
integrity inhibiting further migration of lymphocytes across that barrier. Patients with MS that 
start early with interferon therapy have the possibility to attenuate the disease course but 
have to face strong flu-like side effects and immune responses to the drug after a certain 
application period [67].  
Glatiramer acetate (Copaxone®, Cop1®) is a non-steroidal, peptide-based substance with 
immunomodulatory functions. It is is a random polymer composed of four amino acids that 
are found in the myelin basic protein (MBP), one of the major autoantigens in multiple 
sclerosis. Its specific function is predicated upon a shifting of the immune response from pro-
inflammatory Th1 cells to regulatory Th2 cell populations that are able to suppress the 
autoimmune reaction to myelin proteins [68, 69]. Regulatory T suppressor cells are activated 
after binding of Cop1 to relevant MHC by suppressive determinants shared between MBP 
and Cop1. In addition, Cop1 is able to compete for MHC II binding with several myelin-
associated antigens, leading to an inhibition of antigen-specific T cell effector cells 
(proliferation, interleukin secretion, cytotoxicity). Glatiramer acetate was able to decrease MS 
relapses in two different clinical trials with RR MS patients, but its effectivity has to be further 
evaluated [70]. Mitoxantrone® is a synthetic drug that was originally developed for cancer 
therapy with the goal to inhibit the topoisomerase II of dividing cells. This agent was 
evaluated for the treatment of primary progressive MS patients and resulted in moderate 
slowing down of the relapses of patients albeit accompanied by several side effects like hair 
loss, heart damage and immunosuppression [71].  
The most effective treatment for MS patients to date is the application of the monoclonal 
antibody Natalizumab® [72] that targets the cellular adhesion molecule α4-integrin. Upon 
binding to this target, the adhesion and migration of activated lymphocytes through the blood 
brain barrier is effectively inhibited, resulting in a reduction of relapses [73] and a general 
reduction of MS symptoms. In spite of several side effects like fatigue, allergic reactions and 
a low risk of anaphylaxis it is still the best choice for the treatment of RR MS patients. As 
most of these therapies follow a rather ‘systemic approach’ with a more or less unspecific 
depletion of cell populations (e.g. Rituximab®, Mitoxantrone®), or immunomodulatory and 
immunosuppressive functions (Methylprednisolon, Avonex®, Copaxone®), there is still a 
need for effective therapies for the targeting of antigen-specific autoreactive cell populations 
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that contribute to the development of inflammatory lesions in the pathogenesis of multiple 
sclerosis.  
 
1.4 The myelin sheath and the demyelination process 
 
The myelin sheath is a dielectric phospholipid layer surrounding the axons of many neurons. 
It is often called ‚white matter’ and functions as insulator to electrical signals which are 
conducted down the axons as a neuron fires. Its main composition consists of 80% lipids 
(mainly cholesterol, galactocerebroside and sphingomyelin) and 20% proteins. The myelin of 
the peripheral nervous system (PNS) is formed by Schwann cells, whereas it is produced by 
oligodendrocytes in the central nervous system (CNS).  
 
 
Figure 4: The structure of a typical neuron. Neurons are composed of a ‘soma’ which contains the nucleus of the 
cell and ‘dendrites’, cellular extensions with branches that extend from the cell body of the neuron. They allow for 
a large number of neurons to interconnect forming a network. Dendrites detect the electrical signals transmitted to 
the neuron by the axon of other neurons. The ‘axon’ is along process that emerges from the cell body of a neuron. 
Its extremity divides into branches that connect to other neurons through synapses. Axons transmit messages 
under the form of an electrical signal. The insulating envelope of myelin (‘myelin sheath’) that surrounds the core 
of a nerve fiber or axon facilitates the transmission of nerve impulses by saltatory conduction. In the peripheral 
nervous system (PNS) the sheath is formed from the cell membrane of Schwann cells and in the central nervous 
system (CNS) from oligodendrocytes. Picture was taken from www.wikipedia.org. 
 
The myelin sheath around axons facilitates and increases the speed of nerve impulse 
transmissions along the myelinated nerve fiber. Action potentials are propagated by saltatory 
conduction, ‚hopping’ from one node of Ranvier to the other [74]. Additionally, the myelin 
sheath prevents the electrical current from leaving the axon and is responsible for the 
protection and nourishment of the axon [75]. In multiple sclerosis, inflammatory 
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demyelinating lesions are induced by various immune mechanisms including cytotoxic T 
lymphocytes, autoreactive antibodies and processes of the innate immunity. Active lesions 
within the CNS of MS patients are mainly composed of an interaction of these different 
mechanisms but the involvement of autoreactive cell populations differ in between patients’ 
cases. Some patients are characterized by lesions that are dominated only by autoreactive T 
cells and macrophages and others exhibit an immense accumulation of autoreactive 
immunoglobulins and complement proteins within demyelinating lesions. Autoreactive T 
helper cells and/or B cells are thought to be the key initiators of the myelin destruction. The 
trigger of the disease still remains to be investigated but one main hypothesis put forth that 
could reconcile the pathologic reactions and the etiology of multiple sclerosis is the process 
of ‘molecular mimicry’ [76, 77]. This phenomenon is thought to occur when peptides from 
pathogens share sequence or structural similarities with self-antigens [78]. The infection of 
the body with various pathogens, each with an individual molecular mimic to a CNS antigen, 
could explain the inability of investigators to relate one specific pathogen to MS. Molecular 
mimicry may be associated with human leukocyte antigen class I- and class II-restricted T 
cells and antibodies, which would explain the diversity in phenotype of this disease. Upon 
activation, these cell populations start to express integrins allowing them to bind to the 
endothelium next to the blood brain barrier. In parallel, the secretion of TNF-α and IFN-β 
induces the capillary endothelial cells to express VCAM and MHC class II molecules. Then, 
the activated cells are able to adhere and pass the ‚inflamed’ endothelium [79, 80]. The 
extracellular matrix, composed of type IV collagen is destroyed by gelatinases (matrix 
metalloproteinases) produced by activated autoreactive T lymphocytes [81, 82]. After 
entering into the CNS the immune reaction is directed against the entire supramolecular 
myelin complex. Autoreactive B lymphocytes secrete antibodies that bind to different proteins 
and lipids of the myelin sheath or to oligodendrocytes [83] leading to the activation of pro-
inflammatory complement components like C1, C3 and C9. The main targets of autoreactive 
T and B lymphocytes are found in the myelin sheath, including myelin basic protein (MBP) 
[84], myelin oligodendrocyte glycoprotein (MOG) [85, 86] and proteolipid protein (PLP) [87] 
and other associated proteins. The cytokine environment attracts macrophages, microglial 
cells and astrocytes leading to the phagocytosis of myelin fragments and the production of 
free radicals (NO) and inflammatory inducers [88]. This combined attack of T cells, B cells, 
complement, macrophages and inflammatory mediators is responsible for the demyelination 
process that is followed by axonal destruction and the loss of electrical conduction.  
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1.5 Autoantigens  
1.5.1 Myelin oligodendrocyte glycoprotein (MOG) 
 
This CNS-specific glycoprotein with a size of 26-28 kDa is located on the external surface of 
oligodendrocytes and as a minor component (0.05% of total myelin protein) on the peripheral 
lamellae of compact myelin sheaths in the central nervous system. MOG is a type I integral 
membrane protein with a single extracellular Ig variable domain (Ig-V) and its amino acid 
sequence is highly conserved among different species (>90%) indicating an important 
biological task in the body. In comparison to other myelin proteins, MOG is not expressed in 
the thymus leading to the fact that B and T lymphocytes are not subclonally deleted for this 
special antigen and potentially pathogenic MOG-reactive lymphocytes are retained within the 
healthy immune repertoire and may be activated due to mimicry with epitopes derived from 
environmental agents. It has been shown that MOG is recognized by autoreactive T 
lymphocytes predominantly over MBP and PLP by lymphocytes from more than 50% of MS 
patients [89, 90]. Subsequently, MOG showed a very high encephalitogenic potential in mice 
[91, 92], rats [93] and marmosets [94, 95] and is to date identified as a major target antigen 
in the pathogenesis of multiple sclerosis. The autoimmune reaction to myelin oligodendrocyte 
glycoprotein is mainly directed against the extracellular epitopes aa 1-22, 34-56 and 64-96 
(Figure 5).  
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Figure 5: Model for the myelin oligodendrocyte glycoprotein topology. The Ig-like domain and the associated N-
linked carbohydrate unit are located extracellularly followed by a hydrophobic transmembrane domain (aa 121-
151). The second hydrophobic domain is associated with the membrane without spanning it. The cystein residues 
177 and 198 appear to be ideal targets for reversible palmitoylation and providing a mechanism for further 
modulating the interaction of MOG with the cell membrane. It is proposed that long-chain fatty acids found in Gal-
C may interact with the lipid-modified form of MOG, although the exact nature of this interaction is unknown. 
Picture was modified from ref [96].  
 
1.5.2 Proteolipid Protein (PLP)  
 
The PLP gene encodes two strongly hydrophobic integral membrane proteins with 4 
membrane-spanning domains, PLP and its splice variant DM20. The DM20 protein differs 
from the PLP major isoform (30 kDa, 276 aa) by an internal deletion of 35 amino acids within 
exon 3. The PLP gene is strongly conserved in different species and shows the same amino 
acid sequence in man, mouse and rat. The PLP protein is the most predominant myelin 
protein in the central nervous system with a percentage of 50% and is thought to function as 
structure protein in the integrity of the extracellular surface of the plasma membrane and 
formation of the intraperiod line of myelin. PLP was the first myelin protein that has been 
identified as ‘encephalitogenic’ [97] and is associated with insoluble membrane fractions 
(lipid rafts) but its role in the formation of the myelin membrane is still ambiguous. Studies 
showed that PLP contains several encephalitogenic epitopes in several mouse strains [97-
101] with clusters in the amino acid residues 40-70 and 178-209. In addition, the residues 
90-119 can be considered as encephalitogenic since this region elicits a strong immune 
response in SWR mice, NZ/W rabbits and SJL/J mice [102].  
 
1.5.3 Other antigenic determinants in MS  
 
The myelin basic protein (MBP) which amounts up to 40% of total myelin protein is located at 
the interface of the cytoplasm and membranes of the CNS and PNS myelin interacting with 
lipid head groups by hydrogen bonding [103]. MBP has 170 amino acid residues (18.5 kDa) 
with 24% basic amino acids like lysine and arginine leading to a net charge of +20 at 
physiological pH and a high isoelectric point (pI > 10). MBP is responsible for the stabilization 
of compacted myelin by connecting opposite cytoplasmatic myelin membranes with its 
positive charging. MBP is not characterized by a special secondary or tertiary structure but 
the protein assumes random conformations depending on the surrounding medium in an 
aqueous environment. In lipid-rich surroundings, the protein has a tendency to fold [104] but 
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there is no formation of alpha- or beta-helices [105]. MBP is recognized as a potent 
encephalitogen that plays a major antigenic role in multiple sclerosis and its animal model - 
experimental allergic encephalomyelitis (EAE). The presence of MBP-reactive T cells in the 
blood of multiple sclerosis patients [106] and its encephalitogenic potential in several animal 
models lead to the appreciation of MBP as one of the main autoantigens in the myelin sheath 
with the residues 82-100 region being immunodominant for T cells and autoantibodies. The 
aa 82-100 peptide is binding to the disease-associated HLA-DR2 molecule and is recognized 
by restricted T cell clones from MS patients with a very high affinity. The same region is 
immunodominant for MBP-specific autoantibodies with a more precise localization to the 
residues 82-99 for tissuebound autoantibodies and residues 75-106 for free antibodies [107, 
108]. The myelin associated glycoprotein (MAG) has a size of ~100 kDa and amounts to 
approximately 1% of total protein in the myelin sheath and appears in two different isoforms 
resulting from alternative splicing of the MAG gene. It belongs to the immunoglobulin 
superfamily and shares a sulfated glucoronic acid carbohydrate epitope with several cell 
adhesion molecules. The MAG protein is proteolytically cleaved by activated proteases 
resulting in the appearance of a soluble, 90 kDa protein. The amount of this soluble form is 
dramatically increased in MS patients derived white matter [109]. Upon injection, MAG 
induces inflammatory lesions in the cerebellum, the centrum synoviale and in the forebrain of 
Lewis rats comparable to the distribution of lesions in MOG-induced animals [110]. In MS 
patients, MAG-reactive CD4+ T-cells with an increased secretion of interferon-γ and IL-2 can 
be found in the peripheral blood and the cerebrospinal fluid [111, 112]. Encephalitogenic 
epitopes evaluated by in vitro assays using peptide-specific HLA-A2 restricted CD8+ cytotoxic 
T-cells have been determined to residues 287-295, 509-517 and 556-564 [113]. The 
transaldolase (TAL) is a key enzyme of the pentose phosphate pathway and its presence 
can be linked to oligodendrocytes and the myelin sheath [114]. During development of the 
brain and myelination processes this enzyme plays a major role in providing components for 
biosynthesis of lipids and nucleic acids. In MS patients, anti-TAL antibodies and T cells 
reactive to the TAL protein were found [115]. Some non-myelin antigens also play a critical 
role in the pathogenesis of MS: S100β is a calcium-binding acidic peptide that can be found 
in astrocytes, in the PNS and in many other tissues in the body. The cellular transfer of 
S100β-reactive T lymphocytes into Lewis rats leads to a vast inflammatory response in spinal 
cord and cortex [116, 117] with a high amount of strongly autoreactive T cells. Further 
possible candidate autoantigens in the pathogenesis of multiple sclerosis are several heat 
shock proteins like hsp60 and hsp 70 [118, 119] and αB-crystallin. 
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1.6 Experimental allergic encephalomyelitis (EAE) 
 
Experimental allergic encephalomyelitis (EAE) is the animal model for multiple sclerosis and 
is generally used to evaluate therapeutic strategies that have been developed for MS. EAE 
displays several clinical and histological features of MS and is caused by inducing 
autoimmune reactions to autoantigens, typically protein antigens from the myelin sheath 
[120]. Upon peripheral injection of whole white matter or myelin derived peptides such as 
MOG, PLP or MBP applicated in complete Freund's adjuvant (CFA) or the direct transfer of 
autoreactive T cells in susceptible inbred rodent or monkey strains [121], animals develop a 
neuroinflammatory disease that is typified by limb paralysis. Pathologically, the model is 
associated with a disfunction of the blood brain barrier, the infiltration of mononuclear cells 
into the CNS and a conduction block, resulting in impaired neurotransmission. Some EAE 
models are characterized by significant axonal loss, which is the main reason for persistent 
disability of the animals. The clinical course is either acute or chronic relapsing and can vary 
depending on antigen, such as MOG, MBP or PLP, used for immunization, and on the 
strain/species of animal used [122]. While the acute course of EAE is comparable to the 
human acute disseminated encephalomyelitis (ADEM), the chronic relapsing course is 
similar to multiple sclerosis. Therefore the EAE model is a very useful model for studying the 
pathophysiology of immune responses in multiple sclerosis. The most important similarities 
between MS and EAE are: association of the disease with MHC II, the higher susceptibility of 
females, the association of early infection with relapses, the presence of several autoreactive 
cell populations (T cells, macrophages, B cells secreting antibodies) in the lesions, the 
degeneration of axons in the gray matter, inflammations in optic nerve, spinal cord and 
periventricular white matter and the presence of relapsing-remitting and proressive disease 
forms. The pathologic initiation of EAE was initially described as an interleukin-12 (IL-12) 
driven T helper (Th1) mediated disease. This assumption could be supported by the fact that 
the deficiency in the IL-12 gene in a transgenic mouse which is expressed in a Th1 response 
leads to the loss of susceptibility to EAE [123] and the use of anti-IL-12 antibodies are able to 
inhibit the development of EAE [124]. The priming process of autoreactive T lymphocytes 
occurs within the systemic immune compartment. After the immunization of susceptible 
animals with the above mentioned neuroantigens, activated encephalitogenic Th cells leave 
the lymphoreticular environment and invade the bodies’ tissues, scanning for antigen 
presenting cells presenting their cognate antigen. Apparently, myelin-reactive T cells get 
reactivated by MHC II-positive dendritic cells in the perivascular space enabling them to 
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invade the CNS parenchyma subsequently. There, T cells can activate resident microglia 
resulting in the secretion of vasoactive substances, cytokines and chemokines followed by 
the invasion of other leukocytes like macrophages and B cells [125]. The presence of 
inflammatory mediators including IL-23 finally leads to the development of a tissue lesion 
[126].  
 
1.7 Transgenic IgHMOG mice  
 
Transgenic mice are genetically modified animals carrying one or more inserted foreign 
genes in their genome. For the insertion, the structural gene additionally contains sequences 
for the incorporation into the host genome and the correct expression in the host cells. Two 
common methods are known for the generation of transgenic animals: the transformation of 
embryonic stem cells (ES cells) growing in tissue culture with the desired DNA and the 
injection of the desired gene into the pronucleus of a fertilized mouse egg. In the transgenic 
IgHMOG mouse model the rearranged VDJ gene of the heavy chain from the MOG-reactive 
hybridoma cell line 8.18-C5 was knocked-in to study the development and control of 
conditionally pathogenic B lymphocytes in vivo [127]. In detail, the genomic region containing 
the JH segments and the DQ52 elements was replaced by the rearranged VDJ anti-MOG 
gene in embryonic stem cells. The model has the advantage that in gene-targeted mice 
almost all B cells express transgenic IgH chains exclusively as identified using both allotypic 
and idiotypic markers. These heavy chains join with endogenous light chains to form a large 
population of MOG-reactive B lymphocytes with fully functional B cell receptors in the bone 
marrow and the periphery. As a result, high titers of MOG-reactive autoantibodies can be 
found in the serum of transgenic IgHMOG mice. The presence of high amounts of MOG-
reactive B lymphocytes being conditionally pathogenic lead to the predisposition of this 
mouse strain for an accelerated and very severe onset of EAE upon the challenge with MOG 
or other encephalitogenic CNS antigens in combination with CFA.  
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Figure 6: Transgenic IgHMOG mouse. These animals on a C57BL/6 background were generated by knock-in 
technology, inserting the recombined heavy chain of a demyelinating anti-MOG antibody (8.18-C5) in the Ig J 
region, yielding mice in which 30% of circulating B cells produce anti-MOG antibodies and express B cell 
receptors (BCR) that recognize MOG protein. Picture was modified from ref [128].  
 
1.8 Immunotoxins 
 
Immunotoxins were invented as a special class of antitumor drugs composed of a tumorcell-
specific binding domain and a toxic protein molecule [129]. By combining the binding 
specificity of the ligand (e.g. monoclonal antibodies) with the efficiency of the conjugated 
toxic protein, these fusion proteins can serve as an efficient therapeutic tool for a directed 
targeting and depletion of malignant cell populations [130]. Their mode of action is generally 
based upon the binding of the immunoconjugate to the specific target structure via its binding 
domain followed by receptor-mediated endocytosis. In the cytosol of the target cell, the toxin 
moiety gets activated upon cleavage and specifically inhibits the protein synthesis leading to 
its apoptosis [131]. The story of immunotoxins began 38 years ago when immunotoxins were 
produced by chemically coupling native toxins to a binding structure for target specific cell 
populations [132]. The efficacy of these first-generation immunotoxins in depleting specific 
tumor cells was demonstrated in clinical studies [133, 134] but their low in vivo stability [135] 
as well as the minor tumor penetration in solid tumors [136] due to their enormous size were 
serious obstacles in the development of novel and potent anticancer drugs. The laborious 
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chemical fusion procedure of two independently expressed and purified proteins led to the 
problem that it was impossible to generate a defined and reproducible amount of ligand-toxin 
fusion. Further problems concerned the specificity of the immunotoxin was the application of 
entire toxin proteins that still contained their natural binding domains harbouring the danger 
of unspecifically binding and eliminating non-targeted cells. The fundamental improvement in 
the generation of second-generation immunotoxins - still produced by chemically coupling 
technologies - was based upon the downsizing of therapeutic proteins by deleting the native 
binding domains of the toxin moieties leading to a significant higher binding specificity of the 
immunotoxins. Nevertheless, these therapeutic proteins still had the drawback of 
heterogeneity. Upon intravenous application, several immunotoxin compounds produced an 
unwanted effect that is called ‘vascular leak syndrome’ (VLS) triggered by the damage of 
unspecifically bound endothelial cells. The destruction of endothel can lead to severe 
leakage of fluid from the circulation into tissues, edema, hypotension and sometimes 
vascular collapses [137]. Recombinant DNA cloning techniques are substantially involved in 
the success of third-generation immunotoxins that are mainly composed of a cytokine, an 
antibody fragment (e.g. single chain or Fab fragments) or a growth factor in fusion with a 
potent toxin efficiently reducing the size of the therapeutic drug [138, 139]. The production of 
these recombinant proteins is inexpensive, homogeneous and reproducible while the 
bacterial expression system guarantees high expression rates. With the application of 
mutated toxin fragments e.g. the truncated form of Pseudomonas exotoxin A (ETA’) [140] or 
diphteria toxin (DT), the cytotoxic effect against target cell could be increased dramatically. 
They are internalized and transported to acidic compartments by endocytosis, then 
processed by furin cleavage and released into the cytosol. There, both toxins ADP-ribosylate 
elongation factor 2 causes the inhibition of protein synthesis and the apoptosis of the target 
cell. Another toxin moiety that was succesfully used for the generation of immunotoxins is 
ricin A, a plant toxin from the castor bean Ricinus communis which cleaves ribosomal RNA 
and thereby inhibits protein synthesis.  
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Figure 7: Mode of action of immunotoxins. In this picture, the properties of an immunotoxin are examplified by the 
antigen-specific targeting of an autoreative B lymphocyte. The immunotoxins bind to the B cell receptors on the 
surface of the target cell via its antigen binding domain (1) and is subsequently internalized by receptor-mediated 
endycytosis (2). After its release from acidified endosomes of from the Golgi-/ER-System into the cytosol, the 
toxic component (bacterial toxin, plant toxin, eukaryotic RNase) induces the inhibition of protein synthesis 
followed by the apoptosis of the cell. The picture was provided by Dr. Michael Stöcker (RWTH Aachen, Biology 
VII, Aachen, Germany).  
 
Preclinical evaluations of recombinant immunotoxins include the performance of cytotoxicity 
assays on their specific target cell lines in comparison to the effect on non-target cell lines. 
These experiments were expanded using immunodeficient mice strains. Human carcinoma 
cells were injected subcutaneously into these mice to produce solid tumors or intravenously 
for metastases induction. The animal data can provide essential in vivo toxicity data but 
monkey models (marmosets, rhesus monkeys) have a higher impact on evaluating the 
efficacy and specificity of the immunotoxins. Unfortunately the therapeutic properties for the 
treatment of solid tumors investigated until now are still disappointing because the size of the 
recombinant proteins limits the tumor penetration significantly. In addition, the treatment is 
accompanied by humoral responses against the toxin moieties of immunotoxins. In many 
hematologic cancer diseases, the immune system is defective and constant application of 
immunotherapeutics bears lower risk of antibody reactions. The main goal in designing novel 
and potent immunotoxins lies in the identification of new antigenic targets in malignant and 
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autoimmune diseases to enhance the specific binding and elimination of pathogenic cell 
populations.  
 
1.8.1 Immunotoxins for the depletion of autoreactive cells in MS 
 
Currently, immunotoxin applications are largely restricted to the treatment of malignancies. 
Autoimmune diseases like multiple sclerosis that are characterized by an immune response 
of autoreactive lymphocyte populations to own body tissues are mainly treated using 
systemic drug approaches without clear antigen specificities towards pathogenic cells. There 
have been some immunotoxin approaches for the treatment of experimental allergic 
encephalomyelitis (EAE) but most of these approaches were aimed for the depletion of 
activated T cells. DT390-IP-10 [141] could specifically target and eliminate activated T cells 
via the overexpressed CXCR3 chemokine receptor leading to a later onset of the disease 
and milder symptoms. The DAB(389)IL-2 immunotoxin [142] was able to deplete activated 
IL-2R positive T cells resulting in complete suppression during the active disease period and 
reduced infiltration of autoreactive cell populations into the spinal cord. Furtheron, T cell 
targeting was carried out via CCR5 chemokine receptor targeting using DT(390)-RANTES 
[143] and mMIP-Iα-DT(390) [144] leading to a later onset of the disease as well. Another 
approach succesfully concentrated on the targeting and elimination of antigen-presenting 
cells, mainly macrophages, via their IL-18 receptor leading to a reduction of inflammatory 
cells in the brain of mice compared to control groups [145]. These examples clearly 
demonstrate the general efficiency of immunotoxins in the depletion of autoreactive 
lymphocytes but these approaches still lack antigen specificity. Pathogenic cell populations in 
autoimmune diseases are all characterized by one major feature - their specificity for an 
autoantigen - resulting in the presence of antigen-specific receptors on their cell surface, 
namely the B cell receptor (BCR) on autoreactive B lymphocytes or the T cell receptor (TCR) 
on the surface of T cell populations. As these cell populations have a high specificity towards 
their cognate antigen, we developed novel immunotoxins that are composed of an 
autoantigen fragment directly fused to a potent bacterial toxin - ‘autoimmunotoxins’. The 
difference between the application of immunotoxins in cancer therapy and the application of 
autoimmunotoxins lies in the binding process and in cell specificity. The novel 
immunoconjugates are bound by the above mentioned receptors (BCR, TCR) on the surface 
of autoreactive cells whereas the standard immunotoxin actively binds to a certain target on 
a pathogenic or malignant cell population. As autoimmunotoxins are exclusively bound and 
internalized by their antigen-specific cell population, unspecific effects on other cell 
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populations can be generally excluded. The proof of principle was successfully established 
within our group by specifically targeting and eliminating grass pollen allergen-reactive B cell 
hybridomas as well as primary EBV-transformed B cells using an allergen-Pseudomonas 
exotoxin A (ETA’) conjugate [146]. In detail, the protein conjugate was specifically bound via 
its allergen domain and subsequently internalized by receptor-mediated endocytosis. The 
protein synthesis of the target cell was inhibited after cytosolic activation of the ETA’-toxin 
moiety leading to the apoptosis. In the present work, this concept was transferred to the 
application of autoimmunotoxins for the targeting of specific B cell populations in multiple 
sclerosis and its animal model EAE. The autoreactive domains of the myelin oligodendrocyte 
glycoprotein (MOG) and the proteolipid protein (PLP) were fused to the truncated version of 
the Pseudomonas exotoxin A (ETA’) for the specific targeting and depletion of MOG- and 
PLP-reactive B lymphocytes respectively. We have chosen the complete extracellular Ig-like 
domain of the myelin oligodendrocyte glycoprotein (MOG1-125) and a peptide sequence of the 
proteolipid protein (PLP88-152) as antigen domains. Both protein sequences contain major 
dominant B cell epitopes that serve as targets for autoantibodies in the pathologic humoral 
immune response of multiple sclerosis. Membrane-bound B cell receptors of autoreactive B 
lymphocytes are thought to bind to their specific antigen (autoantigen) followed by receptor-
mediated internalization of the protein for subsequent processing and presentation. That 
occurence will be fully utilized to deliver the recombinant autoimmunotoxins into their specific 
target cells leading to apoptosis and therewith to the elimination of these cell populations 
 
1.8.2 Expression of recombinant autoimmunotoxins  
 
The expression of ETA’-based autoimmuntoxins (AT) and control proteins without toxin 
moiety was carried out in a procaryotic expression system. Procaryotic expression systems 
are advantageous concerning their efficient and time-saving productions as well as their high 
expression rates. The cytoplasmic expression of proteins leads to the formation of inclusion 
bodies [147] containing non-functional protein products that require laborious de- and 
renaturating procedures for the purification of functional protein. The amount of functionally 
expressed proteins is often limited to <10% [148]. Based on this, an efficient expression 
plasmid called ‘pBM’ was developed by Matthey et al. [149, 150] where expressed proteins 
are transported into the periplasmic space enabled by a N-terminal fused signal sequence 
from Erwinia carotovora. The expression rate of recombinant proteins can be increased by 
the addition of compatible solutes [151]. Upon periplasmic extraction by easy sonication 
procedures, the proteins can be easily purified via their histidine tag. The disadvantages of 
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the procaryotic stress expression are missing posttranslational modifications or differences in 
the codon usage of pro- and eukaryotes. Furthermore, proteins with sizes above 80 kDa are 
difficult to express in adequate amounts. For the expression of eGFP fusion proteins in the 
human embryonic kidney cell line 293T, the pMS vector system [152] was used.  This 
expression system represents an alternative to the expression of proteins in bacteria as it 
has the major advantage of constantly producing the recombinant protein in a functional 
state without eliminating the producer cells. The successful transfection of 293T cells and the 
subsequent expression of recombinant eGFP proteins can easily be monitored by the 
presence of green fluorescent 293T cells using UV microscopy. To eliminate non-transfected 
cells and facilitate the growth of successfully transfected cells, the cultivation was continued 
under Zeocin® selection pressure resulting in green fluorescent clones. Due to the N-
terminal Igκ leader sequence which is encoded in the pMS plasmid, the recombinant proteins 
are efficiently transported - after their translocation via the endoplasmatic reticulum (ER) and 
the golgi apparatus - into the cells’ supernatant [152, 153]. The cultivation of transfected cells 
can be efficiently continued for several months without deviation in expression rates. 
 
1.9 Objectives 
 
This work was aimed to invent novel, tailor-made fusion proteins for specific targeting and 
elimination of autoreactive B lymphocytes in multiple sclerosis and its mouse model, EAE. 
For antigen-specific imaging purposes of autoreactive B lymphocytes in EAE and multiple 
sclerosis, two different fusion proteins were generated. Both MOG and PLP were cloned C-
terminally to the enhanced version of the green fluorescent protein (eGFP) in the pMS vector 
system, a eukaryotic expression vector for the transfection of 293T cells. The expressed 
proteins were secreted into the cell supernatant and could easily be purified. After 
characterization via western blot analysis using the above mentioned hybridoma cell 
supernatants, they were used as imaging tool for the direct staining of autoreactive B cell 
populations in flow cytometry and will subsequently be used to investigate the specific 
internalization of proteins in confocal microscopy and confocal microplate imaging (OPERA 
HCS System, Perkin Elmer). It was recently shown within our group that the application of a 
fusion protein composed of a grass pollen allergen fragment and a truncated version of a 
potent bacterial toxin, Pseudomonas exotoxin A (ETA’), exclusively binds to allergen-reactive 
B lymphocytes. The bound fusion protein was subsequently internalized through receptor-
mediated endocytosis, followed by inhibition of protein synthesis via the toxic moiety and 
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apoptosis of the target cells [146]. In the present work, this concept was adapted to the 
targeting and elimination of autoreactive B lymphocytes in MS. The autoantigens MOG 
(myelin oligodendrocyte glycoprotein) and PLP (proteolipid protein) were recombinantly 
fused to the truncated form of Pseudomonas exotoxin A and their specific toxic effect was 
evaluated on autoreactive B lymphocytes. As a negative control for toxicity assays, both 
proteins were cloned without toxic moiety. After the periplasmic expression of proteins in 
E.coli BL-21 DE3 cells under osmotic stress conditions, all proteins were purified by IMAC 
and subsequent size exclusion chromatography (SEC). The characterization of recombinant 
proteins was done by western blot and ELISA using antigen-specific antibodies. To 
determine the binding specificity and the toxic effect of autoimmunotoxins, MOG and PLP-
specific hybridoma cell lines were available. The supernatant of both cell lines was used to 
specifically detect MOG and PLP proteins in western blot and ELISA assays. The specific 
binding of recombinant proteins on the hybridoma cell lines was subsequently evaluated by 
flow cytometry. The above mentioned hybridoma cell lines were incubated with 
autoimmunotoxins to investigate their specific toxic potential. As a control, the autoantigens 
without toxin moiety were applied. Additionally, the depletion effect of the MOG-ETA’ 
autoimmunotoxin were investigated in vivo using the transgenic IgHMOG mouse model. The 
application of controlled doses of recombinant MOG-ETA’ protein and its resulting effect on 
the number of remaining MOG-reactive B lymphocytes were evaluated by subsequent 
splenocyte preparation and investigation by flow cytometry. To determine the influence of the 
autoimmunotoxin MOG-ETA’ on the disease progression of an EAE mouse model in DBA/1 
mice, the recombinant protein were applied 2 days after EAE induction and then every other 
day (6 applications in total). As a control, a non-specific immunotoxin with the same ETA’-
toxin moiety but another binding ligand were administered in a different group of EAE-
induced mice. Both groups were monitored for clinical symptom development signs over 14 
days.  
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   Figure 8: Flow chart of the PhD thesis.  
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2 Material and Methods 
2.1 Material 
2.1.1 Chemicals and Consumables 
  
Unless otherwise noted consumables and chemicals were purchased from Becton Dickinson 
Bioscience (Franklin Lakes, USA), BioRad (München), Biozym (Oldendorf), Clontech 
(Heidelberg), Corning Inc. (Schiphol-Rijk, Nederland), Cytogen (Obermörlen), Dharmacon 
(Lafayette, USA), Eppendorf (Hamburg), ICN (Eschwege), Greiner (Solingen), Hampton 
Research (Aliso Viejo), Hewlett-Packard (München), Invitrogen (Eggenstein), Kodak 
(Stuttgart), KMF Laborchemie (St. Augustin), Millipore (Eschborn), MWG-Biotech 
(Ebersberg), New England Biolabs (NEB; Schwalbach), Nunc (Wiesbaden), Novagen 
(Madison, USA), Pall Filtron (Northborough, USA), Perkin-Elmer (Applied Biosystems, Foster 
City, USA), Pierce (Rockford), Promega (Mannheim), Qiagen (Hilden), Roche Molecular 
Biochemicals (Mannheim), Roth (Karlsruhe), Sarstedt (Nümbrecht), Schott-Glaswerke GmbH 
(Neufahrn/San Diego), Serva (Heidelberg), Sigma (Deisenhofen), Starlab (Ahrensburg), 
Whatman (Maidstone, England), VWR (Darmstadt). 
 
2.1.2 Media stock solutions, buffers and equipment  
 
Standard medium buffer and stock solutions were prepared according to standard 
procedures using de-ionized water. Solutions were sterilized by autoclaving (25 min/121°C/2 
bar). Heat-sensitive components, such as antibiotics, were prepared as stock solutions, filter-
sterilized (0.2µm) and added to the medium/buffer after cooling below 50°C. To adjust the 
pH, 1M HCl or 1M NaOH was used. 
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    Tab. 1: Used equipment 
Application Equipment 
Centrifuges MicrofugeR, Avanti J-30I Centrifuge, Allegra 6KR Centrifuge 
(Beckman, Fullerton, USA),  
Biofuge Pico (Heraeus Instruments, Hanau, Germany) 
Picofuge (Stratagene, Heidelberg, Germany) 
Rotilabo Centrigue with Butterfly-Rotor (Roth, Karlsruhe, 
Germany) 
Rotors F241.5, 16.250, JA-30.50, GH 3.8 (Beckman, Fullerton, USA) 
#3324 (Heraeus Instruments, Hanau, Germany) 
Gelelectrophoresis Mini Protean III gel chamber (BioRad), XCell II Blot 
Module (Invitrogen), Protein Gel-Apparatus and 
supplies Mini PROTEAN II™, Gel Air Dryer (BioRad) 
DNA sequencing ABI Prism 3700 Capillary-Sequencer (Perkin-Elmer) 
Incubators Innova™ 4340 incubator shaker (NewBrunswick 
Scientific), Thermomixer compact (Eppendorf) 
Vortex Vortex-Genie 2 (Scientific Industries Inc., Bohemia, USA) 
PCR-Cylers Primus 96 Plus (MWG-Biotech), Programmable Thermal 
Controller PTC-200™ (MJ Research Inc., Watertown, 
USA) 
Incubators Innova™ 4340 incubator shaker (NewBrunswick 
Scientific), Incubator (Heraeus Instruments), 
Thermomixer compact (Eppendorf) 
Laminar flow Hera Safe HS12 (Kendro) 
Photometer Biophotometer (Eppendorf) 
ELISA plate reader Elisareader ELx808 (Bio-TEK) 
Transilluminator Molecular Imager Gel Doc XR System; Biorad 
Software AIDA image analyzer 
Electroblotting 
equipment 
Mini Trans-Blot Cell (Biorad) 
Flow cytometry FACScalibur, Becton Dickenson 
Pipetting Pipetman P (Gilson) Multichannel Pipettes (Eppendorf) 
Protein purification Äkta Purifier (Amersham Pharmacia Biotech, Freiburg) 
Sonication Sonication probe UW2070 (Bandelin Electronic, Berlin) 
Micro tip MS72, micro Tipp MS73 
Cell washer  Dade Serocent Cell Washer (Baxter, LA, USA) 
Fluorescence microscopy DM R fluorescence microscope (Leica), Leica L5 filter cubus 
Life cell imaging OPERA HCS System (Perkin Elmer) 
Confocal microscopy Leica DM RE + TCS SP confocal laser microscope (Leica) 
 
 
2.1.3 Standard buffer and media compositions 
 
The following standard buffers and media were used: 
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Tab. 2: Standard buffers and media compositions 
No. Buffer Composition Concentration 
1 10xPBS (pH 7.4) 
NaCl  
KCl  
Na2HPO4 x 12H2O  
KH2PO4  
1.37 
27  
81 
15 
 M 
 mM 
 mM       
 mM 
2 
1xPBST 
 
1x PBS (pH 7.4) 
Tween 20  
 
0.05 
 
% (w/v) 
3 
50x TAE 
Electrophoresis 
Buffer (pH 7.5) 
Tris-base  
Glacial acetic acid  
EDTA  
2      
5.7 
50  
M 
% (v/v) 
mM 
4 
5x OrangeG Loading 
Buffer 
OrangeG  
Glycerol  
 
0,01 
30    
in 1x 
TAE 
% (w/v) 
% (v/v) 
 
5 
5x SDS PAGE 
running buffer  
 
Tris-HCl (pH 8.3)  
Glycine  
SDS  
125  
960 
0.5 
mM 
mM 
% (w/v) 
6 
Coomassie Staining 
Solution 
Coomassie bb. G-250  
Methanol   
Glacial acetic acid  
0.25 
50    
9      
%(w/v) 
% (v/v) 
% (v/v) 
7 
Coomassie 
Destaining Solution 
Methanol  
Glacial acetic acid  
10    
10 
% (v/v) 
% (v/v) 
8 
5x Reducing Protein 
Loading Buffer 
Tris-HCl (pH 6.8)  
Glycerol  
SDS  
Bromphenolblue  
ß-Mercaptoethanol  
62.5 
30  
4    
0.05  
10  
mM 
% (v/v) 
% (w/v) 
% (w/v)  
% (v/v) 
9 
5x Non-Reducing 
Protein Loading 
Buffer 
Tris-HCl (pH 6.8)  
Glycerol  
SDS  
Bromphenolblue  
62.5 
30 
4    
0.05  
mM 
% (v/v) 
% (w/v)  
% (w/v) 
10 
10xTBE 
electrophoresis 
running buffer 
Tris-HCl 
H3BO3 
EDTA (0,5 M) 
0,685  
0,9      
0,02  
M 
M 
M 
11 
SDS PAGE gel  
(Separating gel) 
 
Acrylamide/Bisacrylamide (30/1) 
Tris-HCl (pH 8.8) 
SDS (10 %, w/v) 
TEMED 
APS (20%, w/v) 
x  
375 
0,1    
0,1 
0,1  
mL 
mM 
% (w/v) 
% (v/v)  
% (v/v) 
12 
SDS PAGE gel 
(stacking gel) 
Acrylamid/Bisacrylamide (30/1) 
Tris-HCl (pH 6.8) 
SDS  
TEMED 
APS 
5 
150 
0,1  
0,1 
0,1  
% (w/v) 
mM 
% (m/v) 
% (v/v) 
% (v/v) 
13 LB (pH 7.0) 
NaCl 
Peptone 
Yeast extract 
1 
1 
0,5 
% (w/v) 
% (w/v) 
% (w/v) 
14 SOC  
Peptone 
Yeast extract 
NaCl 
KCl 
MgCl2 
MgSO4 
glucose 
2% 
0,5% 
10 
25 
10 
10 
20 
(w/v) 
(w/v) 
mM 
mM 
mM 
mM 
mM 
14  
Erythrocyte lysis 
buffer 
KHCO3 
NH4Cl 
EDTA (pH 8.0) 
10 
150 
0.1 
mM 
mM 
mM 
15 TfBI buffer RbCl 100 mM 
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MnCl2 
Potassium acetate 
CaCl2 
Glycerine, sterile 
50  
30 
10 
15%  
mM 
mM 
mM 
(v/v) 
16 TfBII buffer  
RbCl 
MOPS 
CaCl2 
Glycerine, sterile 
10 
10 
75 
15% 
mM 
mM 
mM 
(v/v) 
17 Blotting buffer 
Tris-HCl, pH 8.3 
Glycine 
methanole 
25 
192 
20% 
mM 
mM 
(v/v)  
18  AP buffer 
Tris-HCl, pH 9.6 
NaCl 
MgCl2 
100 
100 
5 
mM 
mM 
mM 
19 ELISA Coating buffer 
Na2CO3 
NaHCO3 
1,59 
2,93 
g 
g 
 
 
2.1.4 Kits  
 
Restriction enzymes, ligases, dephosphorylation enzymes, restriction buffers and bovine 
serum albumin (BSA) were all supplied by New England Biolabs (Frankfurt am Main) and 
Roche Molecular Biochemicals (Mannheim). The enzymes were applied following the 
manufacturers’ instructions. The following kits were used:  
 
• QIAprep Spin Miniprep Kit (Qiagen, Hilden)  
• QIAfilter Plasmid Maxi Kit (Qiagen, Hilden)                                  
• QIAquick gel extraction Kit (Qiagen, Hilden)          
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2.1.5 Buffers for protein work      
  
Tab. 3: Buffers for protein work 
No. Buffer Composition Concentration 
1 Protein extraction buffer 
Tris-HCl, pH 8.0 
NaCl 
DTT 
EDTA 
Glycerole 
Protease inhibitor 
75 
300 
5 
10 
10%  
1 
mM 
mM 
mM 
mM 
(v/v) 
Tabl./50mL 
2 4x incubation buffer  
NaH2PO4, pH 8.0 
NaCl 
Imidazole 
200 
1.2 
40 
mM 
M 
mM 
3 Elution buffer 
NaH2PO4, pH 8.0 
NaCl 
Imidazole 
50 
300 
250 
mM 
mM 
mM 
4  SEC running buffer  
PBS 
NaCl   
1 
1 
 x 
M  
5  Lyophilization buffer  
NaH2PO4, pH 7.5 
NaCl 
10 
150 
mM 
mM 
 
 
2.1.6 Antibodies and enzyme-labelled antibodies 
 
For the detection of recombinant proteins in western blotting and ELISA, the following 
antibodies were used:  
 
• mouse-anti-penta-His [α penta-His Ab] (Qiagen, Hilden): monoclonal mouse antibody for 
the detection of the C-/N-terminal histidin-tag of recombinant proteins 
• goat-anti-mouse, horseraddish peroxidase (HRPO) labelled [GαMHRPO (α-IgG Fc)] 
(Sigma Aldrich, Taufkirchen): polyclonal antibody for the detection of the Fc part of murine IgG  
• goat-anti-mouse, alkaline phosphatase (AP) labelled [GαMAP (α-IgG Fc)] (Sigma 
Aldrich, Taufkirchen): polyclonal antibody for the detection of the Fc part of murine IgG 
• 8.18-C5: monoclonal mouse antibody from hybridoma supernatant for the detection of the 
extracellular domain of MOG (University of Aberdeen, UK) 
• F4-2D2: monoclonal mouse antibody from hybridoma supernatant for the detection of the aa 
100-123 domain of PLP (Harvard Medical School, Boston, USA) 
• F3-9E9: monoclonal mouse antibody from hybridoma supernatant for the detection of the aa 
50-69 domain of PLP (Harvard Medical School, Boston, USA) 
 
The binding activity of the different myelin fusion proteins in flow cytometry was investigated 
using the following antibodies:  
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• rat-anti-mouse CD19, phycoerythrin (PE) labelled [RAMPE (α-CD19)] (BD 
Biosciences, Heidelberg, Germany): mlonoclonal rat antibody for the detection of mouse 
CD19  
• goat-anti-mouse IgG, F(ab’)2, fluorescein isothiocyanate (FITC) labelled [GAMFITC 
(α-IgG heavy/light chain)] (Millipore, Schwalbach, Germany): polyclonal antibody for the 
detection of the heavy and light chain of murine IgG 
• mouse-anti-penta-his, ALEXA Fluor® 488 Conjugate (Qiagen, Hilden): monoclonal 
mouse antibody for the detection of the C-/N-terminal histidin-tag of recombinant proteins 
 
2.1.7 Bacterial strains 
 
For amplification and cloning of recombinant plasmids, the following Escherichia coli strain 
was used: 
 
• XL1-Blue: genotype: supE44 hsdR17 recA1 endA1 gyr A46 thi relA1 lacF’ [pro AB+ lacIq 
lacZ∆M15 Tn10(tetr)] (Stratagene, California, USA) 
 
For recombinant protein expression, the following Escherichia coli strain was used:   
 
• BL21(λDE3): genotype: F- ompT hsdSB (rB
- mB
-) gal dcm- lon- (Novagen, Wisconsin, USA). 
 
2.1.8 Eucaryotic cell lines 
 
The following cell lines were used for the expression and for the functional verification of 
recombinant proteins: 
 
• HEK 293T: ATCC-Nr.: CRL-11268; human embryonic kidney cells; adherent; [154] 
 
• 8.18-C5: murine hybridoma cell line, specific for the extracellular domain of the myelin protein 
MOG; suspension growth; [155] 
 
• F4-2D2: murine hybridoma cell line, specific for the aa 100-123 of the myelin protein PLP; 
suspension growth; [156] 
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• F3-9E9: murine hybridoma cell line, specific for the aa 50-69 of the myelin protein PLP; 
suspension growth; [156] 
 
2.1.9  Vector systems 
 
• pBM1.1 bacterial expression vector              
 
The pBM1.1 expression vector [150] was used for the cloning and expression of recombinant 
immunotoxins. It is derived from the bacterial expression vector pET27b (Novagen, Madison, 
USA) and was kindly provided by Dr. Michael Stöcker (RWTH Aachen, Biology VII, Aachen). The 
vector is available with a deletion mutant of the Pseudomonas exotoxin A (ETA’) allowing the 
direct cloning of specific ligands or antibodies to the 5’-end of the ETA’ translocation domain.  As 
target vector for the cloning of autoimmunotoxins, the pBM-PV-ETA’ (Figure 9B) which is 
composed of a grass pollen allergen fragment (PV) and the ETA’ toxin domain was used [146]. 
Additionally the pBM vector is available as pBM-PV expression plasmid (Figure 9A) containing 
the PV fragment without ETA’ toxin domain. To generate novel expression plasmids, the PV 
fragments are cut out by SfiI/NotI digest, followed by the insertion of the SfiI/NotI digested genes 
of interest (2.1.10). The N-terminal His10-tag enables the purification and detection of the 
recombinant proteins. Furthermore, the plasmid contains a leader sequence for the pelB-directed 
periplasmic secretion of expressed protein under the control of a T7lac promoter.  
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Figure 9: pBM expression plasmids. The genes of interest (2.1.10) were cloned into the above mentioned pBM-
PV vector systems which contain a leader sequence for pelB-directed periplasmic secretion of expressed protein 
under the control of a T7lac promoter. For purification via affinity chromatography a poly-histidine cluster is 
introduced into the plasmid. For expression in E.coli BL-21 DE3 the pBM plasmids are available without fusion 
partner (A) and in fusion with a deletion mutant of the Pseudomonas Exotoxin A (B). 
 
• pMS eukaryotic expression vector 
 
The pMS expression vector is a derivative of the pSecTag2 vector (Invitrogen, Carlsbad, 
USA) and the pIRES-eGFP vector (Clontech, Mountain View, USA) [157] and is used for the 
eukaryotic expression of GFP fusion proteins. The successful transfection of eukaryotic cells 
and the subsequent establishment of transfected cell populations can be controlled by UV 
microscopy. The ampicillin resistance gene (AmpR) and the bacterial origin of replication 
(ColE1) are used for plasmid propagation in E. coli. The Zeocin resistance gene (ZeoR) 
permits the selection of transfected cells. The mouse Igk-leader (Igk-L) is responsible for the 
secretion of recombinant protein into the cell supernatant. As target vector for the cloning of 
novel eGFP fusion proteins, the pMS-L-eGFP-PV expression plasmid from Dr. Michael 
Stöcker (RWTH Aachen, Biology VII, Aachen) was used. The genes of interest can be 
inserted into the SfiI/NotI digested pMS plasmid from Figure 10.  
 
 
 
Figure 10: Schematic illustration of the pMS-L-eGFP-PV expression plasmid. The expression of recombinant GFP 
fusion proteins occurs under the control of the CMV promotor (pCMV). The Igκ-leader sequence is responsible for 
the secretion or recombinant proteins into the cell supernatant. For the detection and purification of proteins the 
plasmid contains a carboxyterminal his-tag and a successional myc-tag. Both tags can be detected by their 
specific antibody. The Zeocin®-resistance gene permits the selection of transfected cells in Zeocin®-containinig 
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medium while expressed eGFP leads to strongly fluorescent cells. Thereby a differentitation between transfected 
and untransfected cells is possible. According to the pBM plasmid the restriction sites SfiI and NotI serve as 
appropriate insertions sites for the genes of interest (2.1.10) into the pMS vector.   
 
2.1.10 Myelin protein clones 
 
The following full length clones of myelin oligodendrocyte glycoprotein (MOG) and proteolipid 
protein (PLP) were ordered at ImaGenes (Berlin, Germany). The required protein domains 
for the generation of fusion proteins were amplified by polymerase chain reaction (PCR) 
using sequence-specific primers. In addition, SfiI/NotI restriction sites for the cloning into the 
target vectors (2.1.9) were added.  
 
    IRAK p961L06176Q - murine MOG full length cDNA clone  
 
    IRAV p968G0365D - murine PLP full length cDNA clone 
 
2.2 Methods 
 
2.2.1 Polymerase Chain Reaction (PCR) 
 
The polymerase chain reaction (PCR) was carried out following the protocol of SAIKI et al. 
[158]. The PCR reaction was prepared as follows in 25 µl samples in 200 µl „PCR-strip“ 
reaction tubes:  
 
Tab. 4: Concentration and volume of the used PCR components 
component end concentration/volume 
10x Taq DNA Polymerase Buffer 1x 
dNTP-Mix (1,25 mM/dNTP) 0,2 mM 
MgCl2 1,5 mM 
5´-Primer 5-10 pmol 
3´-Primer 5-10 pmol 
Template DNA 1-10 ng 
Taq-DNA Polymerase 1 U 
Aqua bidest. (sterile) ad 25 µl 
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Tab. 5: PCR reaction protocol 
 temperature [°C] time [min] step  
1. 95 3 initial denaturation  
2. 95 0.5 denaturation 
3. TP 0.5 primer annealing 
4. 72 1 elongation 
 
    X30 cycles 
5. 72 7 final elongation  
 
 
The optimal primer annealing temperature was determined experimentally (by temperature 
gradient PCR) as the highest annealing temperature at which the PCR reaction still worked 
with good amplification rates. At the end of the PCR reaction the amplified products were 
separated by preparative agarose gel electrophoresis (2.2.4.2). After determining size, purity 
and amount the PCR product was isolated from the gel and used for subsequent cloning 
steps.  
 
2.2.2  Synthetic oligonucleotides  
 
All synthetic oligonucleotides (primer) were purchased from MWG Biotech (Ebersberg). The 
primers were diluted following the manufacturers instructions and were used for PCR 
reactions and for the sequencing of cloned DNA fragments.  
 
Tab. 6: Synthetic oligonucleotides used for cloning and sequencing of cloned DNA fragments.  
name sequence 
cloning primer  
MOG-5’-Sfi-for 5‘-GAGTGGCCCAGCCGGCCATGGCCTGTTTGTGGAGCTT-3‘ 
MOG-3’-NotI-back 5‘-AGCTGCGGCCGCAAGGGGGTTTCTTAGCTCTTC-3‘ 
MOG-3’-GlySer-Sfi-back 5‘-GCTCGGCCGGCTGGGCCCCCGAGCCACCGCCACCTGAAAGGGGGTTTCTTAGCTCTTC- 3‘ 
PLP-5’-Sfi-for 5‘-GAGTGGCCCAGCCGGCCATGGGCTTGTTAGAGTGTTG -3‘ 
PLP-3’-NotI-back 5‘-AGCTGCGGCCGCGAACTTGGTGCCTCGGCCC-3‘ 
PLP-3’-GlySer-Sfi-back 5‘-GAGCGGCCGGCTGGGCCCCCGAGCCACCGCCACCTGAGAACTTGGTGCCTCGGCCC-3‘ 
PLP-AS151-back 5’- AGCTGCGGCCGCCACAAACTTGTCGGG-3’ 
PLP-II-for 5- GAGTGGCCCAGCCGGCCGAGGGCTTCTACACCACC-5’ 
sequencing primer  
Seq-GB-for 5’-CAGATCATAAGAAAAGCCATG-3’ 
pMS-Seq-Sac-back 5‘-GCTCTCTGGCTAACTAGAGAACCC-3‘ 
Seq-pBM-Blp-for 5‘-CGCCGCTACAGGGCGCGTCC-3‘ 
5‘-pBM-seq-forw 5‘-GCTGCTGGTCTGCTGCTCCTCGC-3‘ 
3‘-pBM-seq-back 5‘-CCGCGCGGCTGGCGATGACGGG-3‘ 
3‘-Seq-pBM 5‘-CCCGCCGCGCTTAATGCGCCGC-3‘ 
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3_ETA 5’-CCAGCGGCAGGTGGCAGG-3’ 
5’-pMT 5’-GTCTGCTGCTCCTCGCTGC-3’ 
GFP-back 5’-CCAGGATGTTGCCGTCCTCC-3’ 
H22-back 5’-GCTCAGGCTGCTTGGGC-3’ 
MOG for 5’-GCCTGTTCTTGGACCCCTGG-3’ 
MOG reverse 5’-GGGAAATCAAGTTCTACTCGG-3' 
PLP for 5’-GGCTCCTGCTAGAAATGGG-3’ 
PLP reverse 5’-GGAGGCAGATTTGGGCAAATGC-3’ 
SP6 5’-ATTTAGGTGACACTATAG-3’ 
T3 5’-TAATACGACTCACTATAGGG-3’ 
T7 5’-ATTAACCCTCACTAAAGGGA-3’ 
 
2.2.3 DNA cloning techniques 
 
2.2.3.1 Restriction of DNA 
 
The restriction of DNA was performed with the supplied buffers following the manufacturers’ 
instructions. The restriction endonucleases and specific buffers were purchased from New 
England Biolabs (NEB, Ipswich, USA). The restriction of DNA with two different 
endonucleases (double digest) was carried out following the manufacturers’ instructions in 
the most appropriate buffer system. 
 
2.2.3.2 Dephosphorylation of restricted vectors  
 
The dephosphorylation of restricted plasmid DNA (2.2.3.1) was carried out using the shrimp 
alkaline phophatase (SAP, Roche Diagnostics GmbH, Mannheim) following the 
manufacturers instructions. SAP catalyzes the 5’-phosphate of DNA and prevents the 
religation of the plasmid after restriction.    
 
2.2.3.3 Ligation of restricted DNA 
 
The ligation of two restricted DNA fragments (2.2.3.1) was performed using T4-DNA-Ligase 
(NEB) following the manufacturers’ instructions in a total volume of 10-20 µl. The ligation 
reactions with „sticky end“ DNA fragments contained the insert in a 3 times molar excess to 
the vector amount and was incubated for 30 minutes at room temperature.  
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2.2.3.4 Precipitation and determination of DNA concentration  
 
2.2.3.4.1 Ethanol precipitation 
 
Ethanol precipitation was used for the recovery of DNA fragments from PCR reactions (2.2.1) 
or restriction endonuclease digestion (2.2.3.1). 1/10th volume of 3M NaOAc pH 5.4 was 
added to the nucleic acid solution and then 2.5 volumes of pure ethanol were added. After 
vortexing, the mixture was incubated at -80°C for 15 min and subsequently centrifuged at 
4°C for 15 min at 25.000xg. After centrifugation the supernatant was removed leaving a 
pellet of crude DNA.  Subsequently, the pellet was washed with 150µL 70% (v/v) ethanol and 
centrifuged again for 5 min. The supernatant was removed again and the pellet is dried at RT 
for 5 min. Finally, the pellet was resuspended in H2O. 
 
2.2.3.4.2 Isopropanol precipitation 
 
The DNA samples were mixed with the 0.7 times volume of isopropanol and stored for 30 
minutes at room temperature. The precipitated DNA was pelleted by centrifugation 
(13.000xg/20min/4°C), the pelletwas washed with 70% (v/v) ethanol and centrifuged again 
(13.000xg/5min/4°C). The DNA was dried at RT, resuspended in sterile water and stored at -
20°C.   
 
2.2.3.4.3 Determination of DNA concentration 
 
For the determination of DNA concentration an analytical agarose gelelectrophoresis was 
carried out (2.2.4.1). The estimation of DNA concentration in ethidium bromide agarose gels 
was performed by comparison of the fluorescence intensity of the DNA fragments with 
marker DNA (2-Log DNA Ladder, NEB) of known concentration at 302nm [159].  
 
2.2.4 Agarose gel electrophoresis 
2.2.4.1 Analytical agarose gel electrophoresis of DNA 
 
Plasmids (2.2.7), restriction fragments (2.2.3.1) and PCR products (2.2.1) were separated by 
analytical agarose gel electrophoresis regarding their size and concentration (2.2.4.1). The 
separation of DNA fragments was carried out using 0.8-2% (w/v) agarose gel at a field 
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intensity of 4-5V/cm. The electrophoresis was performed following the protocol of Sambrook 
et al. [159] in 1xTAE buffer with 0.1µg/mL ethidium bromide. 1µg of 2-Log DNA Ladder 
(NEB) served as size and concentration standard. After the electrophoretic separation the 
DNA fragments were visualized using the Molecular Imager Gel Doc XR System (BioRad, 
Hercules, USA) at a wavelength of 302nm.           
 
2.2.4.2 Preparative agarose gel electrophoresis of DNA  
 
For the isolation of PCR products (2.2.1) or restricted DNA (2.2.3.1) a preparative agarose 
gel electrophoresis (2.2.4.2) was carried out. After separation of DNA fragments the band of 
interest was visualized on a UV transilluminator and cut out of the gel using a scalpel. The 
DNA was purified from the gel using the QIAquick gel extraction kit (Qiagen, Hilden, 
Germany) following the manufacturers instructions. The concentration of purified DNA was 
determined by agarose gel electrophoresis (2.2.4).  
 
2.2.5 Culturing of bacteria 
 
The culturing of E.coli bacteria was performed in LB medium overnight (37°C, 225rpm) on a 
shaker. For the selection of recombinant clones after transformation (2.2.6) agar plates with 
100µg ampicilline or 25µg kanamycine per mL respectively was used (incubation overnight at 
37°C). E. coli glycerol stocks were established by culturing recombinant cultures in LB 
medium with the required antibiotic overnight. 700µl of the ON bacterial culture was mixed 
with 700µl sterile glycerine 40% (v/v) in sterile Eppendorf tubes and the glycerol stocks were 
shock-frozen in liquid nitrogen and stored at -80°C. 
 
2.2.6 Transformation of bacteria with plasmid DNA 
 
The transformation of competent bacteria served for the introduction and amplification of 
plasmid DNA and was carried out using the heat shock transformation protocol. Rubidium 
chloride competent E.coli were manufactured following the protocol of Maniatis et al. [159]. 
Plasmids were transformed into competent E. coli DH5α using 5µl of the ligation reaction 
(2.2.3.3) mixed with 50µl of competent E. coli cells. The mixture was incubated for 10 
minutes on ice, 90 seconds at 42°C, and then again on ice for 5 minutes. Then 800µl SOC 
medium was added and the expression of the ampiciliin resistance gene was induced for 30 
minutes at 37°C while shaking. The transformed bacteria were plated on LB-Amp/Kan agar 
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plates (100µg ampicillin/mL; 25µg kanamycin/mL) and incubated at 37°C for 16h. The 
identification of recombinant clones was additionally verified by plasmid minipreparation 
(2.2.7.1), control digest of plasmid DNA (2.2.3.1) and subsequent agarose gel 
electrophoresis (2.2.4.1). 
 
2.2.7 Preparation of plasmid DNA from E. coli 
 
2.2.7.1 Minipreparation of plasmid DNA from E. coli 
 
For minipreparation of plasmid DNA the clones of transformed bacteria (2.2.6) were 
incubated at 37°C overnight in 5mL LB medium supplemented with kanamycin or ampicillin. 
The bacterial cultures were then pelleted by centrifugation (7000xg/5min/RT) and the DNA 
was purified using the QIAprep Spin Miniprep Kit (Qiagen) following the manufacturers’ 
instructions. 
 
2.2.7.2 Maxipreparation of plasmid DNA from E. coli 
 
For the isolation of larger amounts of plasmid DNA a maxipreparation of plasmid DNA was 
carried out using the Qiagen Plasmid Midiprep Kit (Qiagen) following the manufacturers 
instructions. The concentration of isolated DNA after restriction digest was determined by 
analytical agarose gel electrophoresis (2.2.4.1). 
 
2.2.8 DNA sequencing  
 
DNA sequencing reactions were based on the Dideoxy-chain-termination-method described 
by Sanger et al. [160]. Fluorescent labeled dideoxynucleotides were used for sequencing of 
genes or DNA fragments of interest. Sequencing analysis was performed by using an “ABI 
Prism 3700” Capillary-Sequencer (Applied Biosystems) and BigDye™ cycle sequencing 
terminator chemistry. The extension products were detected by exciting the unique dyes 
attached to each dideoxynucleotide with a laser, followed by a measurement of fluorescent 
emission using a CCD camera. Subsequently, the signals were interpreted by the Applied 
Biosystems Sequencing Analysis Program in order to determine the nucleotide sequence of 
the DNA template. Resulting chromatograms and sequences were analyzed with DNA-Star 
software.                  
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Tab. 7: PCR reaction for the sequencing of DNA 
reaction step temperature [°C] time 
28 cycles: 
denaturation 
primer annealing 
chain elongation 
 
98 
52 
59 
 
10 sec 
10 sec 
3 min 
 
2.2.9 Cell culture  
 
All cell culture works were carried out on a Hera Safe HS12 clean bench (Kendro, Hanau). 
The used cell lines were cultured in RPMI 1640 medium (Gibco, Karlsruhe, Germany) 
supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS) (Gibco, Karlsruhe, 
Germany), 50µg/mL penicillin and 50µg/mL streptomycin. The cells were maintained at 37°C 
in a humidified atmosphere of 5% CO2.  
 
2.2.9.1 Transfection of eukaryotic cells 
 
The transfection of eukaryotic cells was carried out using Rotifect®, a synthetic cationic lipid 
(Roth, Karlsruhe) following the manufacturers instructions. The applied plasmids contain the 
eGFP (enhanced green fluorescent protein) reporter gene. The transfection rate of 293T 
cells amounts of 50-80% and was verified by UV fluorescence microscopy using an 
excitation wavelength of 488nm. Transfected cells were subsequently transferred into cell 
culture vessels (75 cm2) and further on grown under antibiotic selection using Zeocin® 
(Invitrogen, Carlsbad, USA).  
 
2.2.9.2 Culturing and maintaining of hybridoma cell lines  
 
The myelin oligodendrocyte glycoprotein (MOG) specific hybridoma cell lines 8.18-C5 was 
kindly provided by Professor Christopher Linington (University of Glasgow, Department of 
Clinical Neuroscience, Glasgow, UK). The proteolipid protein (PLP) reactive hybridoma cell 
lines F3-9E9 and F4-2D2 were kindly made available by Professor Vijay Kuchroo (Harvard 
Medical School, Boston, USA). All hybridoma cell lines were delivered on dry ice. For 
thawing the vials were placed to a water bath at 37°C for one minute until a small piece of ice 
was left inside. The thawed cells were transferred in 10mL of RPMI medium in a sterile 15mL 
Greiner tube, spun down for 5 minutes at 200 rpm, the supernatant was discarded and the 
pellet resuspended in 10mL of fresh RPMI medium supplemented with 20% (v/v) FCS. The 
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hybridoma cells were splitted 1:10 every 3 days in fresh RPMI medium and were exchanged 
by freshly thawed samples every three months. To freeze the cells they were collected in an 
exponential growing phase at >90% viability in a 50mL Greiner tube and spun down for 5 
minutes at 200 rpm. The supernatant was discarded, the cells were resuspended in fresh 
and sterile freezing medium (90% (v/v) FCS, 10% (v/v) DMSO) and subsequently aliquoted 
in 1mL samples in sterile cryogenic vials. The vials were kept at -20°C for 1 hour and then 
placed into the -70°C freezer. After 24h, the vials were transferred to liquid nitrogen for long 
time storage. 
 
2.2.9.3 Preparation and culturing of splenocytes from transgenic IgHMOG mice 
 
Transgenic IgHMOG mice were sacrificed by neck dislocation. The mice were placed on their 
right side, the fur was rinsed with 70% (v/v) ethanol and the skin of the left side overlying liver 
and spleen was incised. The revealed muscle layer was lifted away from the body cavity and 
a large incision across the body wall was made. Subsequently, the spleen was drawn out of 
the body cavity and carefully separated from the attached tissue using the scissors. The 
spleens were placed onto a nylon mesh rinsed with 2-3mL prewarmed RPMI 1640 medium. 
Using sterile forceps the splenocytes were forced out of the spleen by pressing down in the 
center. Using a sterile plunger, the extruded cells were carefully pressed through the nylon 
mesh to prepare single cell suspensions in 10mL prewarmed RPMI 1640 medium. The cell 
suspension was centrifuged for 5 minutes at 100xg. The supernatant was discarded and the 
pelleted cells were resuspended in 2mL hypoosmotic lysis buffer and incubated for 10 
minutes at room temperature for erythrocyte lysis. After that, the samples were centrifuged 
again for 5 minutes at 100xg, the supernatant was discarded and the splenocytes were 
resuspended in prewarmed RPMI 1640 medium. The cells were directly used for staining 
and subsequent flow cytometry (2.2.11), or incubated at 37°C in a humidified atmosphere of 
5% CO2 for cytotoxic assays.  
 
2.2.10 Protein analysis and immunological methods 
 
2.2.10.1 Periplasmic protein expression under osmotic stress 
 
The perisplamic expression of proteins in bacteria was carried out under osmotic stress 
conditions [4% (w/v) NaCl, 0.5M sorbitol] in the presence of compatible solutes [151]. With 
the help of these additives the correct folding of recombinant proteins will be enhanced and 
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the solubility and stability of the periplasmic secreted proteins will be ameliorated.  The 
osmotic stress conditions lead to the production of heatshock proteins and other chaperones 
which can support the folding of proteins in the periplasmic space. Recombinant E.coli BL-21 
DE3 bacteria (2.1.7) were grown in a 5mL overnight pre-culture (26°C, 225rpm) in TB 
kanamycin medium supplemented with 10:1 potassium phosphate buffer and 0.5mM zinc 
chloride. The next day the main culture (500mL) was inoculated 1:100 with the preculture 
and incubated on a shaker (26°C, 225rpm) until an OD600 of >1,6 was reached. Furtheron the 
salts (0.5M sorbitol, 4% (w/v) sodiumchloride, 10mM betaine) were added to the main 
culture.  After 30 minutes the expression of recombinant proteins was induced by adding 
1mM IPTG and cultivation was continued for 16 h at the same conditions. The bacteria were 
pelleted (30.000xg/15min/4°C) and the pellet was stored at -20°C. The cell disruption of the 
pellet was carried out by sonication (70%; duty-cycle 9 sec; 5x90 sec) after resuspending the 
pellet in 30 mL of extraction buffer. The bacterial lysate was cleared by centrifugation 
(30.000g/25min/4°C) and the periplasm supernatant was desalted by overnight dialysis 
before purification.  
 
2.2.10.2 Purification of recombinant E. coli proteins by IMAC (immobilized metal   
ion affinity chromatography)  
 
Recombinant proteins can be easily purified by affinity chromatography using specific 
columns by terminal integration of an Oligo-histidine-tag (“his tag”). The principle bases upon 
the chelate formation of histidin residues with bivalent cations (Ni2+, Cu2+ and Zn2+) [161]. 
These cations can be immobilized as Ni2+-NTA (Nitrilotriacetic acid)-agarose columns or Ni2+-
IDA (iminodiacetic acid)-agarose columns and used for the chromatography (metal ion 
affinity chromatography). To elute the protein from the column the applied elution buffer 
contains imidazole. This organic compound is a histidine analogon and competes with his-
tagged proteins in the elution step. For protein purification from the periplasmic fraction a 
prepacked Ni2+-NTA-agarose column (Ni2+-NTA Superflow 5mL, GE Healthcare) was used 
on an ÄKTAFPLC system following the manufacturers’ instructions. The bacterial lysate was 
cleared by using a syringe filter unit (Whatman®, Sigma Aldrich; pore size 0.22µm) before 
loading it onto the Ni2+-NTA at a flow rate of 1mL/minute. The column was washed 
subsequently with the standard incubation buffer (10mM imidazole) and the washing buffer 
(40mM imidazole) until a base line was reached. The elution was carried out using the 
elution buffer with 500mM imidazole and the elution fractions were collected in sterile 1.5mL 
Eppendorf tubes.    
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2.2.10.3 Purification of recombinant eukaryotic proteins   
 
The purification of eukaryotic proteins was carried out as described in 2.2.10.2. To purify 
higher amounts of protein the supernatant of transfected 293T cells was collected for 2-3 
weeks and stored at 4°C in a sterile erlenmeyer flask. Before the purification step the 
supernatant was cleared using a MF75™ 500ml vacuum filter unit (Nalgene, pore size: 
0.22µm) and subsequently mixed with 4x incubation buffer.  
2.2.10.4 Protein enrichment and lyophilization   
 
To enrich the concentration of protein in a defined sample, the recombinant proteins were 
concentrated using Vivaspin 6 Centrifugal devices (Sartorius, Göttingen) and Nanosep 
Centrifugal Devices (Pall Lifesciences, East Hills, NY) both with a 10 kDa cutoff following the 
manufacturers’ instructions. In general, the proteins were concentrated 10-fold and reduced 
to a volume of 500µl/purification. The protein concentration was subsequently determined by 
Bradford assay (2.2.10.9) using Roti-Nanoquant (Roth, Karlsruhe). To preserve the stability 
and functionality of the recombinant proteins the samples were freeze dried (lyophilized) 
using a benchtop manifold freeze dryer following the manufacturers’ instructions. The 
samples were previously divided into 250µl portions/Eppendorf tube and the lids of the vials 
were perforated using a needle. After the lyophilization process, the freeze-dried protein was 
hermetically sealed and stored at room temperature for further experiments. To restore the 
protein sample in the appropriate buffer system, it was mixed with 250µl of sterile bidestilled 
water. 
 
2.2.10.5 Size exclusion chromatography (SEC) 
 
To further purify the protein samples from IMAC (2.2.10.2), a size exclusion chromatography (gel 
filtration) was performed. The system bases upon the principle that proteins of different sizes (or 
hydrodynamic volumes) will elute through a column that is packed with small porous polymer 
beads (dextran) with pores of different sizes. When the protein solution is filtered through the 
column by low pressure, some proteins can enter into the pores and linger in these for some 
time. Larger proteins cannot enter and travel quicker through the length of the column. The 
principle then is: the larger the protein, the quicker it elutes through the column. With the help of 
the SEC, the protein of interest can furtheron be released from contaminated proteins (e.g. 
bacterial proteins that were purified by IMAC as well) and degradation products. The gel filtration 
was performed using the Superdex 75 10/300 GL column (Amersham Biosciences) following the 
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manufacturers’ instructions. 500µl of concentrated protein sample were loaded onto the above 
mentioned column with a flow rate of 0.5mL/min. The flowthrough of the column was completely 
collected in 0.5mL fractions after the first UV signal was visible. The fractions were subsequently 
analyzed by SDS-PAGE (2.2.4.1) and western blotting (2.2.10.7).  
 
2.2.10.6 SDS-PAGE gel electrophoresis  
 
For the separation and detection of recombinant proteins (2.2.10.6, 2.2.10.7) the 
discontinuos SDS-PAA gel electrophoresis (SDS-PAGE) according to Laemmli et al. [162] 
was carried out. The protein samples were mixed with 1/10 volume of 10x SDS-PAGE 
loading buffer and denaturated for 5 minutes at 100°C. The separation of protein was 
performed using „Mini-Protean III“-protein gelelectrophoresis equipment (BioRad, Hercules, 
USA). For the detection of protein a western blot using specific antibodies was carried out. 
For an unspecific staining of all separated proteins Coomassie Brilliant blue G-250 [163] was 
used following the manufacturers instructions.  
 
2.2.10.7 Western blot analysis  
 
Western blot analyses [164] using specific antibodies were performed for the detection of 
SDS-PAGE (2.2.10.6) separated proteins. The proteins were transferred from SDS gels to 
nitrocellulose membranes using the electro-tank blotting method ([164], 250mA/1h/4°C). The 
visualization of immobilized proteins was carried out using protein-specific antibodies (Ab) 
and a secondary enzyme-conjugated antibody for the detection of the primary Ab. The 
substrate reaction with NBT/BCIP (Life Technologies) or Sigma-Fast (Sigma) was used for 
the visualization of the protein bands. By comparing the bands with a protein standard 
(„prestained protein marker broad range“, New England Biolabs) the size of the protein of 
interest could be estimated. The steps for the detection of protein are shown in Tab. 8. 
 
Tab. 8: Parameter for the detection of recombinant proteins in western blot 
Step Detection A Detection B 
Blocking  5% (w/v) skimmed milk (fat-free) in PBS, pH 7.2 
(1h, RT) 
5% (w/v) skimmed milk 
(fat-free) in PBS, pH 7.2 
(1h, RT) 
Hybridization Ab I 8.18-C5, F3-9E9, F4-2D2 (cell supernatants) 
200 µl in 10mL PBS, (1h, RT) 
monoclonal mouse-anti-
his-Ab 1:5000 in PBS 
(1h, RT) 
   
                                                                                                                 Material and Methods     
     
     
44 
Hybridization Ab II GAMHRPO (α-IgG H+L) 1:5000 in PBS (1h, RT) GAMAP (α-IgG Fc) 
1:5000 in PBS (1h at 
RT) 
Substrate reaction Sigma-Fast (Sigma) NBT/BCIP 
(10-20 min. in the dark) 
                  
 
The membranes were washed 3 times for 10 minutes in between the incubation steps using 
PBS-T [0.05% (v/v) Tween-20 in PBS]. Before the substrate reaction the membrane was 
washed three times with AP buffer (detection B). The colour reaction was stopped by 
washing the membrane thoroughly.  
2.2.10.8 Enzyme-Linked Immunosorbent Assay (ELISA)  
 
The ELISA was carried out according to Clark & Adams [165]. 
 
Tab. 9: Parameter for the detection of recombinant proteins in ELISA 
Step Volume/well concentration incubation 
Antigen  100 µl 1:20 in coating buffer 1h at RT 
Blocking 200 µl 2% (w/v) BSA in PBS 1h at 37°C 
1st Ab  100 µl Hybridoma supernatant 1-2h at 37°C 
2nd Ab  100 µl 1:5000 in PBS 1-2h at 37°C 
ABTS 100 µl 0,953 mg/mL SP 15-30 min. at RT 
 
In between the different steps the plate was washed 3 times with PBST.  
 
2.2.10.9 Determination of protein concentration 
 
To determine the protein concentration of original samples, a Bradford Assay was carried out 
using Roti-Nanoquant (Roth, Karlsruhe) following the manufacturers’ instructions. A set of 
BSA (bovine serum albumin) standards was created from a protein stock whose 
concentration was known. The Bradford values obtained for the BSA standards were then 
used to construct a standard curve to which the unknown values obtained can be compared 
to determine their concentration using Microsoft Excel.  
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2.2.10.10 Concentration and dialysis of proteins  
 
To desalt, concentrate or rebuffer protein samples with a volume of less than 1mL, Nanosep 
10k Omega micro-concentrator tubes (Pall Life Sciences, East Hills, NY) were used following 
the manufacturers’ instructions. For larger volumes (1-7mL), PD10-desalting columns 
(Amersham Biosciences, Buckinghamshire, UK) were used as described in the 
manufacturers’ protocol. Volumes above 7mL were dialysed with dialysis-tubes (Serva 
dialysis tubing, Serva, Heidelberg) with a cut-off of 6-8kDa at 4°C against a 1000x volume of 
required buffer o/n. Desalting was carried out in order to remove imidazole in the elution 
buffer of Ni2+-NTA or to change buffer system of purified immunotoxins for lyophilization.   
 
2.2.11 Flow cytometry  
 
Flow cytometric studies are used to investigate binding interactions between fluorescence-
labelled probes, e.g. ligands and cell-associated molecules (receptors). The cells are routed 
in a continuous flow through a capillary and pass a laser with a certain excitation wavelength. 
Scattered and emitted light from cells are converted to electrical pulses by optical detectors. 
Collimated (parallel light waveforms) light is picked up by confocal lenses focused at the 
intersection point of cells and the light source. The light is send to different detectors by using 
optical filters. For example, a 525nm band pass filter placed in the light path prior to the 
detector will only allow “green” light into the detector. that leads to the fluorescence of the 
cells. Cell properties like size and granularity have an influence on the quality of the signal 
and are detected independently from the fluorescence signals. The flow cytometry can be 
used analytically or for cell sorting purposes (FACS = „Fluorescent activated cell sorter“). To 
prove the binding properties of the different recombinant proteins the available hybridoma 
cells 8.18-C5 (MOG-specific) and F4-2D2 (PLP-specific) were freshly prepared from cell 
culture. The titer of cells was adjusted to 5x105 cells per sample and the cells were washed 
with 1.8mL PBS in a Dade Serocent (Baxter, USA) cell washer. Afterwards the cells were 
resuspended in 500µl PBS mixed with 500ng of recombinant protein per sample and 
incubated for 30 minutes at 4°C.  Subsequently, the cells were washed again and incubated 
for 20 minutes on ice in the dark with 1µg of the detection antibody (ALEXA Fluor488® anti-
his Ab) in 500µl PBS. The cells were washed again twice and finally resuspended in 500µl 
PBS. The flow cytometry was carried out using the FACSCalibur (Becton Dickinson) 
following the manufacturers instructions with 5000 counts per sample. Cells that were solely 
incubated with the detection antibody were used as reference for the binding measurements. 
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In order to dermine the cell viability of a cell population, dead cells were stained with 
propidium iodide (PI). This compound binds to DNA by intercalating between the bases with 
little or no sequence preference. PI is membrane impermeant and generally excluded from 
viable cells. Commonly, it is used for the identification of dead cells in a given cell population. 
When bound to nucleic acids, the absorbtion maximum is 535nm and the fluorescence 
emission maximum is 617nm. Prior to flow cytometric analysis propidium iodide was added 
to the cell suspension at a concentration of 5µg/mL and the samples were incubated for 3 
minutes on ice. Dead cells were detected as shifted in FL-3 (fluorescence spectrum, 650LP 
filter) direction. The binding of MOG proteins to MOG-reactive B cell populations of IgHMOG 
mice was also examined by flow cytometric analysis. 2x105 splenocytes were washed twice 
with 500µl PBS and subsequently incubated with a PE-conjugated anti-CD19 antibody (BD 
Biosciences). CD19 is a common B-cell marker and is used to discriminate B lymphocytes 
from other PBMC’s. The further incubation with 500µl supernatant from eGFP-MOG 
secreting 293T cells additionally stains the MOG-reactive B-cell population. After a final 
washing step, the cells were analysed by flow cytometry. Data processing was performed 
with the help of the computer software WinMDI 2.8 (© 1993-98 Joseph Trotter).  
 
2.2.12 Cell viability assays  
 
2.2.12.1 XTT viability assays on hybridoma cells 
 
Cell viability after AT treatment was determined using the Cell Proliferation Kit II (Roche 
Diagnostics, Mannheim, Germany). The assay bases upon the reduction of XTT (2,3-Bis(2-
methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilid) to a water soluble orange 
formazan dye. Target cells were plated in a 96-well plate using 104 cells per well and 
incubated overnight in RPMI 1640 medium with 10% (v/v) FCS at 37°C and 5% CO2. The 
supernatants were replaced by fresh RPMI 1640 medium containing 1:3 dilution series in 
triplicate of purified recombinant immunotoxin MOG-ETA’, MOG protein or Zeocin®-
containing RPMI 1640 medium. The plates were further incubated for 48 h at 37°C. The 
subsequent cell proliferation assay was performed as described by the manufacturer. After 
12h incubation, the substrate conversion was measured in the ELISA reader as subtraction 
of OD450nm-OD650nm. The obtained data sets were analyzed using Microsoft Excel and 
GraphPad Prism (GraphPad Software, La Jolla, USA). 
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2.2.12.2 Cytotoxicity assays on isolated splenocytes from transgenic IgHMOG mice  
 
To investigate the toxicity of the autoimmunotoxin MOG-ETA’, 1x106 freshly prepared 
splenocytes (2.2.9.3) were incubated overnight in 6-well cell culture plates (2mL medium per 
well) with different concentrations (1µg, 2µg or 5µg per well) of MOG-ETA’ or the control 
protein MOG without toxin moiety in triplicate. To monitor the decrease of MOG-reactive B 
cells, the cells were analysed by flow cytometry as described in 2.2.11.  
 
2.2.13 Internalization studies  
 
2.2.13.1 Confocal Microscopy 
 
To visualize the B cell receptor internalization upon antigen binding the cells were analyzed 
by confocal microscopy. The different hybridoma cell lines 8.18-C5 and F4-2D2 (5x105 cells 
per sample each) were incubated with 1µg of recombinant eGFP-MOG fusion protein. The 
studies were performed in different approaches using variable incubation times (30 minutes, 
1 hour, 2 hours) and temperatures (incubation on ice, incubation at 37°C). After incubation at 
the different time intervals and temperatures, the cells were washed 2 times with PBS and 
subsequently placed on ice to terminate internalization. After that the cells were fixed for 15 
minutes on ice using 2% (w/v) paraformaldehyde in PBS. For nuclear staining the cells were 
mixed with 1:100 diluted DRAQ5® right before confocal microscopy. This DNA-interactive 
agent is characterized by strong cell permeability with a fluorescence signature that extends 
into the infra-red region of the spectrum. Due to this far-red emission it is ideal to combine 
with GFP and FITC-based fluorophors. The prepared samples were added to cover slips and 
then mounted to glass slides. The pictures were taken using a Leica TCS laser scanning 
confocal microscope. The eGFP-MOG fusion protein was excited at 488nm using an argon 
laser. DRAQ5 was excited using a helium-neon laser at 633nm. The images of different 
excitation wavelengths within one sample were superposed using the LEICA software and all 
approaches (different time periods, temperatures) were compared. 
 
2.2.13.2 OPERA  
 
The clathrin-coated-mediated endocytosis of the eGFP-MOG protein into the target cell line 
8.18-C5 was screened using the OPERA ultra-high throughput confocal screening system 
(Evotec Technologies, Hamburg; Germany). The Opera is a fully automated 3 colour laser 
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excitation confocal system based on an inverted microscope architecture to image cells 
cultivated in coverslip bottomed microtitre plates. 488, 532 or 633 nm laser excitation is 
delivered to a dual wheel Nipkow spinning disk that ensures confocality. Images were 
acquired using an Olympus 20 x 0.7 numerical aperture water immersion objective mounted 
on a piezo element for focusing and fitted at the top with a sealing ring and a perfusion 
system to permit automated water immersion and water withdrawal at the face of the 
objective. Emitted light from the sample was delivered to a 630 nm dichroic mirror that split 
the emitted light between two 12 bit high quantum efficiency 1.3 megapixel CCD cameras. All 
operating parameters for the instrument were controlled by the Opera software running on a 
PC connected to a 1 Gbps local network of three image analysis computers. Image 
alignment, flat field and background correction were automatically performed based on 
reference and orientation images. Automated experimental acquisition protocols were 
defined for each screening based on trial samples. 12 bit grey scale image pairs were 
captured, quantitatively analysed and stored in a compressed format. The cells were 
adjusted to 1x105 cells per mL and were then washed 2 times with PBS. After that the cells 
were resupended again in PBS and mixed with 500ng eGFP-MOG and transferrin for specific 
staining of clathrin-coated vesicles. The incubation was performed on ice and stopped after 5 
minutes. The cells were washed 2 times with PBS. The samples were quickly transferred into 
a Greiner 96-well microplate (black) and incubated in the temperature conditioned OPERA 
screening system. The images were recorded in a section of ~50 cells over a time period of 
1h with 30 second intervals.  The co-internalization process of the recombinant eGFP-MOG 
protein and transferrin was demonstrated exemplary for one hybridoma cell within the above 
mentioned section. The pictures were merged to a short movie using the LEICA software. 
The movie can be found as Windows Media files on the CD that is attached to this work.     
 
2.2.14 Animal experiments 
 
2.2.14.1 Targeting autoreactive B lymphocytes in transgenic IgHMOG mice 
 
Transgenic IgHMOG mice pairs were kindy provided by the Max-Planck Institute for 
Neurobiology, Department of Neuroimmunology (Martinsried, Germany). The animals were 
crossed and 8-12 week old female littermates were used for in vivo evaluation of MOG-ETA’ 
immunotoxin. The animals were treated daily with 10 or 20µg of purified recombinant protein 
respectively in 50µl PBS i.v. over a time course of 5 days (n=3). The control animals were 
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treated with the same amount of PBS without protein. The blood from the animals was 
collected every second day from the tip of the tail. The number of residing MOG-reactive 
cells was evaluated by flow cytometry (FACSCalibur, Becton Dickinson) after spleen 
preparation. MOG-reactive B cells were displayed by double staining with recombinant 
eGFP-MOG protein and an anti-CD19-PE antibody (Becton Dickinson). The amount of cells 
in this lymphocyte gate was compared among each other (different protein concentrations) 
and with the control animals.  
 
2.2.14.2 EAE induction in DBA/1j mice and treatment using MOG-ETA’  
 
The EAE animal experiments were performed in close cooperation with Professor Dr. 
Christopher Linington and Dr. Carl Goodyear from the University of Glasgow (UK), 
Department of Clinical Neuroscience. Before disease induction 8-10 weeks old DBA/1j mice 
were divided into two groups of 4 animals each. All mice were injected intradermally using  
50µg of rat MOG (aa 1-125) in Incomplete Freund’s Adjuvant (IFA) supplemented with 3 
mg/mL inactivated Mycobacterium tuberculosis (H37 RA; Difco). On day 2 post 
immunization, 25µg of sterile filtered MOG-ETA’ immunotoxin were injected intravenously 
into the mice from group 1. The immunotoxin treatment was repeated every second day until 
day 21 after EAE induction. The animals from the control group (group 2) were injected in the 
same manner with 25µg of a non-specific control immunotoxin each. This control 
immunotoxin is composed of the same toxin moiety (ETA’) and a short fragment of a Phleum 
pratense grass pollen allergen (‘Bo9’). The mice were monitored and scored for clinical signs 
of EAE every day throughout the whole experiment (2.2.14.3) and weight changes were 
recorded daily. 
 
 
2.2.14.3 Clinical Evaluation of EAE 
 
The clinical disease of the animals was assessed after immunization with the 
encephalitogen. The scoring for clinical signs of EAE was carried out according to the 
following scale: 
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Tab. 10: Scoring tablature for the clinical signs of EAE 
0 no signs of disease 
1 loss of tail tone 
2 partial paralysis of one or both hindlimbs 
3 complete paralysis of one or both hindlimbs 
4 complete paralysis of one or both hindlimbs, paralysis of fore limbs 
5 moribund or dead 
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3 Results 
3.1 Design, expression and characterisation of 
autoimmunotoxins 
 
For periplasmic expression of recombinant myelin-ETA’ autoimmunotoxins in E.coli BL2 
(DE3) and myelin proteins without fusion partner the pBM expression vector [150] was used. 
The synthesis of recombinant proteins is controlled by the T7lac promotor. Additionally the 
vector contains the pelB signal peptide for the secretion of expressed proteins into the cell 
supernatant and an N-terminal His10-tag for detection and purification purposes. The 
multiple cloning site contains several uncommon restriction sites for easy insertion of the 
immunotoxin sequences. Specifically SfiI and NotI restriciton sites could not be detected in 
murine or human myelin protein sequences inhibiting an unintentional restriciton in the midst 
of the inserted sequences [150]. The target pBM-PV-ETA vector and the cloned myelin 
sequences from the MOG and the PLP protein were digested using SfiI/NotI. Sequences of 
the proteins can be found in the appendix of the present work. The restricted fragments were 
isolated from the restriction digest using preparative agarose gel electrophoresis (2.2.4.2).  
Furtheron the SfiI/NotI-digested pBM vector was dephosphorylated to prevent a religation 
that can occur at unefficient vector digest (2.2.3.1). By „sticky-end“ ligation (2.2.3.3) the insert 
was ligated into the pBM vector to fuse the recombinant protein fragments (MOG, PLP) with 
the deletion mutant of Pseudomonas Exotoxin A. Additionally the above mentioned myelin 
proteins were cloned into the pBM-PV vector without ETA’ toxin moiety. The expression of 
these ‚non-toxic’ proteins will be taken as negative control in further cytotoxicity assays with 
ETA’-based autoimmunotoxins.   
 
3.1.1 Cloning of MOG fusion proteins for bacterial expression 
 
Both myelin protein full length clones (MOG, PLP) were ordered at Imagenes (Berlin, 
Germany). The full length sequence of the myelin oligodendrocyte glycoprotein (clone: IRAK 
p961L06176Q) was inserted at the multiple cloning site (MCS) of the pYX-Asc vector (6.4). 
The N-terminal extracellular domain of the murine MOG (aa 1-125) was amplified by PCR. 
Restriction sites that were required for the cloning into the target expression vectors were 
added to the gene sequence by PCR reaction using the following primers:  
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Primer 1:     MOG-5’-SfiI        5’-CTAGGGCCCAGCCGGCCGGACAATTCAGAGTGATAGG-3’ 
Primer 2:     MOG-3’-NotI       5’-AGCTGCGGCCGCCACACCGGGGTTGACCC-3’ 
 
After PCR reaction the expected size of the gene product (413 bp) was detected by agarose 
gel electrophoresis, furtheron purified from the gel, SfiI/NotI restricted and then ligated into 
the different target vectors via their SfiI/NotI restriction sites. For bacterial expression the 
MOG fragment was fused with the Pseudomonas exotoxin A in the pBM-PV-ETA’ vector 
(Figure 9B) and additionally cloned into the pBM vector pBM-PV without toxin fusion (Figure 
9A).  
 
 
 
Figure 11: Expression cassettes, expression and purification of MOG-ETA’ and MOG. (A) The fusion protein 
includes an N-terminal pelB-leader sequence, which mediates protein transport into the periplasmic compartment. 
This leader peptide is followed by a 10x polyhistidine tag (10xHis-Tag), which allows protein purification by affinity 
chromatography. The MOG fragment (aa 1-125 of myelin oligodendrocyte glycoprotein) is fused to the 
translocation domain (Transl.) and catalytic domain (ETA′) of Pseudomonas Exotoxin A. The control construct (B) 
consists of MOG without a toxin moiety. 
 
3.1.2 Restriction analysis of pBM-MOG vector constructs 
 
The ligations were directly transformed into E.coli XL-1 blue by the heatshock method (2.2.6) 
and bacteria were cultivated on kanamycine LB agar plates. One of the colonies was picked 
and subsequently grown overnight in 5mL LB medium. The plasmid DNA was isolated by 
minipreparation (2.2.7.1) and controlled by restriction analysis (2.2.3.1) using the restriction 
enzymes KpnI/BlpI for pBM-MOG-ETA (expected fragment sizes: 5433 bp, 1481 bp) and 
NcoI/NotI for pBM-MOG (expected fragment sizes: 5236 bp, 474 bp). 
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Figure 12: Restriction analysis of cloned pBM-constructs for bacterial expression. 2µl of each restriction digest 
(2.2.3.1) was separated by 1% (w/v) agarose gel electrophoresis (2.2.4) after digest. The expected fragment 
lengths are shown in bp below the gel pictures.  [M: DNA 2 log ladder; lane A1: pBM-MOG-ETA’ (clone 1); lane 
A2: pBM-MOG-ETA’ (clone 2); lane B1: pBM-MOG]. 
 
3.1.3 Expression and characterization of pBM-MOG-ETA’ and pBM-MOG  
 
Recombinant proteins were expressed under osmotic stress conditions in the presence of 
compatible solutes (2.2.10.1) using E.coli BL-21 DE3 (2.1.7). For purification the proteins 
were desalted overnight by dialysis (2.2.10.10) and subsequently purified by ion metal affinity 
chromatography (IMAC) on an ÄKTAFPLC system following the manufacturers’ instructions 
(2.2.10.2). After IMAC purification the protein was furtheron purified by size exclusion 
chromatography, sterile filtered and finally stored at 4°C.   
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Figure 13: SDS-PAGE (2.2.10.6) and corresponding western blot (2.2.10.7) of recombinant MOG-ETA’ (A) and 
MOG (B) after IMAC (2.2.10.2) and SEC purification (2.2.10.5). After separation of proteins by 12% SDS-PAGE 
(2.2.10.6) the gel was stained with Coomassie Brilliant Blue (Serva) [A, B left]. Proteins in western blots [A, B 
right] were detected using hybridoma cell supernatant from MOG-reactive 8.18-C5 cells (primary antibody) 
followed by a goat-anti-mouse-HRPO secondary antibody (Sigma) and SigmaFast (Sigma) substrate. M: 
Prestained protein marker, broad range (NEB). 
 
The detection of bacterially expressed recombinant MOG proteins in western blot was 
carried out using supernatant from the MOG-reactive 8.18-C5 hybridoma cell line. Their 
secreted antibodies recognize a non-linear conformation-dependent epitope within the 
extracellular Ig-like domain of myelin oligodendrocyte glycoprotein. Beyond this, the integrity 
of proteins was illustrated by western blotting using a primary anti-his antibody which binds to 
the N-terminal his-tag of the proteins (data not shown). As secondary antibody a goat-anti-
mouse labelled with horseradish peroxidase (HRPO) was used in a concentration of 1:5000 
in PBS. Figure 13 shows the expression of MOG-ETA’ (57.5 kDa) and MOG (17.9 kDa). The 
protein size was determined by comparison with a prestained protein marker (NEB) and by 
using the DNA analyzing software ‚DNAStar’ (DNASTAR Inc., Madison, USA). The elution 
fractions after IMAC purification showed the expected protein sizes and were pooled and 
concentrated (2.2.10.10) to a volume of 1mL for further purification by size exclusion 
chromatography. The proteins could be further purified and no contaminating bacterial 
proteins or degradation products were visible in SDS-PAGE or western blot. The average 
final concentrations of purified protein from 1.0L of bacterial culture were determined to 0.75 
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mg/L (MOG) and 1 mg/L (MOG-ETA′). The samples were sterile filtered and stored at 4°C for 
further binding and toxicity analyses.  
 
3.1.4 Cloning of PLP fusion proteins for bacterial expression 
 
The full length sequence proteolipid protein (clone: IRAV p968G0365D) was supplied in the 
multiple cloning site (MCS) of the pCMV-SPORT6 vector (6.4). The B cell epitope-containing 
domain of murine PLP (aa 88-152) was amplified by PCR. The restriction sites SfiI and NotI 
that are required for the cloning into the target pBM expression vectors were added to the 
gene sequence by PCR reaction using the following primers:  
 
Primer 1:     PLP-II-for         5’- GAGTGGCCCAGCCGGCCGAGGGCTTCTACACCACC -3’ 
Primer 2:     PLP-AS151-back       5’- AGCTGCGGCCGCCACAAACTTGTCGGG-3’ 
 
After PCR reaction the expected size of the gene product (216 bp) was controlled by agarose 
gel electrophoresis, furtheron purified from the gel and then ligated into SfiI/NotI digested 
pBM target vectors from Figure 9.  
 
3.1.5 Restriction analysis of pBM-PLP vector constructs 
 
The ligation reactions of the cloning steps were transformed into E.coli XL-1 blue using the 
heatshock method (2.2.6) and bacteria were cultivated on kanamycine LB agar plates. One 
of the colonies was picked and subsequently grown overnight in 5mL LB medium. The 
plasmid DNA was isolated by minipreparation (2.2.7.1) and controlled by restriction analysis 
(2.2.3.1) using restriction enzymes SfiI/BlpI for pBM-PLP (expected fragment sizes: 5308 bp, 
214 bp) and XbaI/NotI for pBM-PLP-ETA’ (expected fragment sizes: 6334 bp, 409 bp).  
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Figure 14: Restriction analysis of cloned pBM-PLP vector constructs for bacterial expression. 2µl of each 
restriction digest (2.2.3.1) was separated by 1% (w/v) agarose gel electrophoresis (2.2.4) after digest. The 
expected fragment lengths are shown in bp below the gel pictures.  [M: DNA 2 log ladder; lane A1: pBM-PLP 
(clone 1); lane A2: pBM-PLP (clone 2); lane B1: pBM-PLP-ETA’ (clone 1); lane B2: pBM-PLP-ETA’ (clone 2)]. 
                 
3.1.6 Expression and characterization of pBM-PLP-ETA’ and pBM-PLP 
 
The expression of recombinant proteins was carried out under osmotic stress conditions in 
the presence of compatible solutes (2.2.10.1) using E.coli BL-21 DE3 (2.1.7). For purification 
the proteins were desalted overnight by dialysis (2.2.10.10) and subsequently purified by ion 
metal affinity chromatography (IMAC) on an ÄKTAFPLC system following the manufacturers’ 
instructions (2.2.10.2). After IMAC purification the protein was furtheron purified by size 
exclusion chromatography, sterile filtered and finally stored at 4°C. 
 
 
 
 
  
                                                                                                                                        Results 
               
     
57 
 
 
Figure 15: SDS-PAGE (2.2.10.6) and corresponding western blot (2.2.10.7) of recombinant PLP-ETA’ (A) and 
PLP (B) after IMAC (2.2.10.2) and SEC purification (2.2.10.5). After separation of proteins by 12% SDS-PAGE 
(2.2.10.6) the gel was stained with Coomassie Brilliant blue (Serva) [A, C]. Proteins in western blots [B, D] were 
detected using hybridoma cell supernatant from PLP-reactive F4-2D2 cells (primary antibody) followed by a goat-
anti-mouse-HRPO secondary antibody (Sigma) and SigmaFast (Sigma) substrate. M: Prestained protein marker, 
broad range (NEB). 
 
Recombinant PLP proteins were succesfully expressed and subsequently detected in 
western blots using the supernatant from PLP-reactive F4-2D2 hybridoma cells. The target 
epitope of PLP-reactive antibodies within the PLP sequence is aa 100-123. Figure 15 shows 
the expression of PLP-ETA’ (54.5 kDa) and MOG (10.7 kDa). The average final 
concentrations of purified protein from 1 l of bacterial culture were 0.1mg/L (MOG) and 0.5 
mg/L (MOG-ETA′). The samples were sterile filtered and stored at 4°C for further binding and 
toxicity analyses. 
 
 
3.2 Design, expression and characterisation of GFP-fusions for 
imaging purposes 
 
The expression of the myelin proteins MOG and PLP in direct fusion with the enhanced 
green fluorescent protein (eGFP) for imaging purposes in flow cytometry and confocal 
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microscopy was carried out by transfection of 293T cells with the genes of interest. As vector 
system, the pMS expression vector (2.1.9) was used.  
 
3.2.1 Cloning of GFP-ligand fusion proteins  
 
The basis for the generation of eGFP-myelin fusion proteins was the pMS-L-eGFP-PV 
construct. It is composed of an N-terminal enhanced green fluorescent protein in fusion with 
a grass pollen allergen from Phleum pratense (PV). After restriction digest of the plasmid 
using SfiI and NotI, the PCR products of MOG and PLP (SfI/NotI digested) were ligated into 
the target plasmid. The cloning strategy is depicted in Figure 16. 
 
 
Figure 16: Cloning strategy for the generation of pMS-L-eGFP-MOG and pMS-L-eGFP-PLP expression plasmids. 
The PCR products from the myelin proteins MOG and PLP (3.1.1; 3.1.4) were cloned into the pMS vector 
containing the sequence for the enhanced green fluorescent protein (2.1.9). Both the target vector pMS-L-eGFP-
PV and the PCR products were digested using SfiI/NotI restriction enzymes (2.2.3.1). The digested PCR products 
were subsequently ligated into the target pMS vector (2.2.3.3). 
 
3.2.2 Restriction analysis of pMS-L-eGFP plasmids  
 
The ligation was transformed into E.coli XL-1 blue using the heatshock method (2.2.6) and 
bacteria were cultivated on ampicilline LB agar plates. Two colonies were picked and 
subsequently grown overnight in 5mL LB medium. The plasmid DNA was isolated by 
minipreparation (2.2.7.1) and controlled by restriction analysis (2.2.3.1) using restriction 
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enzymes KpnI/HindIII for pMS-L-eGFP-MOG (expected fragment sizes: 6310 bp, 538 bp) 
and XbaI/NotI for pMS-L-eGFP-PLP (expected fragment sizes: 5689 bp, 979 bp).  
 
 
Figure 17: Restriction analysis of cloned pMS-eGFP vector constructs for eukaryotic expression. 2µl of each 
restriction digest (2.2.3.1) was separated by 1% (w/v) agarose gel electrophoresis (2.2.4) after digest. The 
expected fragment lengths are shown in bp below the gel pictures.  [M: DNA 2 log ladder; lane A1: pMS-L-eGFP-
MOG (clone 1); lane A2: pMS-L-eGFP-MOG (clone 2); lane B1: pMS-L-eGFP-PLP (clone 1); lane B2: pMS-L-
eGFP-PLP (clone 2)]. 
 
3.2.3 Expression and characterization of eGFP fusion proteins  
 
293T cells were transfected (2.2.9.1) using the above mentioned pMS plasmids and 
subsequently cultivated for 2 weeks at 37°C and 5% CO2. Recombinant proteins could be 
easily purified from cell supernatant by Ni2+-NTA purification (2.2.10.3). Unfortunately, cells 
that were transfected with pMS-L-eGFP-PLP had a shortened lifetime of only 5-6 days with 
slight to no expression of protein. The transfection was repeated several times but the 
protein expression was not succesful. The expression of eGFP-MOG, on the other hand, 
worked very efficiently. Transfected cells were grown in two large culture flasks (~150mL) 
over a time period of 2 weeks. The supernatant was collected and filtered before Ni2+-NTA 
purification.   
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Figure 18: SDS-Page (A) and corresponding western blot (B) of eGFP-MOG fusion protein after IMAC (2.2.10.3) 
and size exclusion chromatography (2.2.10.5). After separation of proteins by 12% SDS-PAGE (2.2.10.6) the gel 
was stained with Coomassie Brilliant blue (Serva) [A]. The protein in western blot [B] was detected using 
hybridoma cell supernatant from MOG-reactive 8.18-C5 cells (primary antibody) followed by a goat-anti-mouse-
HRPO secondary antibody (Sigma) and Sigma Fast (Sigma) substrate. M: Prestained protein marker, broad 
range (NEB). [C]: The elution fraction of the eGFP-MOG protein (right) visualized by UV excitation in comparison 
to the elution buffer without protein (control, left).  
 
The expression of eGFP-MOG protein was succesful. It could be specifically detected using 
MOG-reactive antibodies from 8.18-C5 hybridoma cells in western blot. Its molecular weight 
of 46 kDa was calculated using the computer software „DNAStar“. The effective size of ~55-
60 kDa is in accordance with the calculated molecular weight and an expected complex-type 
N-glycosylation pattern. The average yield of expression was on the order of 5-6mg of 
secreted recombinant protein per liter of cell culture supernatant. For further experiments, the 
protein was sterile filtered and stored at 4°C in the dark.  
 
3.3 Binding analysis of recombinant MOG and PLP proteins  
 
3.3.1 Binding analyses by enzyme linked immunosorbant assay (ELISA) 
 
After purification and characterization via SDS-PAGE and western blot, the integrity of 
recombinant proteins was further evaluated by standard ELISA procedure. Proteins were 
coated to 96-well plates at three different concentrations in triplets ranging from 150ng per 
mL to 15µg per mL respectively. As primary antibody the supernatants of antigen-specific 
hybridoma cells were applied followed by a secondary goat anti-mouse-HRPO antibody and 
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ABTS-based colour reaction. The substrate incubation was performed for 20 minutes at room 
temperature on a shaker and the colour reaction was subsequently determined at 405nm 
using an ELISA reader. As negative controls the proteins were incubated with non-specific 
primary antibodies followed by standard secondary antibody and substrate reaction as 
mentioned above.  
 
Figure 19: Detection of recombinant MOG (A) and PLP (B) proteins by ELISA (2.2.10.8) using antigen-specific 
antibodies. For coating the proteins were mixed 1:1 with coating buffer in a 96-well palte. After coating procedure 
unspecific binding sites were blocked with 1% (w/v) BSA/PBS. Subsequently the wells were incubated using 
100µl of supernatant from antigen-specific hybridoma cells. MOG proteins (A) were incubated with MOG-specific 
8.18-C5 cell supernatant (blue columns: MOG-ETA’ in three different concentrations, orange columns: MOG in 
three different concentrations, green: negative controls). PLP proteins (B) were incubated with PLP-specific F4-
2D2 cell supernatant (blue columns: PLP-ETA’ in three different concentrations, orange columns: PLP in three 
different concentrations, green: negative controls). The detection of primary mouse antibodies was performed 
using a goat anti-mouse-HRPO antibody followed by ABTS substrate reaction (reaction time: 20 minutes) 
(2.2.10.8). The negative controls are composed of 1.5µg/mL of coated protein incubated with a non-specific 
hybridoma supernatant followed by the above mentioned detection procedure. The bars represent mean values 
from triplicates from two independent experiments. 
 
Both MOG (MOG-ETA’, MOG) and PLP (PLP-ETA’, PLP) proteins were produced as intact 
molecules and showed a highly specific binding via their specific antibody as shown in Figure 
19. The incubation of recombinant proteins with the supernatant of reactive hybridoma cell 
lines resulted in a dose-dependent signal (protein concentrations from 150ng/mL to 
15µg/mL). MOG proteins, additionally, were bound by the 8.18-C5 antibody indicating the 
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correct folding of the MOG binding moiety as the antibody detects a conformation-dependent 
epitope of the MOG extracellular domain. Furtheron the binding of 8.18-C5 antibodies to their 
target (Figure 19A) was stronger than the binding of PLP-reactive F4-2D2 antibodies to PLP 
proteins as it can be seen on the signal strength of the colour reaction. Negative controls that 
were composed of a non-specific primary antibody did not result in a colour reaction.  
 
3.3.2 Binding analyses by flow cytometry  
 
3.3.2.1 Binding of recombinant myelin proteins to antigen-specific hybridoma cell 
lines 
 
After binding confirmation in western blot (2.2.10.7) and ELISA (2.2.10.8), the binding 
characteristics of MOG and PLP proteins to their antigen-specific hybridoma cell line are 
evaluated by flow cytometry (FACS) (2.2.11). The performed FACS experiments addressed 
the question if the binding of recombinant proteins showed specificity for the hybridoma cell 
line of interest. The cell-surface binding of MOG-ETA’ and MOG to 8.18-C5 cells and the 
binding of PLP-ETA’ and PLP on F4-2D2 cells was analyzed by flow cytometry. All proteins 
were additionally crosschecked on non-specific cell lines. Furthermore, the eukaryotically 
expressed eGFP-MOG which was designed for direct staining processes was tested on 
MOG-specific and control cell lines. The amount of mebrane-bound antibodies (B cell 
receptors) was evaluated using a goat-anti mouse-FITC antibody. The histogram plots 
including the forward/sideward scatter images are shown in Figure 20.  
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Figure 20: Flow cytometric binding analyses of purified MOG and PLP proteins. Hybridoma cell lines 8.18-C5 and 
F4-2D2 cells were pepared for binding analyses (2.2.11). (A) Purified proteins MOG (green curve) and MOG-ETA’ 
(black curve) successfully bound to the MOG-specific cell line 8.18-C5. (B) On the control cell line F4-2D2 no 
binding of MOG proteins was detectable. (C) Purified proteins PLP (green curve) and PLP-ETA’ (black curve) 
succesfully bound to the PLP-specific cell line F4-2D2. (D) On the control cell line 8.18-C5 no binding of PLP 
proteins was detectable. Bound proteins were verified using the anti-his ALEXA488 antibody (Qiagen, Hilden, 
Germany). To check for unspecific binding, cells were incubated with the secondary anti-his ALEXA 488 antibody 
alone (red curves with filling). The presence of membrane bound antibodies on the used hybridoma cell lines 
were demonstrated using a FITC-labelled goat anti-mouse antibody. The flow cytometry histograms are shown on 
the right. The specific binding of the eGFP-MOG protein could be demonstrated on the MOG-specific hybridoma 
cell line 8.18-C5 (E, left). There was no binding of the eGFP-MOG protein to the control cell line F4-2D2 (E, right). 
 
The binding activity of the recombinant proteins was restricted to their respective target cell 
lines. MOG and MOG-ETA’ bound solely to MOG-specific 8.18-C5 cells (Figure 20, A) 
whereas PLP and PLP-ETA’ specifically bound to F4-2D2 hybridoma cells (Figure 20, C). No 
unspecific binding to control hybridoma cell lines was detectable at all (Figure 20B, Figure 
20D). The presence of membrane-bound antibodies could be demonstrated for both cell lines 
by specifically staining the Fc part of B cell receptors (BCR) using a goat anti-mouse-FITC 
antibody. The results clearly indicate the binding specificities of all expressed proteins to the 
B cell receptors of their target cell lines. The fluorescent eGFP-MOG protein solely bound to 
8.18-C5 hybridoma cells (Figure 20E, left) without showing any binding on the control cell 
line F4-2D2 (Figure 20E, right). 
 
3.3.2.2 Binding of recombinant MOG proteins to isolated splenocytes from 
transgenic IgHMOG mice 
 
Two pairs of transgenic IgHMOG mice were kindly provided by Professor Hartmut Wekerle and 
Dr. Florian Kurschus from the Max-Planck-Institute for Neurobiology (Martinsried, Germany). 
The breeding of the offspring was carried out in the ‘Institute for the care and use of 
laboratory animals’ in the University Hospital Aachen. Due to the availability of mice strains 
that are transgenic for myelin-reactive antibodies, only MOG-based proteins could be 
evaluated in binding primary splenocytes from so-called ‘IgHMOG mice’ [127]. For the analysis 
of PLP proteins no such transgenic model is available at present. After preparation of 
splenocytes from IgHMOG mice as mentioned above (2.2.9.3), the cells were stained using 
eGFP-MOG fusion protein in combination with an anti-CD19-PE antibody to display MOG-
reactive B lymphocytes. Furtheron, the splenocytes were incubated with MOG and MOG-
ETA’ followed by anti-his ALEXA488 detection antibody to demonstrate binding of these 
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proteins. For flow cytometry procedures, the cells were prepared as described above 
(2.2.11).  
 
Figure 21: Characterisation of MOG-reactive B cell population of isolated splenocytes from transgenic IgHMOG 
Mice. Isolated cells were stained for flow cytometry using recombinant eGFP-MOG protein and anti-CD19-PE 
antibody. (A) Gated cell population of splenocytes. (B) Binding of eGFP-MOG protein to single cell suspensions 
of splenocytes co-stained with anti-CD19-PE antibody. The CD19-/MOG-negative cell population is located in the 
lower left panel. The percentages of CD19+ B cell populations out of the total splenocyte population are quoted in 
the upper panels. MOG-positive cells are located in the upper right panel. (C) Histogram of CD19+ splenocytes 
(referring to the upper panels from B). MOG-negative (left peak) and MOG-reactive (right peak) cell populations 
are shown. The percentage of MOG-reactive B cells out of the total CD19+ cell population is quoted.  
 
The fluorescent protein eGFP-MOG was used to specifically stain the MOG-reactive B 
lymphocyte population of IgHMOG mice in flow cytometry. This mouse strain is transgenic for 
the rearranged VDJ gene segment of the heavy chain from MOG-specific 8.18-C5 hybridoma 
so that all B lymphocytes express the MOG-specific heavy chain in combination with 
endogenous light chains. One third of these B lymphocytes from IgHMOG mice bind to 
recombinant MOG with very high affinity, as previously observed. The specific binding of 
recombinant MOG to MOG-reactive B lymphocytes was confirmed by labeling the isolated 
splenocytes from IgHMOG mice using eGFP-MOG and anti-CD19-PE antibody. Recombinant 
MOG bound to ~30% of CD19-positive B lymphocytes, while the other 70% showed no 
significant interaction with the protein (Figure 21B, upper panels and Figure 21C). The upper 
left panel in Figure 21B consists of the 70% of nonreactive, CD19-positive B lymphocytes 
that failed to bind the eGFP-MOG fusion protein, whereas the upper right panel displays the 
population of MOG-reactive B lymphocytes.  
 
Splenocytes were furtheron used for binding analysis of MOG and MOG-ETA’. To display the 
fluorescence shift of MOG-reactive cells upon binding to the recombinant proteins, the 
population was pre-gated for the presence of CD19 as B cell marker by using an anti-CD19-
PE antibody (Figure 22B, upper left panel). Binding of proteins to MOG-reactive B 
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lymphocytes will result in a fluorescence shift into the gate R3 (Figure 22B, upper right 
panel). The results of the underlying binding analysis of recombinant MOG and MOG-ETA’ in 
comparison to cells that were incubated with the anti-his ALEXA488 detection antibody only 
is shown in Figure 22C.  
 
 
 
Figure 22: Binding analysis of MOG and MOG-ETA’ to isolated splenocytes from IgHMOG mice. After isolation of 
splenocytes the cells were gated in forward/sideward scatter (A, gate R1) and subsequently used for anti-CD19 
staining procedure to display the population of B lymphocytes (B, gate R2). Binding of proteins to MOG-reactive 
cells will result in a fluorescence shift in gate R3 (B). The binding analysis of MOG and MOG-ETA’ proteins are 
shown in (C).  As a control, cells were incubated with the anti-his ALEXA488 detection antibody only (C, red filled 
curve). 
 
Both MOG and MOG-ETA’ specifically bound to MOG-reactive splenocytes from IgHMOG 
mice. CD19+ B cells out of the whole splenocyte population are shown in Figure 22B (upper 
left pannel). The binding of MOG proteins will result into a fluorescence shift into gate R3 
(Figure 22, upper right panel). This shift is illustrated in a histogram in Figure 22C. In 
comparison to the negative control where cells were incubated with the detection antibody 
alone (red curve), the binding of MOG and MOG-ETA’ to MOG-reactive B lymphocytes was 
clearly demonstrated by a shift into FL-1 (black and blue curve). The results clearly 
demonstrate that all expressed MOG proteins (eGFP-MOG, MOG and MOG-ETA’) were able 
to bind to primary splenocytes from IgHMOG mice. To evaluate the toxicity of the 
autoimmunotoxin MOG-ETA’ and the MOG without toxin moiety (control protein), the proteins 
were subsequently used for cytotoxic analysis on MOG-specific hybridoma cells and on 
IgHMOG splenocytes.  
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3.4 Internalization studies of eGFP-MOG on MOG-reactive 
hybridoma cells 
 
3.4.1 Confocal microscopy 
 
After binding verification of MOG proteins to their specific hybridoma cell line 8.18-C5 
(3.3.2.1) the internalization process of bound protein was visualized by confocal microscopy 
using the recombinant eGFP-MOG fluorescent fusion protein. The target cell line 8.18-C5 
(MOG-specific) and the PLP-specific hybridoma cell line F4-2D2 were incubated at 4°C and 
37°C for two different time points (1h, 2h) with 1µg of recombinant eGFP-MOG protein. After 
cell fixation the internalization process of GFP fusion process was visualized by confocal 
microscopy using a argon laser with an excitation wavelength of 488nm. The cell nucleus 
was stained shortly before the measurement using DRAQ5® which was excited with the help 
of a helium-neon laser at 633nm. The resulting images of the two different excitation 
wavelengths were merged using the LEICA software and the approaches using the target 
cell line 8.18-C5 and the control cell line F4-2D2 were compared.  
 
 
 
Figure 23: Internalization studies of recombinant eGFP-MOG using confocal microscopy (2.2.13.1). The 
hybridoma cell lines 8.18-C5 (A; MOG-specific) and F4-2D2 (B; control cell line) were stained for different time 
periods at different temperatures. Subsequently the binding and internalization process was investigated by 
confocal microscopy.  
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The eGFP-MOG fusion efficiently bound to its specific hybridoma cell line 8.18-C5 (Figure 
23A, upper panels). At 4°C/1h (Figure 23A, upper left), the binding of the recombinant protein 
to its target cell could be documented but rather low amounts were observable on the cell 
surface. After two hours at 4°C (Figure 23A, upper right), a strong and extensive binding 
‘ring’ but no internalization of the protein was visible. At 37°C/1h, the binding could be clearly 
documented and the internalization of the protein upon receptor-mediated endocytosis was 
visible by the presence of fluorescent endosomes. After 2 hours, the endocytosis of the 
fusion protein was further proceeded with a high amount of strongly fluorescent vesicles. 
Only little protein was left on the surface of the target cell. The negative control cell line F4-
2D2 (Figure 23B) did not show any unspecific binding or internalization using the above 
mentioned parameters.  
 
3.4.2 Live cell imaging (OPERA) 
 
The incubation of 8.18-C5 hybridoma cells with eGFP-MOG resulted in efficient cell 
membrane labelling followed by internalization into the target cell as shown by confocal 
microscopy (3.4.1). To better understand the internalization process and the intracellular 
pathway of the eGFP-MOG, co-localization studies with the subcellular endosomal marker 
transferrin-ALEXA Fluor633 (Invitrogen, Karlsruhe, Germany) was carried out. The 
hybridoma cells were preincubated with eGFP-MOG protein and subsequently incubated 
with transferrin-ALEXA Fluor633. The co-localization was visualized as yellow signals in 
merged images and appears strongly in the perinuclear region. The internalization process 
was recorded by live cell imaging (Opera High Content Screening System, Perkin Elmer, 
Waltham, USA) over a time period of 30 minutes with 30 second intervals. Figure 24 
exemplifies three internalizing 8.18-C5 hybridoma cells. Pictures of the internalization 
process were converted into a short Windows Media File movie and attached to this work 
(CD-ROM).  
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Figure 24: Internalization and colocalisation studies of recombinant eGFP-MOG and transferrin by life cell imaging 
(OPERA) (2.2.13.2). 8.18-C5 hybridoma cells were incubated with eGFP-MOG and transferrin-ALEXA633, and 
the internalization process and subsequent endosomal transport was recorded over a time period of 30 minutes. 
(A) Section of 8.18-C5 hybridoma cells during internalization process (approx. 10 minutes). Three cells were 
taken exemplarily for specified internalization process. (B) Exemplified single cells from (A). Actively internalizing 
endosomes are marked by grey arrows. Most of the internalized proteins accumulate as endosomes close to the 
perinuclear region.  
 
The co-localization of internalized eGFP-MOG and transferrin-ALEXA Fluor633 could be 
clearly detected as yellow signals and appeared primarily close to the perinuclear region 
(Figure 24B, merged). This co-internalization of eGFP-MOG and transferrin indicates that B 
cell receptors are internalized through a clathrin-dependent endocytic mechanism and is 
constitutive or can be quickly induced upon antigen binding. These results confirm that the 
internalized eGFP-MOG protein is localized to the recycling endosomal compartment (REC) 
as proven by the co-localization with transferrin.  
 
3.5 Quantitative cell viability assays  
 
3.5.1 Toxic in vitro activity of MOG-ETA’  
 
After verification of functionality of MOG and MOG-ETA’ by ELISA and FACS, the specific 
toxic activity of the ETA’ domain was examined. After binding of the autoimmunotoxin to its 
target cell line (8.18-C5 hybridoma cells) via the MOG domain, the protein gets internalized 
and the ETA’ moiety unfolds its toxic effect by inhibition of the protein synthesis. To measure 
this cytotoxic activity, XTT viability assays with the target cell line 8.18-C5 and a non-specific 
  
                                                                                                                                        Results 
               
     
70 
control cell line (PLP-reactive J-4 hybridoma cells) was performed. The inhibition of protein 
synthesis by MOG-ETA’ was measured by metabolization of a yellow tetrazolium salt (XTT) 
to a orange-coloured formazan derivative. By ADP-ribolyzation of the elongation factor 2 (EF-
2) and the subsequent inhibition of protein synthesis, the amount of expressed mitochondrial 
dehydrogenase is reduced which can be visualized by a decrease of XTT turnover. The 
sterile filtered protein samples were available in PBS and were incubated in triplicates in 
decreasing concentrations with the target cells and a control cell line. Cells under normal 
growing conditions were used as negative control. Zeocin® (Invitrogen) was used as positive 
control on both cell lines in a concentration of 1,6mg/mL.  
 
Figure 25: Cytotoxic activity of recombinant MOG-ETA′ on 8.18-C5 hybridoma cells. The 8.18-C5 hybridoma cells 
and J-4 hybridoma cells (control cell line) were incubated with serial dilutions of sterile-filtered MOG-ETA′ or MOG 
in complete RPMI 1640 medium. The cytotoxicity assay (2.2.12.1) was performed in triplicate. After incubation for 
48h at 37°C in 5% CO2, cells were refreshed with 50µl of RPMI 1640 medium containing XTT/phenazine 
methosulfate (final concentrations of 0.3mg/50µl) for 4 h. Absorbance was measured at 450 and 650nm 
(reference wavelength) with an ELISA reader (MWG Biotech). The half maximal inhibitory protein concentration 
(IC50) relative to untreated control cells was calculated using GraphPad Prism software. (A) 8.18-C5 (□) and J-4 
(∆) hybridoma cells were incubated with different concentrations of MOG-ETA’ immunotoxin. Dose dependent 
decreasing viability of the target cell line (8.18-C5) is shown as sigmoidal curve. The average half maximum 
inhibitory concentration (IC50) value was determined at 40ng/mL. (B) Cell viability of 8.18-C5 hybridoma cells 
(white columns) and J-4 hybridoma cells (black columns, controll cell line) after incubation with 0.25µg/mL MOG-
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ETA’ and MOG. Cells under normal growing conditions were used as negative control. Zeocin® (Invitrogen) was 
used as positive control on both cell lines in a concentration of 1,6mg/mL. 
 
To evaluate the specific cytotoxicity of the MOG-ETA′ immunotoxin in vitro, an XTT-based 
colorimetric cell proliferation assay was carried out on MOG-reactive 8.18-C5 cells, with the 
nonreactive J-4 cell line used as a control. Decreasing concentrations of MOG-ETA′ were 
added to the cells and their proliferation was determined in comparison to untreated cells and 
to cells incubated with the recombinant MOG protein lacking the toxic ETA′ moiety. As shown 
in Figure 25A, MOG-ETA′ was toxic specifically to the 8.18-C5 cells, with a calculated 
median IC50 of 40ng/mL (corresponding 0.66nM). In contrast, the MOG-negative cell line J-4 
was not affected at immunotoxin concentrations of up to 9µg/mL. Neither the PBS control nor 
the MOG protein alone showed any toxic effect on the 8.18-C5 or J-4 cells (Figure 25B). 
 
3.5.2 Toxic in vitro activity of PLP-ETA’ 
 
To support the proof-of-concept of specifically targeting B lymphocytes by their cognate 
antigen and to demonstrate the efficient mode of action of autoimmunotoxins, the cytotoxic 
effect of PLP-ETA’ towards its target cell line F4-2D2 was observed. As a control, the protein 
was incubated with a non-specific cell line (8.18-C5 hybridoma cells).  Furtheron the 
influence of PLP without toxin moiety on PLP-reactive hybridoma cells was evaluated. The 
biological activity is described by the overall efficacy as well as by the concentration at which 
the half maximal response (IC50) is obtained; the cell viability was tested in a dose dependent 
manner. The target cell lines were incubated for 48h with PLP-ETA’ or PLP alone at 
increasing protein concentrations as mentioned above. The resulting dose response curves 
are shown in Figure 26A.  
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Figure 26: Cytotoxic activity of recombinant PLP-ETA′ (F4-2D2 hybridoma cells). The F4-2D2 hybridoma cells 
and 8.18-C5 hybridoma cells (control cell line) were incubated with serial dilutions of sterile-filtered PLP-ETA′ or 
PLP in complete RPMI 1640 medium. The cytotoxicity assay (2.2.12.1) was performed in triplicate. After 
incubation for 48h at 37°C in 5% CO2, cells were refreshed with 50µl of RPMI 1640 medium containing 
XTT/phenazine methosulfate (final concentrations of 0.3 mg/50µl) for 4h. Absorbance was measured at 450 and 
650nm (reference wavelength) with an ELISA reader (MWG Biotech). The half maximal inhibitory protein 
concentration (IC50) relative to untreated control cells was calculated using GraphPad Prism software. (A) F4-2D2 
(□) and 8.18-C5 (∆) hybridoma cells were incubated with different concentrations of PLP-ETA’ immunotoxin. Dose 
dependent decreasing viability of the target cell line (F4-2D2) is shown as sigmoidal curve. The average half 
maximum inhibitory concentration (IC50) value was determined to >500ng/mL. (B) Cell viability of F4-2D2 
hybridoma cells (white columns) and 8.18-C5 hybridoma cells (black columns, controll cell line) after incubation 
with 0.4µg/mL PLP-ETA’ and MOG. Cells under normal growing conditions were used as negative control. 
Zeocin® (Invitrogen) was used as positive control on both cell lines in a concentration of 1.6mg/mL.  
 
The recombinant PLP-ETA’ autoimmunotoxin showed a dose-dependent increase of 
cytotoxicity. Although the cell viability of F4-2D2 hybridoma cell lines was solely reduced to 
45% using the highest protein concentration (400ng/mL), the specific effect could be clearly 
verified by XTT viability assay. The PLP-ETA’ protein revealed no toxic effect on the 8.18-C5 
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control hybridoma cell line even in the highest protein concentration. Due to small expression 
rates of PLP-ETA’ and time constraints, the exact IC50 value could not be exactly determined 
but estimated to ~500ng/mL.  
 
3.5.3 FACS-based cell viability assay of MOG-ETA’ on IgHMOG splenocytes 
 
To determine the effect of MOG-ETA′ on primary B lymphocytes from transgenic IgHMOG mice 
carrying membrane-bound, MOG-reactive antibodies a FACS-based viability assay was 
established. Splenocytes were isolated from IgHMOG mice and resuspended in complete 
RPMI 1640 medium containing different concentrations of the MOG-ETA′ fusion protein. As 
controls, cells were incubated with equivalent concentrations of MOG protein (lacking the 
toxin moiety) or with complete RPMI 1640 medium alone. Untreated splenocytes (Figure 
27B) showed the anticipated distribution of MOG-reactive (11.37% of total splenocytes, 
upper right; equivalent to 100% MOG-reactive B lymphocytes) and nonreactive (18.85% of 
total splenocytes, upper left) B lymphocytes. 
 
 
Figure 27: Cytotoxic activity of recombinant MOG-ETA′ on IgHMOG B lymphocytes (1.7). Reduction of isolated 
MOG-reactive B lymphocytes from IgHMOG mice after treatment with different concentrations of MOG-ETA’ 
immunotoxin. Cells were analysed by double staining using CD19-PE antibody (BD Biosciences) and 
recombinant eGFP-MOG protein. To demonstrate the decreasing population of CD19+/MOG+ after incubation with 
MOG-ETA’ cells were gated in four different regions (LL (lower left): CD19-/MOG-; LR (lower right): CD19-/MOG+; 
UL (upper left): CD19+/MOG-; UR (upper right): CD19+/MOG+). (A) Isolated IgHMOG splenocytes were analysed in 
FSC/SSC to detect target cell population. (B) Gated splenocytes under normal growing conditions. (C-E) Gated 
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splenocytes incubated with increasing concentrations of sterile-filtered MOG-ETA′ (1, 2 and 5µg/mL, respectively) 
in PBS. 
 
The viability of total MOG-reactive cells was successfully reduced to 30% (from 11.37% to 
3.23%) in the presence of 1µg of immunotoxin (Figure 27C, upper right), with no toxicity 
towards other B-lymphocytes (Figure 27C, upper left). Higher protein concentrations (2 and 
5µg) reduced the viability of the MOG-reactive target cell populations almost to zero (Figure 
27D and E, upper right panels) but also had some influence on MOG-negative B 
lymphocytes (upper left panels). Incubation of splenocytes with MOG protein had no effect 
(data not shown). 
  
3.6 Animal Experiments 
 
3.6.1 In vivo targeting of MOG-reactive cells in IgHMOG mice  
 
The in vivo effect of MOG-ETA’ on primary MOG-reactive B lymphocytes was furtheron 
investigated using transgenic IgHMOG mice that were kindly provided by Professor Hartmut 
Wekerle and Dr. Florian Kurschus from the Max-Planck-Institute of Neurobiology 
(Martinsried, Germany). After having proven a specific binding and efficient depletion of 
isolated autoreactive splenocytes in vitro and ex vivo, the specific effect of the MOG-ETA’ 
autoimmunotoxin was subsequently tested in vivo. Two different protein concentrations 
(10µg, 20µg) of MOG-ETA’ were applied daily over a time period of one week intravenously 
in 50µl of PBS. Each group consisted of two 12 week-old, female IgHMOG mice (homozygous) 
that were kindly bred by the “Institut für Versuchstierkunde” of the UK Aachen. The control 
group was injected with 10µg of MOG in PBS. After treatment with the proteins, the animals 
were sacrificed and all spleens were removed. Splenocytes were washed and subsequently 
stained using anti-CD19-PE antibody and recombinant eGFP-MOG protein.   
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Figure 28: Cytotoxic in vivo activity of MOG-ETA’ in homozygous transgenic IgHMOG mice. After in vivo targeting of 
MOG-reactive B lymphocytes from IgHMOG mice (1.7) the reduction of MOG-reactive cells were measured by flow 
cytometry analysis. After splenocyte isolation of treated mice, the cells were double-stained using CD19-PE 
antibody (BD Biosciences) and recombinant eGFP-MOG protein. To demonstrate the decreasing population of 
CD19+/MOG+ after incubation with MOG-ETA’ cells were gated in four different regions (LL (lower left): CD19-
/MOG-; LR (lower right): CD19-/MOG+; UL (upper left): CD19+/MOG-; UR (upper right): CD19+/MOG+). The 
reduction of cells in the upper right panels in comparison to the control (A) corresponds to the depletion of MOG-
reactive B lymphocytes. (A) Splenocytes from mice that were treated with daily doses of MOG protein without 
toxic moiety. Splenocytes from mice treated with the autoimmunotoxin MOG-ETA’ in daily doses of 10µg (B) and 
20µg (C). 
 
 
Figure 29: Quantitative comparison of MOG+ cell reduction in IgHMOG mice (1.7) after treatment with MOG-ETA’. 
Transgenic IgHMOG mice were treated with MOG-ETA’ autoimmunotoxin (2.2.12.2). The treatment with two 
different concentrations of MOG-ETA’ efficiently reduced the number of MOG-positive B lymphocytes in the 
spleen to 65% (left white column, 10µg dose) and to 58% (right white column, 20µg dose). As a control, the MOG 
protein without toxic moiety was applied in a 10µg/day dose (black column).  
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Although MOG-specific B-lymphocytes are constantly produced in the bone marrow of 
IgHMOG mice with a number of 10
7 cells per day which constantly refreshes the pool of 
depleted B cells, MOG-ETA’ protein was able to reduce the number of MOG-specific B 
lymphocytes in vivo (Figure 28, upper right panels; Figure 29). The number of MOG-reactive 
cells was reduced by 35% after application of 10µg/day of autoimmunotoxin and by more 
than 40% after treatment of animals with a 20µg/day dose. The control group where mice 
were injected with MOG alone did not show any negative effect on MOG-specific B 
lymphocytes. The distribution of MOG-reactive to non MOG-reactive B lymphocytes (Figure 
28, upper panels) is 50% each - as it can always be found in blood and spleen of 
homozygous IgHMOG mice. Finally, the MOG-ETA’ autoimmunotoxin specifically eliminated 
MOG-autoreactive B lymphocytes in the transgenic IgHMOG mice model, even in the presence 
of a high MOG-antibody titer that is present in transgenic MOG mice.  
 
3.6.2 Evaluation of MOG-ETA’ autoimmunotoxin in an EAE mouse model 
 
The promising in vivo effect in the depletion of MOG-reactive B lymphocytes in transgenic 
IgHMOG mice required the subsequent evaluation of the protein in the established EAE 
disease model. The experimental autoimmune encephalomyelitis is thought to be mainly Th1 
response-driven but anyway autoreactive B lymphocytes seem to play a crucial role in the 
pathological progression and the severity of this animal model. The goal was to investigate if 
the MOG-ETA’ autoimmunotoxin has an inhibiting impact on the course and the proceeding 
of the disease. To exclude an unspecific mode of action through nondirectional 
internalization of the recombinant fusion protein, a control protein consisting of the same 
ETA’-domain but a non-specific ligand was implicated in the experiment setup (control 
group). This ligand is called ‘Bo9’ and is a grass pollen allergen fragment that was used for 
the targeting of allergen-reactive B lymphocytes in another project within our research group. 
MOG-ETA’ and Bo9-ETA’ were both expressed, purified, tested for functionality and finally 
lyophilized at the Fraunhofer Institute for Molecular Biology and Applied Ecology in Aachen. 
The lyophilized samples were subsequently sent to our cooperation partners Professor 
Christopher Linington and Dr. Carl Goodyear at Glasgow University (UK) who performed the 
animal experiments that are described as follows: EAE was induced in 8-10 weeks old 
DBA/1j mice by intradermal injection of 50µg of rat MOG (aa 1-125) in Incomplete Freund’s 
Adjuvant (IFA) supplemented with 3mg/mL inactivated Mycobacterium tuberculosis (H37 RA; 
Difco). The above mentioned groups of mice (target group, control group) subsequently 
received 25µg of either Bo9-ETA’ (control protein) or MOG-ETA’ by intraperitoneal injection 
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on day 2 after EAE induction and every other day thereafter. The mice were monitored daily 
for clinical signs of EAE and the experiment was stopped 5 days after the first animals 
reached stage 4 of clinical disease symptoms.   
 
 
 
Figure 30: Effect of MOG-ETA’ autoimmunotoxin on the clinical score of EAE-induced DBA/1 mice. Mice were 
EAE-induced by immunization (2.2.14.2) with 100µg MOG1-125 rat protein in a 1:1 volume mix with Incomplete 
Freund’s Adjuvant (iCFA). On days 2, 4, 6, 8, 10 and 12 past EAE induction, the mice were injected with 25µg 
autoimmunotoxin MOG-ETA’ (black squares) or the same amount of control immunotoxin Bo9-ETA (white 
circles). The clinical score of the mice (n=3 per group) was recorded daily.  
 
The MOG-ETA’ treated animals showed no clinical symptoms of EAE for a time period of 11 
days. Even after day 11, just one single animal from the MOG-ETA’ group appeared with 
very light clinical symptoms at a score of about 1. In comparison, the control group in which 
the unspecific immunotoxin Bo9-ETA’ was applied, revealed a strong clinical response 
starting on day 9 after EAE induction. Due to the severity of clinical symptoms (average 
score of >3.5) in the control group, the experiment was stopped by sacrifice of the animals on 
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day 14. Hence, the autoimmunotoxin MOG-ETA’ efficiently prevented the occurrence of 
clinical symptoms in an EAE-induced mouse model.  
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4 Discussion 
MS is clinically and pathologically a very heterogeneous autoimmune disease with an 
inflammatory and demyelinating pathology, and contributions towards disease progression 
from B- and T lymphocytes as well as macrophages [166-170]. Autoreactive B lymphocytes 
are currently regarded as key players in the inflammatory reactions associated with MS and 
its related animal model EAE as they are involved in certain forms of demyelination and 
instrumental in the process of neurodegeneration [171]. In contrast to the proteolipid protein 
(PLP) and myelin basic protein (MBP) autoantigens, the myelin oligodendrocyte glycoprotein 
(MOG) is found exposed on the surface of the myelin sheath. The majority of antibodies 
produced against self structures in MS and EAE are directed against the extracellular part of 
MOG containing the major epitopes aa 35-55 and aa  92-106 for autoreactive B lymphocytes. 
Hence, the present work is mainly concentrated on the design of a functional MOG-based 
immunotoxin with a truncated form of Pseudomonas exotoxin A (ETA’) as toxic domain to 
target and subsequently eliminate MOG-specific B lymphocytes that are prevalent in MS 
pathology. To additionally confirm this proof-of-concept of targeting autoreactive B 
lymphocytes via antigen-based immunotoxins, a PLP-based immunotoxin containing an 
autoreactive PLP peptide sequence as binding ligand and the above mentioned ETA’-toxin 
domain was generated to eliminate PLP-reactive B lymphocytes. Until now, few succesful 
investigations have been made in targeting autoreactive cell populations using antigen-based 
therapeutics [172, 173].  
Within our group, we succeeded in specifically depleting atopic B cell populations using an 
allergen-toxin fusion protein [146]. This procedure has the distinct advantage over already 
established systemic approaches that run the risk of non-specifically depleting the entire B 
cell lineage [174, 175]. The goal of the present work envisions the antigen-specific targeting 
of MOG- and PLP-reactive B lymphocytes in multiple sclerosis using MOG-ETA’ and PLP-
ETA’ autoimmunotoxins. The possibility of targeting MOG-reactive hybridoma cells and 
splenocytes using bispecific fusion proteins to recruit effector cells has been investigated 
[176, 177], but these proteins must be applied in relatively high doses in order to have a 
significant effect. We established practical and scaleable methods for the production of 
MOG-ETA′/PLP-ETA’ and MOG/PLP proteins in bacteria by targeting to the periplasm, which 
avoids the labor-intensive refolding procedures often required for cytosolic recombinant 
proteins. Significantly, our use of osmotic stress conditions yields more than 95% functional 
immunotoxin protein [151]. The specific binding of all proteins was confirmed by western blot, 
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ELISA and flow cytometry using specific antibodies and antigen-specific hybridoma cell lines 
for MOG and PLP. The cytotoxic effects of autoimmunotoxins were succesfully tested on the 
specific hybridoma cell lines and, in addition, MOG-ETA’ was tested on freshly isolated 
splenocytes (ex vivo) from transgenic IgHMOG mice that were kindly provided by Professor 
Hartmut Wekerle and Dr. Florian Kurschus from the Max-Planck-Institute of Neurobiology in 
Martinsried (Germany). Further in vivo experiments using the transgenic IgHMOG mouse 
model validated the efficiency of the MOG-ETA’ immunotoxin.  
To evaluate the therapeutic effect of MOG-ETA’ in an EAE mouse model, we closely 
cooperated with Professor Christopher Linington and Dr. Carl Goodyear from the University 
of Glasgow (UK) who have a strong expertise on MOG-induced EAE mouse models. The 
autoimmunotoxin MOG-ETA’ was designed, expressed and purified at the Fraunhofer 
Institute of Molecular Biology and Applied Ecology in Aachen. The functionality of the protein 
was tested in vitro and ex vivo before sending it to Professor Liningtons’ group at Glasgow 
University where the in vivo evaluations in the MOG-induced EAE model were performed. 
Due to time constraints and the lack of an available mouse model, the PLP-ETA’ 
autoimmunotoxin could not be further evaluated using in vivo experiments but its specific 
toxic effect on PLP-reactive B lymphocytes still remains to be investigated in a PLP-induced 
EAE model [178, 179]. This could help to clarify the role of PLP-reactive B cells in the 
pathophysiology of EAE disease progression [87]. For the antigen-specific staining of 
autoreactive B cell populations, two fluorescent fusion proteins were designed for expression 
in eukaryotic cells. The above mentioned protein fragments were succesfully fused with the 
enhanced green fluorescent protein (eGFP). Unfortunately the eGFP-PLP protein could not 
be expressed in 293T cells. However the eGFP-MOG fluorescent protein could be efficiently 
expressed and purified from 293T cell supernatant. After purification it served as powerful 
and easy-to-use tool for the direct staining of autoreactive B lymphocytes in flow cytometry 
(MOG-reactive 8.18-C5 hybridoma cells, isolated splenocytes from transgenic IgHMOG mice) 
and for in-depth internalization studies of recombinant proteins into their target cells via B cell 
receptor-mediated endocytosis.  
 
4.1 Expression and purification of autoimmunotoxins 
 
The expression of recombinant proteins in E. coli is characterized by high and reproducable 
expression rates. Published data from Pastan and Fitzgerald [180] already described high 
expression rates of fusion proteins that based on the toxic domain of the Pseudomonas 
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exotoxin A (ETA’). But the amount, the functionality and the purification method of the protein 
expressed are determined by its target compartment within the cell. The applied bacterial 
vector system determines if the expressed proteins accumulate in the cytoplasm in a soluble 
form, in cytoplasmic granula, or in the perisplasmic space. Buchner et al. [148] developed an 
expression system that results in production of recombinant ETA’-based immunotoxins and 
their accumulation in inclusion bodies. This method guaranteed a high protein expression 
but, it requires laborious de- and renaturation steps during the purification to ensure the 
activity of immunotoxins. In the present study, the bacterial expression system aims for the 
periplasmic secretion of expressed proteins. The periplasmic space is located between the 
cytoplasmic membrane and the adjacent peptidoglycan layer. The periplasm of gram-
negative bacteria contains just 4% of total bacterial protein [181] which facilitates the 
accumulation and subsequent purification of recombinant proteins. The oxidative milieu in 
the periplasmic space maintains the correct folding and stability of the proteins e.g. by 
disulfide formation [182]. To prevent the accumulation of protein in inclusion bodies [183], 
several groups developed new expression protocols that were based on lower temperatures 
for the efficient expression of proteins. These conditions lead to the production of 
chaperones that support the correct folding of the expressed recombinant proteins. Further 
optimized protocols included the expression of recombinant in osmotic stress conditions 
permitting the bacterial growth in high salt concentrations (Sorbitole, NaCl)  in the presence 
of compatible solutes like Glycine-Betaine [184]. Based on the protocol of Barth et al. [151], 
the recombinant autoimmunotoxins MOG-ETA’ and PLP-ETA’ as well as their counterparts 
without toxin moiety (MOG and PLP) were succesfully expressed using the pBM vector 
system (2.1.9). 
 
4.1.1 Purification and characterization of autoimmunotoxins 
 
The expression of autoimmunotoxins (MOG-ETA’, PLP-ETA’) and myelin proteins without 
ETA’-toxin domain (MOG, PLP) was carried out following the periplasmic expression protocol 
under osmotic stress conditions developed by Barth et al. [151]. The most conclusive 
advantage of the periplasmic protein expression strategy bases upon the deposition of the 
expressed proteins in the periplasmic space in a soluble and functional form. This 
functionality, one of the most important properties of an effective immunotoxin, is additionally 
enabled by the presence of a disulfide oxyreductase [185] and the bacterial expression of 
chaperones [186] within the periplasmic space. A cytoplasmic expression system, on the 
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contrary, leads to the deposition of protein in inclusion bodies with high expression yields 
ranging from 1.5-2mg/L for ETA’-based immunotoxins [187-189]. But it has to be considered 
that this expression system results in the accumulation of non-functional protein in inclusion 
bodies demanding for time- and cost-intensive refolding procedures. Within this work, both 
the ETA’-based autoimmunotoxins and the control proteins without ETA’-domain were 
successfully expressed by periplasmic expression under osmotic stress conditions and could 
be efficiently purified by IMAC and subsequent size exclusion chromatography. The MOG 
proteins both exposed a high purity after the applied purification steps with protein 
expression yields ranging from 0.75mg/L bacterial culture for the MOG protein to 1mg/L 
bacterial culture for the autoimmunotoxin MOG-ETA’ determined by Bradford assay. The 
achieved protein yields of autoimmunotoxins within this work strongly correlate with the 
expression yields of other functional ETA’-based immunotoxins [190-193]. The Coomassie 
stained SDS-PAGEs in Figure 13 (A left, B left) displays the recombinant proteins MOG-ETA’ 
(57.5 kDa) and MOG (17.9 kDa) in the expected sizes without any contaminating bacterial 
proteins or degradation products. The samples were permanently kept at 4°C or on ice to 
inhibit potential protease activity and degradation. In western blot, both MOG proteins were 
specifically detected using diluted supernatant of MOG-reactive 8.18-C5 hybridoma cells. 
These hybridoma cells secrete antibodies that recognize a non-linear, conformational but 
SDS-resistant epitope within the extracellular Ig-like domain of MOG [127]. The expression of 
PLP proteins was carried out using the stress expression protocol (2.2.10.1) and the 
expressed proteins could subsequently be purified by IMAC (2.2.10.2) and size exclusion 
chromatography (2.2.10.5). During initial cloning and expression steps in this thesis, the PLP 
proteins (full length) could not be functionally expressed due to the presence of several 
hydrophobic domains that disturbs the transport of expressed proteins into the periplasm. To 
ensure the expression of PLP proteins and their accumulation in the periplasmic space, the 
PLP binding domain was shortened by cloning to a peptide sequence that contains the major 
epitopes for autoreactive B lymphocytes. In spite of the shortened PLP binding domain, the 
expression rates for PLP proteins were still poor with expression yields ranging from 0.1mg/L 
bacterial culture for the PLP protein to ~0.5mg/L bacterial culture for the PLP-ETA’ protein. 
These difficulties in expressing PLP proteins correlate with the fact that, to our knowledge, 
there are only three groups that were able to express PLP in a recombinant functional form 
[194-196]. Further on, we found out that PLP-ETA’ is the first immunotoxin for an antigen-
specific targeting of PLP-reactive B lymphocytes in EAE and MS. The expected size of the 
recombinant proteins could be confirmed by western blotting for PLP-ETA’ (55 kDA) and PLP 
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(10 kDa) without showing contaminating bacterial proteins or degradation products (Figure 
15, A left, B left). For the specific antibody detection of PLP proteins, diluted cell supernatant 
from PLP-reactive F4-2D2 hybridoma cells was succesfully used. The secreted antibodies of 
this cell line are directed against the PLP epitope aa 100-123 [156] that is contained in the 
cloned PLP binding domain. Concluding, all recombinant proteins were succesfully 
expressed in adequate amounts and detected by their respective antibody (supernatant from 
hybridoma cells). To provide higher amounts of recombinant proteins for extensive in vivo 
characterizations in EAE mouse models, a fermentation and purification protocol remains to 
be established. 
 
4.2 Eukaryotic expression of eGFP fusion proteins 
 
To facilitate the antigen-specific in vitro staining of autoreactive B cell populations, the 
potential binding ligands MOG and PLP were genetically fused to an enhanced version of the 
green fluorescent protein, called ‘eGFP’ [197]. With the application of these eGFP fusion 
proteins, one is able to directly target and stain autoreactive B lymphocytes on an antigen-
specific way. The proteins are easy to express in 293T cells, stable and simply to handle and 
can be used in various applications like flow cytometry analyses or internalization studies in 
confocal microscopy to discriminate antigen-specific B lymphocytes. Furthermore, the 
fluorescent labelling of autoantigens might be a promising approach to specifically visualize 
autoreactive B cell populations in inflammatory loci within the central nervous system of EAE 
(experimental autoimmune encephalomyelitis) mice, the mouse model of Multiple Sclerosis. 
Until now, there have been few investigations in successfully and specifically staining 
autoreactive B lymphocytes using antigen-GFP fusion proteins to target the appropriate B 
cell receptors [173]. To demonstrate the specific binding capacity of the proteins to their 
target cell lines, different flow cytometry based binding assays were performed. The 
internalization pathway of bound eGFP-MOG protein to its target cell line 8.18-C5 was 
successfully visualized by confocal microscopy. The cloning of eGFP fusions was carried out 
using the pMS vector system (2.1.9) for eukaryotic expression in 293T cells. Both vector 
constructs were verified by restriction analysis (Figure 17) and subsequent DNA sequencing. 
After transfection of 293T cells (2.2.9.1), the eGFP-MOG protein was expressed and 
secreted into the cell supernatant by the additional Igκ leader peptide. Successfully 
transfected cells are characterized by their green fluorescent appearance and the growth 
under Zeocin® selection pressure. The efficient expression of protein started 2-3 weeks after 
transfection leading to the continuous availability of eukaryotic expressed fusion protein. 
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Unfortunately, eGFP-PLP could not be expressed in 293T cells. The transfection of its vector 
constructs into the target cells lead to cell death after 3-5 days without detectable 
recombinant protein in the cell supernatant and just very low protein yield after analysis of 
lysed cells. Transfection was repeated several times with freshly prepared vector DNA (also 
with precipitated DNA) without success. Obviously, the nature of the expressed protein 
influences the cell viability in an unknown way. Due to time constraints, the expression of 
eGFP-PLP was not further observed or optimized. The expressed eGFP-MOG protein on the 
other hand, was purified from the cell supernatant (2.2.10.3) with a yield of ~5mg/L cell 
supernatant. After IMAC purification and size exclusion chromatography, the protein could be 
visualized by Coomassie stained SDS-PAGE and western blot (Figure 18) revealing the 
expected protein size including the posttranslational modification pattern through 
glycosylation leading to an increase in size of 10-15 kDa. In western blot, the protein was 
succesfully detected using diluted (1:10 in PBS) cell supernatant from 8.18-C5 cells as 
primary antibody which is directed against an epitope in the MOG binding domain. For further 
applications, the purified protein was sterile filtered using a 0.22µm filter and then stored at 
4°C in the dark to prohibit ‘fading’ of the fluorescent eGFP domain. 
 
4.3 Functional binding characterization of autoimmunotoxins  
 
To functionally characterize the binding of expressed proteins to their respective antibody in 
a native state, standard ELISA assays and flow cytometric analyses were carried out. In 
ELISA, the recombinant proteins were coated to microtiter plates in different concentrations 
and were subsequently detected using supernatants of antigen-specific hybridoma cell lines. 
As controls, the supernatants of unspecific control cell lines were applied as primary 
antibodies. The bound mouse hybridoma antibodies were finally detected using a goat-anti-
mouse-HRPO antibody with following ABTS substrate reaction. For flow cytometry analyses, 
the binding of prokaryotic expressed MOG- and PLP-based autoimmunotoxins and control 
proteins was tested on their respective hybridoma cell line and a non-specific negative 
control hybridoma cell line. As negative controls, the MOG-proteins were tested on the PLP-
specific cell line F4-2D2 and on the other hand, PLP-proteins were tested on the MOG-
reactive cell line 8.18-C5. These analyses served to evaluate unspecific binding of proteins 
to related, but antigen-unspecific cells. The availability of the transgenic IgHMOG mouse model 
permitted the binding evaluation of all expressed MOG proteins (MOG-ETA’, MOG, eGFP-
MOG) on isolated primary splenocytes. The specific binding was thus tested by FACS 
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analysis using the anti-his ALEXA488 antibody for the detection of his-tagged MOG and 
MOG-ETA’ proteins.  
 
4.3.1 Binding analysis on antigen-specific hybridoma cell lines via ELISA  
 
The specific binding of the expressed autoimmunotoxins MOG-ETA’ and PLP-ETA’ and their 
counterparts MOG and PLP without toxin domain was succesfully confirmed by ELISA 
(Figure 19). All proteins were immobilized onto ELISA microtiter plates in different 
concentrations in triplets. The OD405 signal strength that was measured after substrate 
reaction strongly correlates with the amount of coated protein ranging from 150ng/mL to 
15µg/mL showing extinction values between 0.6 to 4.0 (MOG proteins) and 0.3 to 1.6 (PLP 
proteins. By comparing the measured values, the binding efficiency of MOG-reactive 
antibodies from the hybridoma cell line 8.18-C5 is quite stronger than the binding of PLP-
reactive F4-2D2 antibodies to the PLP proteins with respect to the same amounts of coated 
proteins. The steric accessibility of the target epitopes possibly differs between MOG and the 
PLP proteins or the overall affinities of the two different antibodies to their target structure 
varies leading to the differing OD405 values. Curiously, the signal strength of ETA’ fusion 
proteins showed a stronger signal than the control proteins without a toxic domain. Due to 
the application of equal protein concentrations in the ELISA setup, there are more molecules 
of MOG and PLP proteins without fusion partner coated to the microtiter plates as expected 
relating to the differences in molar mass. But the signal strength on the autoimmunotoxin 
MOG-ETA’ is stronger than on the MOG protein without toxic domain. Speculatively, the 
ETA’-domain functions as a kind of ‘chaperone’ supporting a better folding of the MOG 
binding ligand leading to a better accessibility of the epitope. This phenomenon can be 
observed by comparing the first two concentrations of PLP-ETA’ and PLP as well. The 
highest concentrations in Figure 19B showed the expected difference in signal strength value 
of the PLP protein and the autoimmunotoxin. Unspecific binding activities using control 
supernatants of antigen-unspecific hybridoma cells (Figure 19, green columns) could not be 
observed.    
 
4.3.2 Binding analysis on antigen-specific hybridoma cell lines via flow 
cytometry  
 
Besides ELISA binding analyses (3.3.1), the specific binding activity of the recombinant 
proteins on their specific target hybridoma cell line was evaluated by flow cytometry. 
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Compared to ELISA experiments based on the application of cell membranes, flow cytometry 
analyses have the advantage that one is able to examine the binding activity of proteins on 
living cells bearing cell surface molecules in a native conformation [198]. In addition, it is 
possible to differentiate between dead and living cells by mapping their size (FSC, forward 
scatter) and granularity (SSC, sideward scatter). Living cells are gated within the FSC/SSC 
map and the shifts into the fluorescence channel FL-1 correlate with the binding of protein to 
the target cell population. All results generated by flow cytometry confirmed the results from 
the above mentioned ELISA experiments (4.3.1). The specific binding affinity of the proteins 
to their respective target cell line was clearly established. MOG and MOG-ETA’ specifically 
bound to the MOG-reactive hybridoma cell line 8.18-C5 (Figure 20A) but not to the control 
hybridoma cell line F4-2D2 (Figure 20B). The presence of membrane-bound B cell receptors 
was demonstrated using a FITC-labelled goat anti-mouse antibody (GAM-FITC, upper right 
histogram in Figure 20). PLP-ETA’ and PLP bound to their target cell line F4-2D2 (Figure 
20C) without binding unspecifically to the MOG-reactive control hybridoma cell line 8.18-C5 
(Figure 20D). Here the presence of B cell receptors on the cell surface was also 
demonstrated with the help of a goat anti-mouse-FITC antibody. To exclude an unspecific 
binding of the secondary antibody to the used cell lines, all samples were standardized to the 
incubation of target cells with the secondary antibody alone (Figure 20, red curves). Finally, 
all proteins specifically bound to their respective cell line. The detection of proteins was 
succesfully carried out using the secondary ALEXA488-labelled anti-his antibody. In addition, 
none of the proteins showed unspecific binding to the used control cell lines. The 
experiments carried out by Proby et al. [173], Reiners et al. [199] and Stöcker et al. [146] 
already demonstrated the feasibility of a B cell targeting using antigen-based immunotoxins. 
Our results strongly support this proof-of-concept by exclusively targeting distinct 
autoreactive B cell populations in multiple sclerosis using antigen-based fusion proteins 
[200]. Compared to current approaches in targeting autoreactive B cell populations which 
concentrate on a rather systemic elimination of all B cells [53], our approach could be able to 
exclusively target and deplete autoreactive B cell populations without impairing non-
pathologic B lymphocytes.  
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4.3.3 Binding analysis on isolated splenocytes from IgHMOG mice via flow 
cytometry 
 
The availability of IgHMOG mice, a mouse strain that is transgenic for the rearranged VDJ 
gene segment of the heavy chain from MOG-specific 8.18-C5 hybridoma leading to the 
presence of a large number of MOG-specific B lymphocytes and a corresponding high titer of 
MOG-reactive antibodies, allowed for the direct binding evaluation of all expressed MOG 
proteins on isolated primary splenocytes. All binding analyses were performed with freshly 
prepared splenocytes resuspended in RPMI medium and purified MOG proteins using 
standard FACS procedures (2.2.11). Figure 21 displays the specific staining of MOG-reactive 
B lymphocytes of IgHMOG mice using the fluorescent protein eGFP-MOG. To additionally label 
all contained B lymphocytes, the cell preparation was co-stained using an anti-CD19-PE 
antibody. Figure 21B shows the specific binding of recombinant eGFP-MOG to ~30% of 
CD19+ B lymphocytes (upper right panel), while the other 70% showed no significant 
interaction with the protein (Figure 21B, upper left panel and Figure 21C). This distribution, 
which was observed in heterozygous animals, clearly corresponds to the observations made 
by Litzenburger et al. [127] in which approximately one third of B lymphocytes showed a high 
reactivity to the MOG protein. Prokaryotically expressed proteins MOG and MOG-ETA’ 
showed a specific and efficient binding to IgHMOG splenocytes as well. The cells were co-
stained using an anti-CD19-PE antibody as mentioned above. Figure 22B shows a sample of 
a dot plot that was generated with cells that were co-stained with anti-CD19-PE and anti-his 
ALEXA488 (negative control). Bound proteins lead to the appearance of events in the upper 
right panel of Figure 22B (not shown). The resulting histogram which is based upon gating of 
the cell population to the above mentioned panel, is depicted in Figure 22C and displays a 
clear fluorescence shift in FL-1 through the binding of MOG and MOG-ETA’ on IgHMOG 
splenocytes. All expressed MOG proteins efficiently bound to isolated splenocytes from 
transgenic IgHMOG mice.  
 
4.3.4 Internalization studies on MOG-specific hybridoma cells  
 
For an immunotoxin to be toxic, it needs to be internalized by its target cell. In this work, the 
targeting of autoreactive B lymphocytes is based upon the application of antigen-specific 
fusion proteins that are bound by membrane-anchored B cell receptors via their autoantigen 
domain. This antigen-specific binding of the expressed proteins to their target cells has been 
clearly demonstrated by flow cytometry (3.3.2). To further illustrate the specific internalization 
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process of the fusion proteins, MOG-specific 8.18-C5 hybridoma cells and a hybridoma 
control cell line were incubated with the fluorescent eGFP-MOG protein. 1µg of purified 
protein was incubated with the above mentioned cell lines for one hour and two hour 
incubation time as well as at 4°C and 37°C. Subsequently, all samples were washed with 
PBS and fixed using 2% formaldehyde. The eGFP signal distribution was examined by 
confocal microscopy. Significant fluorescent signals were observed in all approaches using 
MOG-specific 8.18-C5 hybridoma cells but not on the negative cell line F4-2D2. At 4°C, the 
binding efficiency of eGFP-MOG on 8.18-C5 was high and GFP fusion proteins that bound to 
membrane-anchored BCRs at the the cell surface appeared as a ‘fluorescent ring’. Due to 
the low incubation temperature, the cell metabolism is arrested and the internalization 
process of antigen bound is actively inhibited. At 37°C, the fluorescent proteins were 
efficiently endocytosed by their target cell line upon B cell receptor-mediated endocytosis. 
After one hour incubation time and subsequent fixation of the cells, the GFP signals were 
detectable on the surface and inside of the cells in endocytotic vesicles. After 2 hours of 
incubation, the receptor-mediated uptake of the target protein had continued and almost no 
fluorescent protein could be detected on the cell surface. The presence of clearly 
differentiated vesicles appearing as early endosomes finally assembling in a distinct region of 
the cytosol, supports the assumption of an antigen-specific endocytotic pathway that could 
finally lead into a lysosomal release of the internalized protein into the cytosol. The efficient 
binding, internalization and cytosolic release of the MOG fluorescent fusion protein 
demonstrated by confocal microscopy illustrates the cellular pathway of an applied MOG-
based therapeutic drug like MOG-ETA’ after incubation with its target cell. Stoddard et al. 
[201] were able to demonstrate that BCR uptake upon antigen binding was reduced by 
approximately 70% in B cells conditionally deficient in clathrin heavy chain expression. This 
corresponds to the results that we generated using the OPERA system (3.4.2) showing a 
colocalization and co-internalization of BCR-Ag complexes and transferrin. The co-incubation 
of MOG-reactive hybridoma cells with recombinant eGFP-MOG protein and transferrin-
ALEXA Fluor633 resulted in the specific staining of the cell surface and the beginning of a 
receptor-mediated endocytosis after ~10 minutes. The colocalization of the BCR-Ag 
complexes and the transferrin in the endocytotic pathway is demonstrated by one particular 
cell (see attached movie file in this thesis). The clear presence of an efficient and specific 
transport of the eGFP-MOG protein is strongly indicative for a cytotoxic potential of the 
autoimmunotoxin MOG-ETA’ that is unfolded after clathrin-mediated internalization followed 
  
                                                                                                                                   Discussion                
 
     
89 
by the endosomal release of the toxin to the cytosol via its translocation domain and the 
inhibition of protein synthesis of the target cell [202].  
  
4.4 Cytotoxicity assays on autoreactive B lymphocytes 
 
After characterization and the verification of binding specificity, the cytotoxic effects of MOG-
ETA′ and PLP-ETA’ were determined using the antigen-specific hybridoma cell line 8.18-C5 
(MOG) and F4-2D2 (PLP). In these experiments the MOG and PLP proteins without toxin 
moiety served as negative control. Both cell lines continuously produce large amounts of 
autoreactive antibodies that can catch and inactivate the proteins in vitro, ex vivo and in vivo. 
The effect of autoimmunotoxins on their specific hybridoma cell line 8.18-C5 and F4-2D2 was 
evaluated using a XTT viability assay (2.2.12.1) according to the manufacturers’ instructions. 
The toxic effect of MOG-ETA’ was additionally tested on freshly isolated splenocytes from 
IgHMOG mice. To determine a specific effect of the protein on isolated splenocytes, the target 
cells were incubated with proteins overnight and subsequently analysed by flow cytometry.   
  
4.4.1 XTT viability assays on autoantigen-specific hybridoma cells  
 
To evaluate the specific cytotoxicity of the MOG-ETA′ immunotoxin in vitro, an XTT-based 
colorimetric cell proliferation assay was carried out on MOG-reactive 8.18-C5 cells, with the 
nonreactive F4-2D2 cell line as control. Decreasing concentrations of MOG-ETA′ were added 
to the cells and their proliferation was determined in comparison to untreated cells and to 
cells incubated with the recombinant MOG protein lacking the toxic ETA’ moiety. The 
cytotoxic potential of different immunotoxin is compared by the IC50 value. This value 
represents the protein concentration that is necessary to eliminate 50% of a targeted cell 
population. As shown in Figure 25A, MOG-ETA′ showed specific toxicity to 8.18-C5 cells with 
a calculated median IC50 of 40ng/mL (0.66nM). In contrast, the MOG-negative cell line F4-
2D2 was not affected at immunotoxin concentrations of up to 9µg/mL. Neither the PBS 
control, nor the MOG protein alone showed any toxic effect on the 8.18-C5 or J-4 cells 
(Figure 25B). This concentration is comparable to that derived from studies using other ETA’-
based immunotoxins [188, 190-192, 203, 204], despite the fact that in our approach the 
immunotoxin is potentially neutralized by freely-circulating antibodies. By comparing the 
efficiency of different immunotoxins, other parameters like the receptor density and the 
affinity of the binding domain crucially influences the cytotoxic efficiency of a certain 
immunotoxin. MOG-ETA’ is the first ‘real’ immunotoxin to specifically target and efficiently 
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eliminate autoreactive B lymphocytes in multiple sclerosis. There have been some 
investigations made by Zocher et al. [176, 177] where the extracellular domain of the myelin 
oligodendrocyte glycoprotein was fused to the Fc domain of an antibody (MOG-Fc) or to an 
anti-CD3 antibody (MOG-αCD3). These proteins had limited immunomodulatory functions by 
redirecting the phagocytosis through FcγR+ cells or cell lysis via stimulation of resting T 
lymphocytes but could show an effective in vitro elimination of MOG-reactive B lymphocytes 
as well. However the advantage of a toxin-based therapeutic in the treatment of lymphoid 
diseases combines a higher efficacy at lower doses with a better monitoring through faster 
clearance from the blood. Furthermore, the application guarantees a high reproducibility and 
a convenient expression of immunotoxins in E.coli  [200, 203, 205]. The data generated in 
the cytotoxicity assays clearly demonstrated the specific elimination of MOG-reactive 
hybridoma cells by the MOG-ETA’ autoimmunotoxin. To pinpoint the toxic effect of the 
protein to the toxic ETA’ domain, a MOG control protein without toxin moiety was incubated 
with the target cells. As it can be seen in Figure 25B, the MOG protein alone had no specific 
effect on the viability of the target cell line 8.18-C5 or the control cell line F4-2D2. This 
observation strongly supports the idea that the reduction of target cell viability bases upon 
the toxic effect of the ETA’-domain. To evaluate the specific toxicity of PLP-ETA’, the above 
mentioned XTT viability was performed on F4-2D2 hybridoma cells with the MOG-reactive 
8.18-C5 cell line as a control. As shown in Figure 26A, the PLP-based autoimmunotoxin 
PLP-ETA’ showed a specific toxicity on its target cell line F4-2D2 without having an influence 
on the control cell line 8.18-C5. Additionally the PLP protein without toxin moiety did not have 
any influence on the target cell lines. Unfortunately, the IC50 value was not reached even in 
the highest concentration of 400ng/mL. The value was estimated to a concentration of 
approximately 500ng/mL but due to time constraints, the exact IC50 value could not be 
determined. By comparing the toxicity of the PLP-ETA’ immunotoxin with the above 
mentioned MOG-ETA’ protein, a 10-fold decrease in effectivity can be observed. This 
difference can be explained by a larger number of free antibodies secreted by the PLP-
reactive F4-2D2 hybridoma cells leading to a higher interception rate of recombinant PLP-
ETA’ proteins. Furtheron the overall affinity of bound proteins to the membrane-bound B cell 
receptors can play a crucial role in effectively internalizing the protein construct via receptor-
mediated endocytosis. This presumption is supported by the ELISA results made in this 
thesis (Figure 19), revealing a stronger binding signal of MOG-reactive antibodies from 8.18-
C5 cells to their MOG target proteins (Figure 19A) in comparison to the binding of secreted 
PLP-antibodies from F4-2D2 cells to their PLP target proteins. In conclusion, both ETA’-
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based autoimmunotoxins specifically bound and eliminated their target cell line without 
having an effect on control cell lines. These promising data supports further in vivo 
evaluations of such recombinant proteins in EAE mouse models. 
 
4.4.2 Ex vivo viability assay of MOG-ETA’ on splenocytes from IgHMOG 
mice 
 
The availability of transgenic IgHMOG mice in this thesis permitted the direct evaluation of the 
MOG-ETA’ immunotoxin on isolated MOG-reactive B-lymphocytes from transgenic mice 
carrying membrane-bound, MOG-reactive antibodies. Splenocytes were isolated and 
resuspended in complete RPMI 1640 medium containing three different concentrations of the 
MOG-ETA′ fusion protein (1, 2 and 5µg/mL). As controls, the cells were incubated overnight 
with equivalent concentrations of MOG protein without toxin moiety or with complete RPMI 
1640 medium alone. The untreated splenocytes showed the anticipated distribution of MOG-
reactive (11.37%, upper right) and nonreactive (18.85%, upper left) B-lymphocytes (Figure 
27B). The viability of MOG-reactive cells was successfully reduced to 30% in the presence of 
1µg of immunotoxin, with no toxicity towards other B-lymphocytes (Figure 27C, upper left). 
When applying higher autoimmunotoxin concentrations (2 and 5µg), the viability of the MOG-
reactive target cell populations was reduced to almost 0% (Figure 27D and E, upper right 
panels) but the amount of protein concentration also had some influence on MOG-negative B 
lymphocytes (upper left panels). The incubation of splenocytes with MOG protein alone had 
no effect on the viability of IgHMOG splenocytes (data not shown). Zocher et al. [177] were 
able to demonstrate a similar depleting effect using a bispecific MOG-Fc protein on isolated 
splenocytes from IgHMOG mice. After application of 10µg/mL of recombinant MOG-Fc protein, 
they were able to reduce B cell population to ~30% but could not demonstrate the particular 
reduction of MOG-reactive B lymphocytes. But they had to apply a higher protein 
concentration to see an effect on the whole isolated splenocytes from IgHMOG mice. Hence, 
our results clearly demonstrates the specific toxicity on MOG-specific B lymphocytes 
supporting the toxicity data that was generated using 8.18-C5 hybridoma cells as target cells 
for the MOG-ETA’ autoimmunotoxin. 
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4.5 In vivo assays 
4.5.1 In vivo targeting of MOG-reactive B lymphocytes in transgenic mice 
 
The in vitro and ex vivo tests of the MOG-ETA’ autoimmunotoxin were promising to such an 
extent that the in vivo efficiency of the protein was further evaluated using transgenic IgHMOG 
mice. The major obstacle in targeting and eliminating MOG-reactive B lymphocytes in IgHMOG 
mice indeed is the extremely high titer of free circulating anti-MOG antibodies in the mice 
serum [127] entailing the risk of intercepting the autoimmunotoxins before binding to 
membrane bound B cell receptors. The autoimmunotoxin was applied daily over a time 
period of 5 days including two different groups regarding the amount of applied protein (10µg 
or 20µg per day respectively) and a control group consisting of animals that were injected 
with PBS only. The treatment of mice with a constant application of autoimmunotoxin 
efficiently reduced the number of MOG-reactive B lymphocytes to 65% (10µg dose per day) 
or 58% (20µg dose per day) respectively in comparison to the control group. Zocher et al. 
[177] were able to reduce MOG-reactive B lymphocytes in IgHMOG mice to ~55% using 
recombinant MOG-Fc protein by recruiting FcγR+ immune effector cells. In their study, mice 
were injected with 2x100µg of recombinant MOG-Fc protein to achieve this reduction. 
Unfortunately, the detailed data of Zocher et al. [177] were not shown in the publication but, 
by trend, we were able to achieve a comparable reduction of MOG-reactive B lymphocytes 
with half of the protein concentration (5x20µg). The ability of specifically targeting and 
depleting MOG-reactive B lymphocytes in a somewhat ‘artificial’ transgenic model reveals 
MOG-ETA’ as a highly potent drug for the treatment of an EAE-induced mouse model. This 
disease model is generally characterized by inflammatory lesions that are maintained by 
autoreactive B cells, T cells, macrophages and other proinflammatory cell populations. The 
frequency of autoreactive B lymphocytes in an EAE model is hard to be compared with the 
state that is found in transgenic IgHMOG mice where large quantities of secreted anti-MOG 
antibodies and MOG-reactive cells are constantly present in the animals’ body. However the 
usage of an EAE model for the evaluation of the in vivo efficiency of MOG-ETA’ will 
additionally provide information about the role and the influence of B cells in the development 
of EAE.  
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4.5.2 In vivo evaluation of MOG-ETA in an EAE-induced mouse model  
 
The final assessment of MOG-ETA’ was carried out using an EAE-induced DBA/1 mouse 
model [206] that can mimic the pathology of multiple sclerosis in a more accurate way than 
the application of transgenic IgHMOG mice that are characterized by disproportionate titers of 
MOG-reactive antibodies [127]. As MOG is one of the most relevant antigens that plays an 
essential role in the development and clinal pathology of MOG-induced EAE and multiple 
sclerosis, its effect as binding ligand for the design of novel autoimmunotoxins was intensely 
studied in the present work. The induction of EAE with brain-isolated or recombinantly 
expressed myelin oligodendrocyte glycoprotein leads to a the development of a T cell driven 
autoimmune response backed up by the appearance of demyelinating autoantibodies [207]. 
MOG-reactive autoantibodies are thought to play a major role in the exarcebation of the 
disease without having an influence on the underlying development of this animal model of 
multiple sclerosis. It has been shown that EAE is inducible even in B cell deficient animals 
[208-213]. Nevertheless, the EAE model is - as the name implies - just a model for an 
autoimmune disease that is represented by various pathologic events rather revealing MS as 
a complicated ‘syndrome’. It has been discovered that severe clinical events in MS animal 
models (rodents, marmosets) and in MS patients are often linked to the appearance of high 
titers of anti-MOG autoantibodies designating them and their secreting MOG-reactive B 
lymphocytes as potential targets for novel therapeutics. In this experimental part, the 
therapeutic effect of the MOG-ETA’ protein was evaluated in an EAE-induced DBA/1 mouse 
model in comparison to a control immunotoxin from a former project in our working group. 
This fusion protein is composed of a non-relevant binding antigen ‘Bo9’, a grass pollen 
allergen from the plant ‘Phleum pratense’, and the Pseudomonas exotoxin A. Two days after 
EAE induction, either proteins were applied intraperitoneally every second day in daily doses 
of 25µg over a time period of 14 days. Each group of mice contained three animals. The 
application of MOG-ETA’ had a positive therapeutic effect on EAE-induced animals as the 
disease development was almost completely prevented. Two of the treated mice actually 
developed no clinical signs, whereas the third mouse showed very slight alteration of the tail 
tension. In the control group that was injected with the non-relevant immunotoxin Bo9-ETA’ 
using the above-mentioned immunization pattern, all animals developed severe clinical 
symptoms starting on day 10 after EAE induction. The disease progression of the control 
group had a very rapid and severe form and the experiment was terminated on day 14 after 
disease induction and the symptom-concerned animals were sacrificed. After termination of 
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the experiment, the MOG-ETA’ treated animals remained in a state that was characterized 
by rather mild to no clinical symptoms for a time period of at least one additional week. This 
observation aligns with several animal studies reporting of the contribution of autoreactive 
anti-MOG B lymphocytes to the severity and the development of the EAE disease [210-213]. 
In conclusion, the efficiency of the MOG-ETA’ autoimmunotoxin could clearly be 
demonstrated using an EAE-induced mouse model. To our knowledge, this is the first 
effective approach in specifically depleting autoreactive B lymphocytes in the MOG-induced 
EAE mouse model using an immunotoxin. Other groups that are working on novel 
therapeutics for the treatment of MOG-induced EAE mainly concentrate on the systemic 
targeting of lymphocytes. Huntington et al. [214] were able to inhibit the onset and 
progression of the EAE disease in MOG-induced mice by targeting T and B lymphocytes 
using a BAFF-antagonist. This protein demonstrated a negative effect both on the survival of 
B cells and on the costimulation of T cell activation but lacked specificity in particularly 
eliminating autoreactive cell populations. The application of methylprednisolone in the MOG-
induced EAE model by Chan et al. [215] induced a reversible remission in the clinical and 
pathological features of EAE in mice accompanied by loss of lymphocyte reactivity to the 
encephalitogen. The anti-inflammatory potential of this glucocorticoid drug is very promising 
but a continued treatment could result in several severe side effects like glaucoma, 
osteoporosis and psychosis and therefore, more specific therapeutics are still in need. 
Although it has a high cell-specific toxicity and holds great promise, the MOG-ETA’ 
autoimmunotoxin still has to be evaluated into more detail and some adaptations might be 
required. The presence of a bacterial toxin as toxic moiety is still able to trigger the mice’ 
immune response to produce antibodies against this foreign protein which remains to be 
controlled in further studies. A possible resort would be the mutation of highly immunogenic 
epitopes within the toxic ETA’ domain [216, 217] or the complete replacement of the bacterial 
toxin domain by functional human proteins with comparable proapoptotic potentials [218-
221]. Nevertheless, the MOG-ETA’ protein is the first antigen-based immunotoxin that 
efficiently and specifically eliminated autoreactive B cell populations in vitro, ex vivo and in 
vivo. The strong therapeutic efficiency in two different mouse models indicates that MOG-
ETA’ is a potent agent that may provide a new therapeutic option for the treatment of MS 
patients. 
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4.6 Outlook 
 
The present work demonstrates the succesful expression, characterization and in vitro 
evaluation of two novel autoimmunotoxins, MOG-ETA’ and PLP-ETA’, designed for the 
antigen-specific depletion of autoreactive B lymphocytes in multiple sclerosis and its animal 
model EAE. Due to time constraints and the lack of an appropriate animal model, the 
efficiency of the PLP-ETA’ fusion protein could not be followed through to in vivo evaluation 
till now. The administration of the protein in a PLP-induced EAE mouse model could show its 
depletion efficiency. MOG-ETA’ could be evaluated ex vivo and in vivo in this work by the 
use of the transgenic IgHMOG mouse model and a MOG-induced EAE model. Future 
experiments should focus on more elaborate in vivo evaluations of the autoimmunotoxin 
MOG-ETA’ concerning its immunogenicity, general compatibility and pharmacokinetics. 
Several properties are required for an efficient in vivo mode of action including high target 
cell specificity, a long half life in the serum and low side effects of the recombinant protein. 
To reveal the most powerful efficiency of the protein, the optimal dose and in vivo application 
frequency has to be the elicited in further experiments. It also remains to be tested if the 
fusion protein has any negative influence on the cytokine pattern of the animals or if - using it 
over a longer time period - can cause vascular leak syndrome [137], hepatotoxicity or 
nephrotoxicity [222] evolving from the unspecific uptake of protein into non-target cells. 
Beneath cell specificity, the protein requirements also bases upon a sustainable mode of 
action together with a quick blood clearance to inhibit an unspecific uptake of circulating 
proteins in the bloodstream. To potentially increase the internalization rate of bound proteins 
to the target cell population, one could investigate the use of a bivalent immunotoxin 
construct for stronger binding to the target cell, crosslinking of B cell receptors and more 
efficient receptor-mediated endocytosis of the autoimmunotoxin. This could lead to a higher 
and/or faster protein uptake into the cytosol via the endosomal-lysosomal pathway followed 
by apoptosis of the target cell population. In some cases, the immunogenicity of immunotoxin 
fusion proteins that are  based upon bacterial toxin domains like Pseudomonas exotoxin A, 
Ricin A or diphteria toxin  still bear a problem in a long-term treatment of autoreactive or 
lymphoid diseases. These toxin domains can elicit a strong humoral immune response 
leading to the expression of neutralizing antibodies that are able to intercept applied 
immunotoxins. The problem could be escaped by designing entirely human fusion proteins 
based upon the usage of human ribonucleases like RNase A or angiogenin and human 
granzymes to prevent an immune response towards the applied protein. But even if the 
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MOG-ETA’ consists of a bacterial toxin moiety, its therapeutic potency is outstanding and 
has to be further evaluated in the EAE mouse model or even in a nonhuman primate model 
of multiple sclerosis using common marmosets. 
 
4.7 Summary 
 
In this thesis, novel autoantigen-specific fusion proteins for the specific targeting and 
elimination on one hand and the staining of autoreactive B cell populations on the other hand 
could be succesfully generated. For staining purposes, the extracellular domain of the myelin 
oligodendrocyte glycoprotein (MOG) and an autoreactive peptide sequence of the proteolipid 
protein were genetically fused to the enhanced green fluorescent protein (eGFP). 
Unfortunately the eGFP-PLP fusion protein could not be expressed using 293T cells. 
Otherwise, the expression of eGFP-MOG showed high expression rates in 293T cells and 
could easily be purified from cell supernatant. The protein was characterized by western 
blotting and ELISA using the supernatant of MOG-specific 8.18-C5 hybridoma cells. In flow 
cytometry, the protein specifically stained the above mentioned 8.18-C5 cells and isolated 
splenocytes from transgenic IgHMOG mice. Its easy-to-use staining properties characterize the 
protein for further in vivo analyses where the protein could specifically bind and stain 
autoreactive B cell population in inflammatory lesions in the brain and the spinal cord. The 
autoimmunotoxins MOG-ETA’ and PLP-ETA’, as well as their counterparts without toxin 
MOG and PLP, were efficiently expressed in bacteria. After their purification via IMAC and 
size exclusion chromatography, they all showed a high purity as analyzed by SDS-PAGE 
and subsequent western blotting using their antigen-specific hybridoma cell supernatants 
8.18-C5 (anti-MOG) and F4-2D2 (anti-PLP). The binding analyses in western blot, ELISA 
and further on in flow cytometry analyses was succesful revealing a high specificity of all 
expressed proteins. The binding of MOG-ETA’ and MOG to isolated splenocytes from IgHMOG 
mice was additionally verified by FACS analysis. MOG-ETA’ and PLP-ETA’ were used for 
XTT viability assays and demonstrated a highly specific, either strong (MOG-ETA’) or 
moderate (PLP-ETA’) toxicity on their specific target hybridoma cell line. As the expressed 
autoantigens without toxin moiety revealed no toxicity upon incubation with the target cell 
line, the toxic effect of the autoimmunotoxins can attributed to functional release of ETA’ into 
the cytosol, followed by inhibition of the protein synthesis and the apoptosis of the cell. 
Subsequent toxicity analyses were carried out using isolated splenocytes from transgenic 
IgHMOG mice. MOG-ETA’ was incubated with MOG-reactive splenocytes in different protein 
concentrations and its depleting effect could be clearly confirmed by quantitative FACS 
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analyses. Succesive animal experiments were carried out using two different mouse models. 
First the toxic effect of MOG-ETA’ was investigated in transgenic IgHMOG mice. The daily 
intravenous application of 20µg MOG-ETA’ administered over a time period of 5 days was 
able to specifically reduce the number of MOG-reactive B lymphocytes to approximately 50% 
in comparison to control animals. As the transgenic IgHMOG mice are not the model of choice 
because they are characterized by high titers of MOG-reactive antibodies which are able to 
intercept applied immunotoxin, the targeting and depletion of MOG-reactive B lymphocytes 
turned out to be too challenging in this model. The use of a MOG-induced EAE model in 
DBA/1 mice for in vivo evaluation of the MOG-ETA’ autoimmunotoxin better represents the 
nature of the inflammatory reaction to be found in multiple sclerosis lesions. The application 
of the MOG-ETA’ autoimmunotoxin had a positive therapeutic effect on EAE-induced animals 
as the disease development was almost completely prevented in the treated group. The 
control group was injected with an immunotoxin that was comprised of a non-relevant binding 
ligand but the same toxic moiety as in the autoimmunotoxin MOG-ETA’. As these animals 
revealed a severe clinical course of 10 days after EAE induction, the specific in vivo mode of 
action of the MOG-ETA’ autoimmunotoxin was clearly demonstrated. In conclusion, the 
present work provides the proof-of-principle for a novel approach that may have a strong 
positive impact on antigen-specific therapies in autoimmune disorders.    
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6 Appendix 
 
6.1 Abbreviations 
 
A  ampere 
aa  amino acid 
AA  acrylamid  
Ab   antibody 
ABTS   2,2’-azino-di-[3-ethylbenzthiazoline sulfonate(6)] 
Ag  antigen 
Amp  ampicilline 
AP  alkaline phosphatase 
bp  base pair 
BSA   bovine serum albumin 
°C  degree Celsius  
DNA  deoxyribonucleic acid 
dNTP  deoxynucleotide triphosphate 
DTT   dithiothreitol 
E. coli   escherichia coli 
EDTA  ethylenediaminetetraacetic acid 
eEF2  eucaryotic elongation factor 2 
eGFP  enhanced green fluorescent protein  
ELISA   enzyme linked immunosorbent assay 
ETA’   Pseudomonas exotoxin A, deletion mutant 
et al.   and others 
EtBr  ethidium bromide 
EtOH  ethanol 
FACS  fluorescence-activated cell sorting 
FITC  fluoresceinethiosemicarbazide 
FSC  forward scatter 
g  relative centrifuge force 
g  gram (mass unit) 
h  hour 
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his-tag  polyhistidine motif 
HRPO   horse radish peroxidase 
IC50  inhibitory concentration causing 50% inhibition 
Ig  immunglobulin  
Igκ leader  Igκ signal sequence 
IMAC   Immobilized metal ion affinity chromatography 
IPTG  isopropyl-beta-D-thiogalactopyranoside 
IRES  internal ribosomal entry sequence 
IT  immunotoxin 
IVS  synthetical intron 
Kan  kanamycin 
kb  kilobase 
kDa  kilo-Dalton 
λ  lambda 
l  liter(s) 
LB  Luria broth 
µg  microgram 
µl  microliter 
m  milli 
M   molarity (mol/l) 
mA  milli ampere 
mAb  monoclonal antibody 
MCS   multiple cloning site 
MHC  major histocompatibility complex 
min  minute(s) 
mL  milliliter 
MOG  Myelin oligodendrocyte glycoprotein 
MW  molecular weight 
NBT-BCIP 
 
nitro blue tetrazolium chloride/5-bromo-4-chloro-3- indolyl 
phosphate 
ng  nanogram 
nm  nanometer 
nt  nucleotides 
NTA  Nitrilotriacetic acid 
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NTP  nucleotide triphosphate 
o/n   over night 
OD  optical density 
ori  origin of replication 
PAA  polyacrylamid 
PAGE  polyacrylamid gel electrophoresis  
PBS  phosphate buffered saline 
PBST  phosphate buffered saline + 0.2% Tween-20 
PCR   polymerase chain reaction 
pH 
 
negative logarithm of the concentration of hydrogen ions 
in solution 
PI  propidium iodide 
PLP  proteolipid protein 
PO  peroxidase 
rpm  rounds per per minute 
rt  room temperature 
scFv  single chain Fv 
SDS  sodium dofecylsulfate 
sec.  second 
SEC  size exclusion chromatography 
Taq  Thermus aquaticus 
TAE  trisacetate EDTA buffer 
Tris  tris(hydroxymethyl)aminomethane 
Tween 20  polyoxyethylene (20) sorbitan monolaurate 
U  unit 
UV   ultraviolet 
V   volt 
v/v  volume per volume 
v/v  volume per volume 
w/v   weight per volume 
w/v   weight per volume 
XTT 
 
sodium3’-[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis(4-
methoxy-6-nitro)benzenesulfonic acid hydrate 
β-ME   β-mercaptoethanol 
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6.2 One-letter code of amino acids  
 
A           alanine 
C           cysteine 
D           aspartic acid 
E           glutamic acid 
F           phenylalanine 
G           glycine 
H           histidine 
I           isoleucine 
K           lysine 
L           leucine 
M           methionine 
N           asparagine 
P           proline 
Q           glutamine 
R           arginine 
S           serine 
T           threonine 
V           valine 
W           tryptophan 
Y           tyrosine 
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6.3 Sequences 
 
 
The sequence data at hand were investigated by DNA sequencing (2.2.8). All sequences are 
displayed with the relevant restriction sites for cloning and their complete reading frame.  
 
 
6.3.1 Myelin oligodendrocyte glycoprotein (MOG), extracellular domain  
 
 
 
 
 
 
 
 
 
The relevant cloning restriction sites SfiI and Not I are accentuated by frames. The first 
amino acid guanine (G) and the last amino acid valine (V) are underlined in red.   
 
6.3.2 Proteolipid protein (PLP), peptide sequence 
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The relevant cloning restriction sites SfiI and Not I are accentuated by frames. The first 
amino acid glutamic acid (E) and the last amino acid valine (V) are underlined in red.   
 
6.3.3 Pseudomonas Exotoxin A 
 
 
 
The first amino acid glutamic acid (E) and the last amino acid lysine (K) are underlined in red.  
  
6.3.4 Enhanced green fluorescent protein (eGFP) 
 
 
 
The first amino acid valine (V) and the last amino acid lysine (K) are underlined in red.  
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6.4 Vector Maps 
 
6.4.1 pCMV-SPORT6 vector  
 
     
 
The pCMV-SPORT 6 expression vector (Invitrogen, Carlsbad, USA) contains a CMV 
promoter followed by the SV40 t-intron and the polyadenylation signal. The ampicillin 
resistance gene (AmpR) and the bacterial origin of replication (ori) are used for plasmid 
propagation in E. coli. The PLP full length cloned was cloned into the multiple cloning site 
using SalI/NotI restriction enzymes. 
 
6.4.2 pYX-Asc vector  
 
 
The pYX-Asc cloning/sequencing vector (Columbia University, Benito Soares, USA) contains 
an ampicillin resistance gene (AmpR) and the bacterial origin of replication (pUC ori) which is 
  
                                                                                                                                     Appendix              
 
     
116 
used for plasmid propagation in E. coli. The MOG full length cloned was cloned into the 
multiple cloning site (MCS) using EcoRI/NotI restriction enzymes. 
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